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Summary 
 
 
The healthy large intestinal mucosa contains a vast pool of macrophages (m ) that 
are close to the local bacterial flora and have several unique phenotypic and functional 
properties compared with other m  populations. Although human colonic m  retain some 
of the hallmark functions of m , such as the ability to phagocytose particulate material and 
exert bactericidal activity, they are unable to produce pro-inflammatory mediators. Thus it 
has  been  suggested  that  intestinal  m   are  functionally  adapted  to  the  microbe-rich, 
immunostimulatory  environment  of  the  gut,  where  strong  inflammatory  responses  to 
harmless commensal bacteria would lead to continuous inflammation and ultimately tissue 
pathology. Indeed, there is mounting evidence that m  play an essential role in maintaining 
homeostasis  and  epithelial  renewal  in  the  normal  intestine.  In  contrast,  m   from  the 
intestine of patients with inflammatory bowel disease (IBD) differ markedly from those 
present physiologically, exhibiting heightened inflammatory and bactericidal activities, and 
contributing  to  the  tissue  damage.  How  these  differing  properties  of  colonic  m   are 
controlled  and  how  this  potentially  dangerous  population  is  kept  quiescent  under 
physiological conditions are important questions. Most existing information comes from 
either simple, observational studies of human tissue, or from work on  cell culture systems 
which  aim  to  reproduce  the  unusual  phenotype  of  resident  intestinal  m   in  vitro. 
Importantly analogous experiments of resident and inflammatory m  have not been carried 
out in murine systems, where it would be possible to characterise the cells fully and explore 
their origin, function and role in inflammatory processes. 
   xiii 
Therefore, the aims of this thesis were first to characterise m  in the resting murine 
colon both functionally and phenotypically, focussing particularly on their expression of 
toll-like  receptors  (TLR)  and  responsiveness  to  TLR  ligation  and  on  their  population 
dynamics in vivo. By comparing colonic m  with other tissue m  populations, I hoped to 
gain  an  understanding  of  how  resident  gut  m   might  have  adapted  to  their  local 
environment. In the second part of my work, I examined how the properties of colonic m  
altered in inflammation, employing a well-established experimental model of colitis, with 
the  aim  of  determining  how resident  and  inflammatory  m   might  relate  to  each  other. 
Lastly, I explored the effects of the ES-62 parasite product, known to have potent anti-
inflammatory effects on m , on experimental colitis in vivo. 
 
Experiments detailing my initial characterisation of the myeloid cells expressing the 
F4/80 m  marker in the colon of normal mice are described in Chapter 3. These revealed 
that the F4/80
+ population in the gut is extremely heterogeneous compared with other m  
populations in the body. Virtually all in vitro-differentiated BM m  (BMM) and m  from 
the  resting  peritoneum  (PEC  m )  exhibited  the  conventional  F4/80
+CD11b
+CD11c
- 
phenotype of classical m  and upregulated costimulatory molecules in response to TLR 
ligation.  In  stark  contrast,  the  colon  contained  three  F4/80
+  subsets,  one 
F4/80
+CD11b
+CD11c
int,  one  F4/80
+CD11b
+CD11c
-  and  a  smaller  population  of 
F4/80
+CD11b
-CD11c
-  cells.  None  of  these  subsets  expressed  co-stimulatory  molecules, 
even after LPS stimulation, but unlike other m , the majority of colonic m  expressed high 
levels of class II MHC without stimulation.  BMM and PEC m  also produced several pro-
inflammatory  cytokines  and  chemokines  following  stimulation,  whereas  colonic  m    xiv 
showed no mediator production under these conditions. Nevertheless, colonic m  did retain 
avid endocytic and phagocytic activities, indicating that colonic m  may engulf bacteria 
without initiating inflammation.   
 
In Chapter 4, I explored the unresponsiveness of resting colonic m  to microbial 
stimuli in more detail and found that the TLR refractoriness is associated with reduced 
expression of TLR2, 3, 4 and 9. Apart from a small proportion of m  that retained TLR2 
expression, TLR expression was downregulated both at the protein level and to some extent 
also at the mRNA level; TLRs were not re-expressed following ex vivo culture of purified 
m . This global downregulation of TLRs could not be reproduced in BMM by treatment 
with TLR ligands, and was also present in colonic m  taken from mice unable to signal via 
TLR2 or TLR4, suggesting it was not simply a form of endotoxin “tolerance”. However, 
the  mechanism  seemed  to  involve  IL-10,  as  colonic  m   from  IL-10-deficient  animals 
displayed a heightened level of TLR expression and responsiveness, even prior to the onset 
of intestinal inflammation.  
 
In Chapter 5, I examined the phenotype and function of m  during the experimental 
colitis  induced  by  feeding  dextran  sodium  sulphate  (DSS).  During  inflammation,  the 
absolute number of F4/80
+ m  increased 6-fold, the majority of which now expressed TLR, 
CD11b and low levels of CD11c. This new population of colitic m  also expressed class II 
MHC, low levels of co-stimulatory molecules and produced large amounts of TNF . In 
Chapter 6, I went on to examine the population dynamics of colonic m  under resting 
conditions and during inflammation, showing that the overall turnover rate of the total m    xv 
population  was  increased  during  colitis,  as  assessed  by  uptake  of  BrdU  in  vivo.  The 
increased turnover was mainly due to the TLR-expressing, TNF 
+ population of m  and 
more detailed analysis showed that the small number of these cells present in resting colon 
had identical turnover rates to those found in colitis. In contrast, the TLR negative m  had 
much lower turnover rates in resting and inflamed colon, suggesting that the TLR
+ and 
TLR
- subsets may represent distinct m  populations with different population dynamics, 
and  that  during  intestinal  inflammation,  the  TLR
+  subset  may  display  a  preferential 
recruitment  into  the  gut.  Indeed,  proliferation  in  situ  was  minimal,  indicating  that  the 
recently  divided,  TLR-expressing  m   proliferated  outside  the  intestine  before  being 
recruited  into  the  gut.  My  subsequent  experiments  suggested  that  this  recruitment  may 
involve the CCR2 chemokine receptor, which was expressed at high levels specifically by 
the TLR
+ subset of m  both in resting and inflamed colon.   
 
Finally in Chapter 7, I treated colitic mice with ES-62, a phosphorylcholine (PC)-
containing  glycoprotein  secreted  by  the  filarial  nematode,  Acanthocheilonema  viteae, 
which has been shown to modulate pro-inflammatory cytokine production by m  in vitro.  
ES-62 treatment had no significant effect on weight loss or pro-inflammatory cytokine 
production in the colon of mice with DSS colitis, although it slightly delayed the onset of 
the clinical signs of disease. Thus further studies of ES-62 as a modulator of m -dependent 
intestinal inflammation may be warranted. 
 
Taken together, my data suggest that under resting conditions, intestinal m  are 
heterogeneous and adapt to their microenvironment by being non-inflammatory via active   xvi 
downregulation of TLR expression and function, which may be partly dependent on IL-10. 
During  inflammation,  large  numbers  of  TLR  expressing,  fully  responsive  m   appear, 
probably via CCR2-dependent recruitment of recently divided blood-derived monocytes. 
Interestingly, small numbers of these TLR-expressing, rapidly turning over m  are also 
present in normal colon and my data suggest that these pro-inflammatory m  may be quite 
distinct from the more sessile m  which are the dominant “resident” population in normal 
gut. A delicate balance between these two m  populations must ensure homeostasis and 
appropriate responses to inflammation. 
 
 1
Chapter 1
General Introduction2
The immune system has evolved complex and stringent regulatory mechanisms to
ensure that whilst it can defend the body against an endless array of invasive pathogens, it
can also actively prevent immune effector responses against its own tissues and innocuous
antigens. Furthermore, the immune system must ensure it can terminate responses once a
pathogen has been eradicated to prevent ongoing inflammation and tissue damage. The
innate and adaptive components of the immune system act in concert to ensure this vital
balance is maintained.
There is no other tissue in the body that the importance of this balance is more
apparent than in the intestine, which is home to a vast and complex microbiota, along with
experiencing lifelong exposure to a large variety of food antigens. At the same time, the gut
mucosa represents one of the main entry routes for potentially lethal pathogens. Therefore,
the intestinal immune system has evolved many unique properties and a complex interplay
of regulatory mechanisms to ensure homeostasis is maintained in this essential tissue.
1.1 The intestinal immune system
The gastrointestinal tract consists of the small intestine, caecum, the large intestine
(colon) and rectum. The small intestine is divided into the duodenum, jejunum, and ileum,
and  is  where  the  majority  of  digestion  takes  place,  whereas  the  colon  is  primarily
responsible for reabsorbing water. There is a marked gradient of the numbers of commensal
bacteria going down the intestine, from the almost sterile jejunum, to the descending colon,
which has a large resident population of microbiota, consisting of at least 10
10-10
123
organisms per gram of luminal contents (1). These organisms play essential roles in many
physiological processes and the normal function of the intestinal immune system is
dependent on colonisation by commensal microbes. These organisms, together with the
antigenic load provided by the diet and the constant threat of potential pathogens, means
the intestinal immune system encounters more antigen than any other part of the body. To
deal with this onslaught, the intestine contains the largest compartment of the immune
system. As many bacterial, parasitic and viral pathogens enter the body via the intestinal
mucosa, it is vital the gut-associated lymphoid tissues (GALT) can provide strong and
effective immune responses when necessary. However, inappropriate responses against
innocuous food and commensal antigens can lead to inflammatory disorders such as coeliac
disease and inflammatory bowel diseases (IBD).
The two main forms of IBD, Crohn’s disease and ulcerative colitis, are chronic,
relapsing inflammatory disorders that result in loss of intestinal architecture and tissue
destruction.  Ulcerative  colitis  is  restricted  to  the  colon  and  involves  a  superficial
inflammation, whereas Crohn’s disease can affect the entire gastrointestinal tract and is
characterised by transmural inflammation and the formation of m -rich granulomas. Both
forms of IBD involve a substantial infiltrate of neutrophils, monocytes/m , eosinophils and
T cells into the intestine. However it is thought that Crohn’s disease has a predominant
Th1-type cytokine profile with elevated levels of IFN  and TNF , whereas ulcerative
colitis is considered a more Th2 polarised disease, with increased levels of IL-13, IL-5 and
TGF  (2). There is considerable evidence that the host’s commensal microbiota are crucial
for the development of IBD, with virtually all experimental models of IBD being dependent4
on the presence of commensal bacteria (3, 4). In addition, broad-spectrum antibiotic
therapy has proven beneficial in several trials in IBD patients (5, 6), and mutations in the
gene encoding nucleotide-binding oligomerisation domain (Nod) 2, a cytosolic receptor for
bacterial muramyl dipeptides (MDP) (7), are associated with 30% of familial cases of
Crohn’s disease (8, 9).
The lymphoid elements of the gut comprise organised lymphoid tissues such as the
Peyer’s patches (PP), which lie at regular intervals along the small bowel, and the
mesenteric  lymph  nodes  (MLN).  In  addition,  isolated  lymphoid  follicles,  whose
architecture resembles that of PP, with the exception that they lack a discrete T zone, exist
along the small intestine and colon (10). The role of all these tissues is in the induction
phase of intestinal immune responses, as they represent the sites where antigens are taken
up and presented to B and T lymphocytes. The effector sites of the intestine are the mucosal
epithelium and underlying lamina propria (LP) in both the large and small intestine. Here
there are many different immune cells including activated T cells, plasma cells, mast cells,
dendritic cells (DCs) and m  even under normal conditions, giving rise to the idea that
homeostasis in the gut is characterised by a state of physiological inflammation. That this
does not result in overt tissue pathology reflects the fact that the effector cells present are
actively held in check by potent regulatory mechanisms.
1.2 Mechanisms of immune protection and inflammation in the intestine5
Although composed of only a single cell layer, the intestinal epithelium itself forms
a barrier against penetration of microorganisms. Defects in barrier function are thought to
be a major contributor to the development and perpetuation of inflammation in IBD (11,
12). Furthermore, the epithelial cells of the small intestine are coated in a glycocalyx of
mucins and other glycoproteins that can interact with and trap bacteria in the mucus so that
they are simply washed away (13). In addition, anti-microbial peptides such as defensins
are secreted by Paneth cells located at the bottom of the intestinal crypts, providing another
level of innate protection (14). Epithelial cells also act as microbial sensors by secreting
chemoattractant factors such as IL-8, MCP-1, TNF  and IL-6 in response to bacterial entry
(15-17). This results in the recruitment of neutrophils, eosinophils, monocytes/m  and T
cells, and so enhances the induction of protective immunity. As mentioned above, the
intestine is also characterised by the presence of many specific immune cells, including
IgA-secreting plasma cells, CD4
+ and CD8
+ T cells, regulatory T cells and   T cells. The
exact functions of mucosal CD4
+ and CD8
+ T cells remain unclear, but the majority have a
‘memory’ phenotype (18) and some show effector function such as pro-inflammatory
cytokine production and cytotoxic T lymphocyte (CTL) activity (19, 20); others are
hyporesponsive to TCR ligation (21), and may be regulatory T cells.
1.3 Mechanisms of immune tolerance in the intestine
A  large number of immune tolerance mechanisms have been described in the
intestine. These result in the usual response of the intestine to innocuous protein antigens,
such as food antigens, being the induction of local and systemic immunological tolerance,6
termed oral tolerance (22). The mechanisms of oral tolerance include the deletion of
specific T lymphocytes (23), induction of T cell anergy (24), and the differentiation of
regulatory T cell populations (25). Many of these T cell properties may be determined by
the presence of inhibitory DC in the gut. Our laboratory has shown that small bowel LP DC
produce IL-10 and type 1 IFN, but not IL-12, and although they present antigen to specific
CD4
+ T cells, this induces hyporesponsiveness to subsequent challenge in these cells (26).
Similarly, regulatory DC populations have been described in the PP and MLN (27-30).
Effector immune responses also do not occur against commensal microbiota, but it is
thought that there may be differences in the way immune responses against commensals are
controlled, compared with protein antigens. Firstly, commensals can themselves actively
downregulate host inflammatory responses. For example, Bacteriodes thetaiotaomicron
inhibits NF B actively in epithelial cells by enhancing its peroxisome proliferator activated
receptor   (PPAR )-dependent nuclear export, thus antagonising NF B (31). Furthermore,
some  non-pathogenic  Salmonella  strains  can  block  the  activation  of  NF B via the
inhibition of I B-  ubiquitination (32). Another reason for the lack of inflammation in the
normal  intestine  could  be  the  nature  of  the  pathogen-associated  molecular  patterns
(PAMPs) found on commensal bacteria. The extent of acetylation of the lipid A component
of LPS seems critical for activating the host innate immune response (33), and the lipid A
of the Bacteroides  genus, one of the predominant species in the lower intestine, is
pentacylated and thus exerts weak endotoxicity (34, 35). Unlike the situation with food
antigens, there may be no systemic immune recognition of, or tolerance to, commensal
bacteria. Instead these antigens are taken up by mucosal DC and thereafter are limited to7
the gut and MLN (36). This may then lead to local secretory IgA production and the
induction of regulatory T cells in the GALT and LP (36), indicating that the mucosal
immune system lies in a mutual balance with commensals, restricting their penetration by
inducing local IgA, and regulatory T cells that prevent inflammation. However, the
systemic immune response remains ignorant of these antigens as is supported by the fact
that normal mice have no serum antibodies to Enterobacter cloacae, but do have specific
IgA in their intestinal washings (37). As a result, intravenous injection of mice with E.
cloacae drives a normal immune response, in contrast to the tolerance found when soluble
proteins are given orally (37).
1.4 Macrophages and intestinal immune responses
Given their number and proximity to the local microbial flora, it seems likely that
m  in the colon may play an important part in the regulation of local immune responses to
bacteria. Indeed, mice deficient in bactericidal mechanisms that generate reactive oxygen
and  nitric  oxide  (NO)  radicals  develop  abscesses  in  the  liver,  spleen  and  intestine
containing commensals (38), suggesting that active killing mechanisms are critical to
maintain a steady level of commensals. One of the aims of this thesis was to investigate
how resident m  may contribute to these processes.
Historically, m  were defined as scavenging and bactericidal tissue-resident cells
with critical innate immune functions. They exhibit stellate morphology, express non-
specific esterase, lysosomal hydrolases and ecto-enzymes, and contribute to non-specific8
uptake of particulate material (39). They also express an array of receptors for the Fc
portions of immunoglobulin (Ig) and complement components. When activated, tissue m 
phagocytose and kill microorganisms, and secrete pro-inflammatory cytokines. They can
also play a role in adaptive immunity, as m  can degrade phagocytosed material and
process antigens for presentation to T cells on MHC molecules, and may even be able to
prime  naïve  T  cells  in  vivo (40).  In  addition,  the  pro-inflammatory  cytokines  and
chemokines they release upon activation contribute to the recruitment and activation of
antigen-specific lymphocytes.
Resident  m  are found throughout the body and can take on many different
appearances and form depending on their tissue of origin. These include Kupffer cells in
the liver, microglia in the central nervous system, osteoclasts in bone, alveolar m  in the
lung,  metallophilic  m   in  the  splenic  marginal  zone,  and  the  resident  m   of  the
gastrointestinal tract (Table 1.1). Every epithelial and endothelial surface in the body has a
significant m  population, generally found in the area underlying the basement membrane
separating the surface layer from the rest of the tissue. In the intestine, m  are abundant in
the lamina propria of the small and large intestines.9
Location Name
Liver Kupffer cells
Bone Osteoclasts
Central nervous system Microglia
Splenic marginal zone Metallophilic macrophages
Splenic marginal zone Marginal zone macrophages
Lung Alveolar macrophages
Germinal centre Tingible body macrophages
Epidermis Langerhans cells
Table 1.1 Macrophage populations throughout the body10
Numerous markers for m  have been described, including F4/80, CD11b (also
known as m -1 (Mac-1); complement receptor 3 (CR3)), CD115, macrosialin (CD68),
CD83 and CD11c, although the latter is generally considered to be a marker of murine DC.
CD68 is used as the conventional marker of human m , while F4/80 is the most widely
used marker of tissue m  in mice. F4/80 is a member of the EGF-like 7 transmembrane
spanning (EGF-TM7) family, which also includes human EGF module-containing mucin-
like hormone receptor 1 (EMR1) and human CD97. No clear function has been described
as yet for F4/80, but it has been suggested that it could be involved in the adhesion and/or
retention of m  in tissues (41), as has been shown for epidermal Langerhans cells (LCs)
which downregulate F4/80 following stimulation, before migrating to draining LNs (42).
F4/80 is expressed on the cell surface of the majority of tissue m  populations, and at lower
levels by blood monocytes (43). However, F4/80 is not expressed by m  in the marginal
zone of the spleen, m  in the lung, or by osteoclasts (44, 45). Instead, marginal zone m  are
identified by a monoclonal antibody, MOMA-1, which recognizes sialoadhesin (CD169,
Siglec-1) and by their strong phagocytic capacity (46, 47). In addition, some other cell
types such as eosinophils can express low levels of F4/80 (48).
1.5 Roles of macrophages in the immune system and beyond
The principal role of m  in the immune system is their unrivalled capacity to engulf
and kill pathogenic microbes including bacteria, protozoa, helminths and fungi. These
processes usually involve actin-dependent phagocytosis, whereby the m  extends part of its
cell membrane around the bacteria as pseudopodia, internalising the resulting membrane-11
bound vesicle into a phagosome. The phagosome then fuses with a lysosome, forming a
phagolysosome that contains the machinery responsible for killing microbes and degrading
cellular material. During this process the m  becomes activated via pathogen recognition
receptors by PAMPs such as TLR ligands present on the microbe (see below) and current
evidence suggests that this may have to happen inside the phagosome itself (49). M 
activation is also enhanced by IFN  released by NK cells and T cells.
An important function of m  under resting and inflammatory conditions is the rapid
uptake of apoptotic tissue and inflammatory cells from tissues. The uptake of apoptotic
cells  is  mediated  by  a  range  of  receptors  such  as  CD36  and  this  induces  an  anti-
inflammatory response, as apoptosis drives the release of TGF  (50). This process is
important for tissue homeostasis (50), as uptake of apoptotic cells by m  prevents their
contents leaking into the environment and hence further limits the release of toxic and pro-
inflammatory mediators. This contrasts with the inflammatory reactions that occur after
uptake  of  necrotic  cells  which  do  leak  their  contents  into  the  local  environment.
Interestingly, the receptors involved in the recognition of apoptotic cells, such as CD36 and
 v 3, may also be involved in the recognition of necrotic cells (51).
M  are much more than just the ‘big eaters’ implied by their name, as it has long
been known that they play important roles in tissue homeostasis, strongly influencing the
function  and  differentiation  of  neighbouring  cells.  They  play  a  non-redundant  and
pleiotropic role in wound healing and tissue homeostasis, and aid tissue repair following
inflammation-induced damage (52, 53). They do this via the clearance of apoptotic and12
senescent  cells,  by  inducing  mesothelial  cell  proliferation  (54),  and  by  producing
extracellular matrix regulators such as thrombospondin 1 and TGF  (55-57). These are
involved in the inhibition of neoangiogenesis and fibroblast accumulation, respectively,
promoting collagen deposition (57). M  also participate in the normal ontogeny of tissues
and m -deficient osteopetrotic op/op mice exhibit sensory neural dysfunction, infertility
and defects in mammary gland development and in insulin-secreting cells of the pancreas
(58-60).
Thus tissue resident m  play apparently contrasting roles in the body, maintaining
tissue homeostasis via the clearance of apoptotic and senescent cells, and cellular debris,
and by initiating inflammatory responses to pathogenic insult.      
1.6 Features of activated macrophages
M  activation is the induction of anti-microbial mechanisms in the cell and this
occurs when m  are exposed to microbial moieties such as LPS, together with immune
signals, particularly IFN . M   activation  is  accompanied  by  the  production  of  pro-
inflammatory cytokines such as TNF , IL-12, IL-6 and IL-1. M -derived TNF  and IL-1
act on the endothelium of small blood vessels at the site of infection, activating the
endothelial cells to upregulate adhesion molecules (61) and thus promoting monocyte
migration  to  sites  of  infection.  This,  together  with  the  production  of  inflammatory
chemokines such as MCP-1, IL-8 and MIP-3  by m , results in further recruitment of m ,
neutrophils and other inflammatory cells. M  activation also results in the induction of13
several bactericidal mechanisms such as the NADPH oxidase enzyme in both the plasma
membrane and the membrane of the phagosome. This converts oxygen into the superoxide
anion and other free radicals, and these reactive oxygen intermediates (ROIs) are toxic to
the ingested microbe via inter alia, DNA degradation and inactivation of metabolic
enzymes. Patients with chronic granulomatous disease (CGD) have a defect in the gene
encoding for NADPH oxidase and therefore their m  are defective in microbial killing,
resulting in recurrent bacterial and fungal infections. Activated m  also release nitric oxide
(NO), formed by the action of the enzyme inducible nitric oxide synthase (iNOS) on the
substrate L-arginine. NO is toxic to bacteria, primarily by causing DNA damage and is
critical in innate immunity, as evidenced by the susceptibility of iNOS KO mice to
infection (62). Activated m  also upregulate the expression of class II MHC and co-
stimulatory molecules, resulting in enhanced antigen-presenting capacity.
1.7 Microbial recognition by macrophages
M  are remarkably well equipped to recognise microbes and microbial products,
achieving this through the expression of germline-encoded pathogen recognition receptors
(PRRs). These PRRs recognise conserved structural motifs found on prokaryotic and lower
eukaryotic organisms, the so-called pathogen-associated molecular patterns (PAMPs). The
best known PRRs are the 11 members of the TLR family, most of which are expressed by
m . The ligands for TLR1-9 are well defined, recognising PAMPs such as bacterial LPS,
lipoprotein, lipoteichoic acid, flagellin, RNA and unmethylated CpG-containing DNA. The
ligand  for  TLR10  has  not  been  determined,  whilst  a  profilin-like  molecule  from14
Toxoplasma gondii has been shown to signal via TLR11 (63). Details of the recognition
patterns and cellular location of the different members of the TLR family are shown in
Table 1.2.
Some TLRs can also bind multiple ligands. For example, in addition to its well
known ability to recognise bacterial LPS, TLR4 can also bind the fusion protein of
respiratory syncytical virus (64, 65), as well as endogenous ligands such as HSP60 and
HSP70 (66-68). TLR2 can also bind zymosan, a glucan present in yeast cell walls (69), and
can form complexes with TLR1 and TLR6, conferring specificity for additional microbial
components (70), as well as the ability to recognise subtle differences between triacyl and
diacyl lipopeptides (71). This means that together, TLRs equip the innate immune system
with the ability to detect pathogens of a bacterial, fungal and viral nature, as well as
endogenous ligands associated with cell stress.15
Receptor Cellular
location
Ligand(s) Expression by
m 
References
TLR1 Plasma
membrane
Triacyl
lipopeptides
Most
populations
(72, 73)
TLR2 Plasma
membrane
Lipoprotein,
peptidoglycan,
lipoteichoic acid
Most
populations
(73, 74)
TLR3 Endosome dsRNA Most
populations
(75)
TLR4 Plasma
membrane
LPS Most
populations
(76, 77)
TLR5 Plasma
membrane
Flagellin Human
monocytes, not
mouse
(78-80)
TLR6 Plasma
membrane
Lipoteichoic acid Most
populations
(70, 71)
TLR7,8 Endosome ssRNA Some
populations
(81-83)
TLR9 Endosome Unmethylated
CpG containing
DNA
Most
populations
(84)
Table 1.2 TLRs, their location in the cell, their ligands and their expression by tissue
macrophage populations16
1.8 Cellular Distribution of TLR
Monocytes and m  have been shown to express mRNA for most TLRs except
TLR3 (85), whereas TLR expression by DC varies with the subset (86). T cells and B cells
also express several TLRs and the roles they play in lymphocyte responses are discussed
briefly below. In addition, tissue cells such as epithelial cells can also express TLR, but
expression by intestinal epithelial cells (IEC) is controversial. IEC may not express any on
the apical surface, but may express TLR5 on their basolateral surface (87), thereby only
inducing an a inflammatory response to those bacteria that have crossed the epithelial
barrier. Finally, human dermal endothelial cells have been shown to express TLR4 (88).
Thus there is a wide range of immune and non-immune cells that can recognise microbes
via TLR, and the importance and the role of TLR expression by m  is discussed below.
1.9 TLR signalling
TLRs recognise their ligands via leucine-rich repeat elements (LRRs) in their
extracellular domain and activate cellular responses by signalling through their intracellular
Toll-interleukin-1 receptor (TIR) domain, which recruits TIR-containing adaptor proteins
(Figure 1.1). For most TLRs, the relevant adaptor protein is MyD88, which then recruits
IL-1 receptor-associated kinase 4 (IRAK4), allowing the association of IRAK1 (89). After
phosphorylation by IRAK4, IRAK1 then binds TNF receptor activated factor 6 (TRAF6),
an event blocked by the negative regulator, IRAK-M (90). Phosphorylated IRAK1 and
TRAF6 then disassociate from MyD88 and activate transforming growth factor  -activated17
kinase (TAK1), which phosphorylates MAP kinases and the inhibitory  B kinase (IKK)
complex. This activates IKK which then phosphorylates I B, promoting its degradation and
liberating NF B from inhibition and allowing nuclear translocation of active NF B (p50
and p65), with resulting transcription of genes for pro-inflammatory cytokines and co-
stimulatory molecules (91).  MyD88-dependent  TLR  signalling  can  also  activate  the
activating protein-1 (AP-1) family of transcription factors (92), which have been shown to
be involved in processes such as cell proliferation and survival (93).
In contrast to other TLRs, TLR3 utilises the TRIF adaptor protein (TIR domain-
containing adaptor protein inducing IFN ) in a MyD88-independent pathway, culminating
in the activation of IRF3 and the IFN  gene (94). TLR4 can also activate this MyD88-
independent, TRIF-dependent pathway, but unlike TLR3, TLR4 uses TRIF-related adaptor
molecule (TRAM) which interacts with TRIF (95, 96), leading to both the activation of
IRF3 and a later phase of NF B activation (97, 98) (Fig 1.1).18
Figure 1.1 Recognition of bacterial moieties and non-self nucleic acids
PAMPs are recognised by numerous families of receptors expressed by m  in different
cellular locations. TLRs: TLR1, 2, 4, 5 and 6 are expressed on the cell surface, whereas
TLR3, 7, 8 and 9 are expressed in intracellular compartments. With the exception of TLR3,
triggering of TLRs results in binding of the adaptor protein MyD88, which then recruits
and activates IRAK4 and IRAK1, an event blocked by the negative regulator MyD88s.
IRAK1 then disassociates from MyD88 and binds TRAF6 (blocked by IRAK-M), which
activates TAK1. TAK1 phosphorylates and activates both MAP kinases and the IKK
complex, liberating NF B from the inhibitor I B, allowing its nuclear translocation and
transcription of pro-inflammatory genes. In contrast, triggering of TLR3 recruits TRIF,
which results in the activation of IRF3 and activation of the IFN  gene. TLR4 also signals
via a MyD88-independent, TRAM- and TRIF-dependent pathway, activating IRF3 and the
late phase activation of NF B. Nod-like receptors: NLRs are expressed in the cytosol and
activation of Nod1/Nod2 by iE-DAP/MDP recruits the adaptor RICK and activates the
NF B and MAPk pathways. Ipaf and Nalp1b form an inflammasome and use ASC to
recruit caspase-1, which then cleaves pro-IL-1 and pro-IL-18 into their active forms. RIG-
I-like receptors: RIG-I and MDA-5 activation by viral RNA results in the activation of the
IRF and NF B pathways.F
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1.10 Regulation of TLR expression and function
The regulation of TLR expression is not well understood, nor are the transcription
factors involved in the control of TLR mRNA expression. However, the transcription factor
PU. 1 and the IFN consensus sequence-binding protein are involved in the basal regulation
of TLR4 in human m  (99). In addition, the expression of TLR2, 4 and 9 mRNA by murine
m  is increased following stimulation with LPS in a ERK MAP kinase and NF B-
dependent manner (100).
In  addition,  other  microbial  components  and  cytokines  have  been  shown  to
modulate TLR expression. For example, LPS has been shown to upregulate TLR2 but
downregulate TLR4 in m  (101, 102). Indeed, one of the commonest forms of TLR
hyporesponsiveness is endotoxin tolerance, in which initial exposure to LPS inhibits
subsequent responses via TLR4. This is accompanied by downregulation of TLR4 (102),
decreased association of TLR4 with the MyD88 adaptor protein and decreased association
of MyD88 with IRAK (103, 104). This phenomenon has not been described as extensively
with other TLR ligands, but BLP tolerance has been associated with reduced TLR2
expression  in  the  THP-1  m   cell  line  (105).  In  addition,  prolonged  stimulation  of
monocyte-derived m   with  the  Nod2  ligand,  MDP,  results  in  similar  tolerance  to
subsequent stimulation via both Nod2 and TLR (106), although the expression of TLR was
not examined in this study. The m  growth factor, colony-stimulating factor (CSF)-1, can
downregulate  TLR9 expression in m   and  suppress  CpG-induced  pro-inflammatory
cytokine production (107).21
The endoplasmic reticulum (ER)-associated heat shock protein, gp96, has been
demonstrated to be an essential chaperone for allowing the shuttling of TLR1, 2, 4, 5, 7 and
9 to the cell surface or correct intracellular compartment of m  (108, 109). Although little
is known of the mechanisms, recycling and degradation are also likely to play a role in
controlling TLR expression and an E3 ubiquitin ligase, Triad3A, has been shown to
enhance the ubiquitination and proteasomal degradation of TLR4 and TLR9 (110). TLR
can also be regulated at the transcriptional level, as shown by the ability of LPS and
inflammatory cytokines such as IL-1 , IFN  and TNF  to induce the expression of the
TLR2 gene in m  (101).
TLR function can also be regulated at the level of intracellular signalling. IRAK-M
lacks  kinase  activity,  but  is  induced  in  response  to  TLR  ligation  and  prevents  the
dissociation of IRAK1 and IRAK4 from MyD88, thus inhibiting the formation of active
IRAK-TRAF6 complexes (90). IRAK-M-deficient mice show an impaired induction of
LPS tolerance. The alternatively spliced variant of MyD88, MyD88s, is induced in
monocytes in response to LPS and blocks the association of IRAK4 with MyD88, and
subsequent IL-1/LPS-induced NF B activation (111) (Fig 1.1). In addition, the ubiquitin-
modifying enzyme, A20, regulates TLR responses by terminating TLR-induced IKK
activation and NF B transcriptional activity by deubiquitinating TRAF6 (112). IL-10 and
TGF  can negatively regulate TLR responses. Indeed, peripheral blood mononuclear cells
(PBMCs) cultured with TGF  and IL-10 show a reduced TNF  response to TLR4 ligation,
comparable to that of LPS desensitisation (113). Furthermore, neutralisation of these22
cytokines during primary culture with LPS prevents the reduced TNF   response to
subsequent challenge. How TGF  and IL-10 mediate these effects is not completely
understood, but it is likely to reflect altered downstream signalling. IL-10 can inhibit TLR-
mediated NF B activation by inhibiting IKK and NF B DNA-binding activity (114), and
by inducing nuclear expression of the inhibitory I B family members, I BNS and Bcl-3
(115, 116). By associating with the p50 subunit of NF B, these negative regulators inhibit
the activation of the IL-6 and TNF  promoters, respectively. TGF  can block NF B
activation  in  response  to  TLR2,  4,  and  5  ligands  by  facilitating  ubiquitination  and
proteosomal degradation of MyD88 (117).
Therefore, TLR expression can be regulated at the transcriptional level, at the level
of protein folding, delivery to the cell surface or correct endosomal compartment, or by
changes  in  recycling.  In  addition,  there  may  also  be  alterations  in  the  downstream
signalling pathways used by TLRs, even when the proteins are still expressed at normal
levels. It will be critical to delineate the mechanisms involved in the regulation of TLR
expression by m , due to the functional impact this will have for m  and for homeostasis in
tissues like the intestine.
1.11 The Role of TLR in immune responses
TLR activation has wide ranging effects on both innate and adaptive immunity. The
downstream effects of TLR ligation include pro-inflammatory cytokine and chemokine
production, microbial killing and enhanced expression of class II MHC and co-stimulatory23
molecules. The importance of TLR in immunity is demonstrated by MyD88 KO animals,
which exhibit increased susceptibility to Mycobacterium avium and Listeria monocytogenes
infection (118, 119), and abrogated Th1 differentiation and increased susceptibility during
Toxoplasma infection (120, 121). Activation of DCs via TLRs drives their production of
cytokines, such as IL-12, and the upregulation of co-stimulatory molecules, events which
are critical for the activation and differentiation of naïve T cells (122). TLR2 KO and
MyD88 KO mice both show increased susceptibility to infection with Staphylococcus
aureus (123). TLR2 activation leads to NO-dependent and –independent killing of M.
tuberculosis in m  from mice and humans, respectively (124). In addition, TLR2 drives the
induction of  –defensin-2 in a human lung epithelial cell line (125), whilst LPS drives the
production of murine  -defensin-2 and -6 (126, 127). TLR2 has also been shown to confer
lipoprotein-induced apoptosis of m  (74), suggesting a potential role of TLRs in infection-
induced cell death. Moreover, activation of m  with LPS, but not TLR2 agonists, mediates
IFN  production and in turn, STAT-1-dependent gene expression and anti-viral immunity
(128).
In addition to their effects on innate cells such as m , TLR expression on CD4
+ T
cells  can  act  as  a  co-stimulatory  signal  for  their  activation  (129).  Similarly,
activated/memory B cells can express most TLR (130, 131) and TLR9 expression induced
by BCR triggering can assist differentiation into Ig-secreting plasma cells (131).
TLRs also interact with other activation stimuli such as IFNs. One of the best
described pathways that integrates with TLRs is the IFN  receptor (132). Associated with24
the ability of IFN  to upregulate TLR4 expression by m  (133), IFN  has long been known
to ‘prime’ m  for heightened LPS responses and this has been shown more recently for
CpG DNA (134, 135). TLRs also synergise with other families of PRRs in the recognition
of microbial products. For example, Dectin-1, the  –glucan receptor, and TLR2 are both
involved in the recognition of yeasts via zymosan (136, 137). Similarly, bacterial flagellin
is recognised by both TLR5 and the Nod-like receptor, Ipaf, inducing divergent signalling
pathways via NF B and caspase-1, respectively (78, 138). Meanwhile, another C-type
lectin, the mannose receptor, inhibits LPS-induced IL-12 production (139).
1.12 Other pathogen recognition receptors
Another family of PRRs receiving increasing interest are the Nod-like receptors
(NLRs), characterised by a conserved Nod domain and LRRs. Whereas TLRs recognise
microbes on the cell surface and in endosomes, NLRs recognise microbial moieties in the
cytosol. 23 NLR genes have been identified in the human genome, but the best known are
Nod1 and Nod2, which recognise bacterial peptidoglycan-related molecules containing
meso-diaminopimelic acid (iE-DAP) and MDP, respectively (140, 141). Whereas Nod1 is
expressed in many cell types, Nod2 is expressed primarily by immune cells, including m ,
and by Paneth cells in the small intestine (142). Ligation of Nod1 and Nod2 by their
respective ligands recruits the adaptor protein, RICK (143), which binds and promotes
polyubiquitylation of IKK  and activation of TAK1 and NF B (144). Like TLRs, Nod1 and
Nod2 stimulation also results in the activation of the MAP kinases p38, ERK and JNK
(145). As mentioned above, mutations in Nod2 are associated with Crohn’s disease, and25
functional studies have shown that the Crohn’s disease-associated variants exhibit reduced
or loss of activity when stimulated with MDP (7). This suggests that Nod2 mutations may
result in impaired clearance of commensal bacteria, allowing inappropriate inflammatory
responses in the gut. However, when the human disease-associated variant was introduced
into the mouse Nod2 locus, the murine m  produced increased IL-1  in response to MDP
(146), and so the exact mechanism by which Nod2 mutations increase the susceptibility to
Crohn’s disease is not clear.
A further set of NLRs include Ipaf and Nalp1b that are activated by bacterial
flagellin in the cytosol (138) and by the Bacillus anthracis lethal toxin, respectively (147).
These receptors are involved in the formation of the ‘inflammasome’, a molecular platform
assembled  by  NLRs  upon  ligand  binding.  The  inflammasome-associated,  caspase
recruitment domain (CARD)-containing adaptor, apoptosis-associated speck-like protein
containing a CARD (ASC), is required for recruitment of caspase-1, which then mediates
the proteolytic maturation of IL-1  and IL-18 (148). Another set of cytosolic PRRs include
the retinoic acid-inducible gene-I (RIG-I)-like receptors (RLRs), including RIG-I and
melanoma differentiation-associated protein-5 (MDA-5), which are involved in anti-viral
responses (149). These receptors recognise different types of dsRNA, but both result in
activation of IRF3 and NF B, and the production of IFNs (150).
1.13 Ontogeny of myeloid cells26
Tissue  m  are derived from myeloid precursors in the BM. In the adult BM,
haematopoietic stem cells (HSC) first give rise to granulocyte/m  colony-forming unit
precursors (GM-CFU), which have the ability to differentiate into either monocytes or
granulocytes. During monocyte development, GM-CFU differentiate into m  colony-
forming unit precursors (M-CFU) which then differentiate into monoblasts, promonocytes
and finally monocytes (Figure 1.2). The same progenitor cell population at the M-CFU
stage of development is thought to give rise to both m  and DC (151, 152). These then
enter the bloodstream and circulate for 1-3 days, from where they are recruited into tissues
as m . Under resting conditions, tissue m  probably survive without dividing for up to
several  weeks  before  undergoing  apoptosis,  to  be  replenished  by  newly  recruited
monocytes. Monoblasts have a cell cycle time of <12 hours, while that of monocytes is ~16
hours (153), and mature monocytes then enter the blood within 24 hours of their formation
(154). Thus the processes of development and replenishment of m  are rapid, meaning
these cells can make an immediate response to infection or tissue trauma.27
Figure 1.2 Macrophage development
Haematopoeitic stem cells (HSC) in the BM give rise to granulocyte/m  colony-
forming units (GM-CFU), which can become granulocyte colony-forming units (G-CFU)
or m   colony-forming  units  (M-CFU).  G-CFU  can  then  differentiate  into  mature
granulocytes such as neutrophils and eosinophils, whereas M-CFU differentiate into
monoblasts, pro-monocytes, monocytes and then finally tissue m . Growth factors such as
IL-3, IL-6, GM-CSF and particularly M-CSF are critical in this developmental pathway.F
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A combination of growth factors is required for the differentiation of myeloid cells,
including m  colony-stimulating factor (M-CSF; also known CSF-1), granulocyte/m 
colony-stimulating factor (GM-CSF), IL-3, IL-6, stem cell factor (SCF; c-kit ligand) and
leukaemia inhibitory factor (LIF) (155-157). Although the exact role of the individual
growth factors at the distinct stages of development are unclear, CSF-1 and its receptor
(CSF-1R; CD115), encoded by the c-fms proto-oncogene, play a particularly crucial role in
m  proliferation, differentiation and survival (158). Indeed op/op mice, which have a point
mutation in the gene encoding CSF-1 (159), are severely m -deficient apart from retaining
some subsets of splenic m , BM monocytes and m  in LNs and the thymus (160-162).
They exhibit reduced body weight and almost a complete lack of osteoclasts, resulting in
bone-remodelling defects and skeletal deformities.
The molecular mechanisms that govern the mobilisation of mature monocytes from
the BM, are also not well defined. After exiting the blood, monocytes differentiate into
mature tissue m  under the influence of ill defined, local tissue factors including signals
received when crossing the endothelium of blood vessels. Thereafter, most tissue m  do not
divide in situ and are thought to be replenished continuously by blood monocytes under
resting conditions. However some m  undergo self-renewal in tissues, including Kupffer
cells, alveolar m   and  microglial  cells,  all  of  which  are  replenished  by  both  local
proliferation and from blood monocytes (163-167).
1.14 Origin of tissue macrophages and the heterogeneity of blood monocytes30
As discussed above, the consensus is that tissue m  derive from monocytes in the
blood,  which  extravasate  continuously  at  a  low  rate  to  replenish  the  resident  m 
populations. However, recent studies indicate that distinct subsets of monocytes may give
rise to different myeloid cell populations in tissues. In mice, DCs appear to derive from a
short-lived CX3CR1
loCCR2
+Gr1(Ly6C)
+ ‘inflammatory’ subset of blood monocytes that
has  a  propensity  to  home  to  inflamed  tissues,  such  as  the  thioglycollate-inflamed
peritoneum, where they can also give rise to inflammatory m  (168). In contrast, the
CX3CR1
hiCCR2
-Gr1
- ‘non-inflammatory’ subset of monocytes is recruited to non-inflamed
tissues and gives rise to long-lived resident myeloid cells in the liver, lung, brain and
spleen, with a proportion acquiring a DC (CD11c
+class II MHC
+) phenotype in the spleen
in the absence of inflammation. Analogous populations may occur in humans, where blood
monocytes can be separated into at least two subsets based on their expression of CD14 and
CD16 (169). The CD14
+CD16
-  subset are also CCR2
+  and are considered to be the
equivalent of the ‘inflammatory’ monocyte, whereas the CD14
+CD16
+  subset, which
constitute about 10% of all blood monocytes, is considered to be the ‘resident’ or ‘non-
inflammatory’ population, expressing CCR5 and higher levels of class II MHC (170).
However the CD14
+CD16
+ monocytes also give rise to DCs in an in  vitro  model of
endothelial reverse transmigration (171), mimicking entry into lymphatic vessels.
The exact relationship between these subsets and at what stage they diverge during
development is unclear. Although phenotypically distinct monocyte subsets exist in the BM
and blood (172), some studies suggest that these subsets actually represent the same cells at
different stages of maturation. When mononuclear phagocytes were depleted by injection of31
toxic  liposomes,  Ly6C
hi  monocytes  reappeared  in  the  circulation  first  but  then
downregulated Ly6C expression while still in the bloodstream, suggesting that Ly6C
hi
monocytes may be the precursors for Ly6C
lo monocytes (173). Furthermore, grafted Gr-1
hi
monocytes can home back to the BM in the absence of inflammation, differentiate into Gr-
1
lo monocytes, and return to the bloodstream (174). It will be important to define these
processes in detail, as it could prove possible to target one subset selectively and so
modulate the function of inflammatory m , without affecting the potential homeostatic role
of the other subset. Indeed the Ly6C
lo monocyte subset has been shown to be recruited into
the  infarcted  heart,  promoting  tissue  healing  by  expressing  high  levels  of  vascular
endothelial growth factor (VEGF) (175). However it has to be noted that such studies have
rarely examined the role of monocyte subsets in health and disease in the same tissue and in
particular, nothing is known of how intestinal m  fit into the scheme outlined.
1.15 Functional heterogeneity of macrophages
There is considerable heterogeneity of function within the mature m  population
during inflammatory responses. ‘Classically’ activated m  are triggered by stimuli such as
TLR ligands and IFN , leading to the upregulation of class II MHC and the production of
pro-inflammatory cytokines and NO. These are important for combating intracellular
infections such as Mycobacterium tuberculosis.
In  contrast,  ‘alternatively’  activated  m   (AAM) develop in response to Th2
cytokines such as IL-4 and/or IL-13, and this subset of m  is thought to be involved in32
allergic and anti-parasite responses, as well as in tissue repair (Figure 1.3). AAM are also
class II MHC
+, but are characterised by the lack of pro-inflammatory cytokine production.
In contrast, they express the mannose receptor, FIZZ1, Ym-1 and produce chemokines such
as CCL22 (MDC), which attract CCR4
+ CD4
+ Th2 cells (176, 177). In addition, whereas
classically-activated m  (CAM) use L-arginine to generate iNOS-dependent NO, AAM
express arginase which converts L-arginine to L-ornithine and then proline, a precursor of
collagen, resulting in fibroblast proliferation and collagen production (178). Arginase plays
a critical role in schistosome egg-induced granuloma formation (179) and together with the
fact that mature AAM express mRNA for angiogenic factors such as TGF  and insulin-like
growth factor (IGF-1) (180),  it  appears  that  AAM  may  play  a  role  in  fibrosis,  re-
vascularisation and tissue remodelling during Th2 responses. Moreover, as they do not
produce pro-inflammatory mediators such as IL-12, TNF , NO or ROIs, m  of this kind
could contribute to protective immunity and tissue repair without driving substantial
immunopathology.33
Figure 1.3 Macrophage differentiation and heterogeneity
Macrophages exposed to Th1 or Th2 cytokines develop into ‘classically’ (CAM) or
‘alternatively’ activated m  (AAM), respectively. A) Following stimulation by LPS and
IFN , m   upregulate  class  II  MHC,  produce  pro-inflammatory  cytokines  and  show
respiratory burst activity. In addition, they convert L-arginine to NO using inducible nitric
oxide synthase (iNOS). B) In contrast, following stimulation with IL-4 or IL-13, AMM
upregulate class II MHC, but do not make pro-inflammatory cytokines. In addition, AAM
express the mannose receptor, Ym-1, FIZZ-1 and using arginase, convert L-arginine to L-
ornithine and proline, leading to collagen production.I
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A group of BM-derived cells termed myeloid-derived suppressor cells (MDSCs)
has been shown to be involved in the suppression of immune responses during cancer.
These express F4/80, CD11b and Gr-1 and represent 20-30% of BM cells in normal mice
(181). Injection of tumour cells, or the development of spontaneous tumours results in a
dramatic expansion of MDSC (182), which exert immunosuppressive effects in both an
antigen-specific and non-specific manner, via factors such as arginase and reactive oxygen
and nitrogen species. In this respect, arginase decreases L-arginine levels, which blocks
translation of the CD3  signalling protein in T cells (183), while NO inhibits the IL-2
signalling cascade (184). Thus, MDSCs exhibit characteristics of both classically and
alternatively activated m , but have the unique property of suppressing T cell function.
1.16 Intestinal macrophages
The healthy intestinal mucosa is home to one of the largest populations of m  in the
body (185), yet relatively little is known about their function. In the colon and small
intestinal mucosa, m  are located in the LP just below the epithelium and in the underlying
muscularis mucosa (Fig 3.1). In the small intestine, which contains slightly lower numbers
of mucosal m  compared with the colon (185), they are also present in the sub-epithelial
dome region of PP. Murine intestinal m  express a number of characteristic markers found
on other m  populations, including F4/80, CD11b, and some class II MHC (115, 186).
Human colonic m  express CD68, and low levels of CD11c, but unlike blood monocytes,
express only low levels of class II MHC and CD11b (187). In contrast, human small36
intestinal m  have been reported to express high levels of class II MHC, but unlike blood
monocytes, fail to express CD11b, CD11c, and the integrin LFA-1 (CD11a/CD18) (188).
By virtue of their location, mucosal m  are in an ideal position to interact directly
with bacteria in the lumen and to detect any microbes or microbial products that may cross
the epithelial monolayer. This could occur via several routes. One possibility is that m 
could behave like mucosal DCs, which have been reported to send processes out between
IEC and into the lumen in response to signals from epithelial cells that have recognised
bacteria (189, 190). Indeed, it is now thought that the myeloid cells that do this are actually
m  (Agace, WW and Pabst, O; personal communication). Other possibilities include
antigen acquisition through breaches of the intestinal barrier, or indirectly via uptake of
dying epithelial cells that have acquired antigen (18). It is also possible that m  may
acquire bacteria or their products indirectly, following uptake and transfer from intact IEC.
Pro-inflammatory mediators released by IEC in response to bacterial products such as LPS,
which can be detected intracellularly (191, 192), could also act as ‘danger signals’ for
adjacent m  (15, 193).
1.17 Unique functional specialisation of intestinal macrophages
As m  are highly phagocytic cells, it seems likely that their close positioning to
intestinal bacteria may allow them to contribute to intestinal homeostasis simply by
clearing organisms from the vicinity. Indeed, m  from the small intestine have been shown
to be very efficient at phagocytosis and killing bacteria even without prior activation (36,37
188). As a consequence, it would seem reasonable to predict that intestinal m  would be
highly activated in situ. However, this is not the case. Although they are highly phagocytic
with prominent phagocytic vacuoles, secondary lysosomes and pseudopodia (194), as well
as expressing some class II MHC, intestinal m  express only low levels of co-stimulatory
molecules such as CD40, CD80, and CD86 (115). In addition, unlike their counterparts in
other tissues, human small intestinal m  do not produce pro-inflammatory cytokines or
bactericidal reactive oxygen and nitrogen intermediates in response to TLR ligation (see
below).
Human small intestinal m  fail to make IL-1, IL-6 or TNF , and produce only low
levels of IL-8, in response to numerous microbial products, including LPS, Helicobacter
pylori urease and heat-killed Staphylococcus aureus (188). Similarly murine colonic m ,
identified on the basis of CD11b expression, fail to produce pro-inflammatory cytokines or
upregulate co-stimulatory molecules in response to microbial stimuli (115, 195). Instead, in
response to stimulation by whole bacteria, intestinal m  may produce the anti-inflammatory
cytokine, IL-10 (195). IFN  or Nod2 stimulation and phagocytosis of FITC-labelled beads
by intestinal m  also fails to induce pro-inflammatory cytokine release (106, 188), nor do
these cells show a respiratory burst after stimulation with phorbol myristate acetate (PMA)
or opsonised zymosan (196). Furthermore, colonic m  fail to produce pro-inflammatory
cytokines after stimulation with whole Escherichia coli (195), suggesting that these cells
are unresponsive to an plethora of PRR ligands. Staining of sections from healthy human
biopsies has also failed to reveal any iNOS expression by intestinal m  (197, 198).38
Thus there is a profound, global state of refractoriness in intestinal m , in which
downregulation of pro-inflammatory functions allows uptake and killing of microbes
without initiating an inflammatory cascade. This would appear to be an ideal behavioural
adaptation in such a microbe-rich environment where inflammation must be avoided. It
remains to be determined how intestinal m  can kill bacteria without being able to recruit
the mechanisms normally associated with this function, although it may involve other anti-
microbial mechanisms such as lysosomal acidification, acid hydrolases, lysozyme, and
nutrient competitors such as lactoferrin. However none of these have been studied directly
in intestinal m .
1.18 Pro-inflammatory receptor expression on intestinal macrophages
As discussed above, a number of different mechanisms have been described which
can regulate TLR function and expression, and which need to be considered as reasons for
the hyporesponsiveness of intestinal m  to TLR ligation. However, this has not been
explored yet and although one group has reported that human large intestinal m  may
express reduced levels of TLR mRNA compared with monocytes (199), this has not been
confirmed in other species. In addition, not all TLRs were examined and only TLR2 and 4
were measured at the protein level, but these were absent in the resting state and increased
during IBD (199). Most human small and large intestinal m  also lack surface expression
of CD14, the glycosylphosphatidyl inositol (GPI)-linked glycoprotein which forms part of
the high affinity complex essential for LPS recognition (187, 194, 200, 201), although
CD14  may  be  expressed  at  low  levels  intracellularly  in  murine  colonic  m   (202).39
Transcriptional control is one obvious way in which TLR expression could be regulated
and it has been reported that human colonic m  fail to express mRNA for TLR1-5 (199).
However others have found that human small intestinal m  express mRNA for TLR2 and 4
(194),  meaning  which  TLRs  are  expressed  by  intestinal  m  and at what level this
expression is regulated, remains to be elucidated.
If correct, this pattern of decreased TLR expression by intestinal m  contrasts with
another myeloid cell population in the intestine, DCs in the LP of the small bowel. These
cells are also hyporesponsive to TLR stimulation, but in this case, retain full expression of
TLRs (203). It is also unusual given that intestinal m  are considered to derive from
circulating monocytes which express a range of functional TLRs (199). However intestinal
m  also fail to express a variety of other receptors present on other m  populations which
could  be  involved  in  activation  by  local  bacteria.  Human  small  intestinal  m   lack
expression of the stimulatory Fc R1 and Fc RIII receptors for IgG, as well as the CR3 and
CR4 complement receptors (188). In addition, they lack the human Fc  receptor (Fc R)
(194).  IgA  is  the  most  abundant  antibody  isotype  in  the  GALT  and  IgA-mediated
phagocytosis can induce a respiratory burst in polymorphonuclear cells (204). Although not
shown directly, if IgA-mediated phagocytosis does induce a similar effect in m , lack of
this receptor could thus contribute to the absence of pro-inflammatory responses in
intestinal m . Finally, in contrast to blood monocytes, the majority of m  from the human
small and large intestine do not express the triggering receptor expressed on myeloid cells-
1 (TREM-1) (205). Although the natural ligand for TREM-1 remains elusive, its ligation on
monocytes with agonistic anti-TREM-1 antibodies leads to upregulation of co-stimulatory40
molecules and pro-inflammatory cytokine production (206). Furthermore, during active
IBD and experimental colitis, TREM-1 is upregulated in the intestine and administration of
an antagonistic peptide blocking TREM-1 activity ameliorates experimental murine colitis
(207), suggesting it may play an important role during intestinal inflammation.
1.19 Origin of the intestinal macrophage pool
The  functional  hyporesponsiveness  of  intestinal  m   correlates  with  the
downregulation of a number of different receptors which could be involved in mediating
inflammatory responses. However, some studies suggest that not all m  in the normal
intestine are identical in terms of responsiveness to pro-inflammatory stimuli, with small
numbers of resident m  expressing CD14 (201). These could represent recently arrived
monocytes recruited as part of homeostatic renewal. Experiments in humans with IBD
show that peripheral blood monocytes can be recruited to the inflamed intestine (208, 209),
and it is generally assumed that this may also occur constitutively under resting conditions.
As discussed above, some tissue m  populations have also been shown to proliferate in
situ, as well as being replenished by blood monocytes, although this has never been studied
in the intestine. Alternatively, there may be separate subsets of intestinal m  with distinct
functions in the resting intestine. These issues remain to be addressed and it is also not
known how m  populations vary between health and disease. In addition, the nature of the
precursors and the molecular mechanisms that govern their recruitment into the mucosa in
the resting state and in response to intestinal inflammation are not well understood. These41
are vital questions, as effective blocking of mononuclear cell infiltration into the gut may
prove to be an effective route for therapeutic intervention.
1.20 Mechanisms underlying unresponsiveness of intestinal macrophages
That the distinctive properties of intestinal m  may be conditioned after arrival in
the local microenvironment would be consistent with the heterogeneity and plasticity of
cells within the myeloid lineage, all of which can adopt highly specialised functional
profiles suited to their role in different anatomical locations. Recent studies also suggest
that mediators produced by epithelial and other mucosal cells can condition intestinal DCs
to become tolerogenic and to imprint T cells with gut homing properties. These mediators
include TGF , IL-10, thymic stromal lymphopoietin (TSLP), vasoactive intestinal peptide
(VIP), prostaglandin (PG) E2 and retinoic acid (210-218). Similar conditioning of blood
monocytes could occur following their arrival in the intestinal microenvironment. Indeed
co-culturing monocytes with IEC in vitro induces an intestinal m -like phenotype, with
reduced CD14 expression and abrogated IL-1  responses to stimulation with LPS (219).
Furthermore, prolonged culture of blood monocytes with intestinal stromal-cell conditioned
medium results in reduced expression of CD14 and decreased TNF  production, but has no
effect on phagocytic ability (188). These latter effects are dependent on TGF , produced by
chymase
+ c-kit
+ mast cells and IEC. Importantly, it appears that continuous exposure to
such factors may not be required, as intestinal m  conditioned in this way fail to re-express
receptors such as CD14 when cultured ex vivo even for long periods (188).42
IL-10 is another cytokine which could play an important role in desensitising
intestinal  m . Recent work in our laboratory shows that IL-10 is responsible for the
mucosal partial refractoriness of DCs to TLR stimulation (203), and colonic m  from IL-10
null mice have enhanced IL-12p70 production in response to stimulation with whole
bacteria and LPS (115, 195). There are several possible sources of IL-10 in the gut,
including m  themselves, which may produce IL-10 constitutively and after stimulation
with whole bacteria (115, 195). Alternatively, IL-10 may be provided by another cell
source, such as the TR-1-like regulatory T cell populations which are particularly abundant
in the intestine (220).
The possibility that IL-10 can affect the expression of a range of TLRs or responses
against a range of purified TLR agonists remains unexplored. However, IL-10 and TGF 
have a synergistic ability to downregulate TREM-1 and CD89 on monocytes in vitro (205),
and as discussed earlier, can reproduce TLR unresponsiveness in vitro (113). The ability of
IL-10 to inhibit NF B activity (114) could also potentially explain the failure to respond to
PMA and the lack of TREM expression which are features of intestinal m  (221). In
support of this role for IL-10, the inhibitory I B family members I BNS and Bcl-3 are
expressed constitutively by m  from the normal intestine, but are absent in colonic m 
from IL-10 KO mice which develop colitis (115). Whether NF B expression and/or its
nuclear translocation is downregulated in normal resident intestinal m  remains unclear.
Not all the features of intestinal m  can be explained by TGF  and/or IL-10,
particularly the lack of TLR expression, as neither of these mediators have been found to do43
this. Thus, additional conditioning factors would need to be considered. VIP has been
shown to downregulate iNOS, and pro-inflammatory cytokine and chemokine production
by m  in response to LPS (222-225), by inhibiting the reduction of cytoplasmic I B , thus
preventing nuclear translocation of NF B (226). One further group of molecules that
warrant  investigation  as  potential  mediators  of  intestinal  m   unresponsiveness  are
inhibitory receptors such as CD200R. Although the role of CD200R has not been examined
in the gut, it has recently been shown to be expressed at high levels by alveolar and small
intestinal m  and it is known to be important for regulating m  activation in tissues such as
the  eye  and  the  lung  (227-229).  How  CD200R  mediates  inhibition  of  myeloid  cell
activation is not completely understood, and unlike many immune inhibitory receptors,
CD200R lacks an ITIM motif in its cytoplasmic tail. However it has been reported that
CD200R-mediated  inhibition  of  mast  cell  degranulation  occurs  via  inhibition  of
Ras/MAPK pathways (230). However, CD200R agonists have been shown to inhibit IFN -,
but not LPS-mediated TNF  production in peritoneal m   (231), perhaps suggesting
CD200R may not be involved in the regulation of intestinal m  function.
Therefore, it seems that the regulation of m  function in the gut may reflect a
modulation of pro-inflammatory receptor function that biases the behaviour of these cells
toward a non-inflammatory phenotype. In this thesis, I assessed the level of expression of
TLRs and the level at which expression is regulated, as well as exploring what factors may
be involved in this regulation. This information is critical to assess the mechanisms
involved in gut m  homeostasis in the resting state, and may also provide information as to
how inflammatory responses are usually controlled to prevent inflammation.44
1.21 Role of intestinal macrophages in health and disease
Homeostatic Effects
As I have discussed, intestinal m  may be critical for maintaining homeostasis in
the face of continuous exposure to commensal bacteria, and this may be due to decreased
expression and/or function of activating receptors. In support of this, a breakdown in this
adapted response of m  is sufficient to provoke intestinal inflammation. It is well known
that mice lacking IL-10-producing regulatory T cells develop colitis spontaneously (232)
and the target for this IL-10 appears to be m , as intestinal inflammation also occurs in
mice with myeloid cell-specific deletion of STAT-3 (233), the transcription factor which
mediates IL-10R signalling. In the absence of IL-10 signalling, m  are induced to produce
pro-inflammatory mediators such as IL-12 or IL-23 which promote the generation of
pathogenic, Th1 or Th17 T cells (195). However, it is important to note that the STAT-3
signalling pathway is shared by other cytokines such as IL-6, which has been shown to be
important for epithelial homeostasis (234). Thus IL-10 hyperresponsiveness may not be the
only role for STAT-3 in homeostatic control of gut m  function.
Intestinal m  are not simply passive targets of IL-10-mediated regulation, as there is
accumulating evidence that they may also play an active role in controlling intestinal
immune responses. Small intestinal F4/80
+CD11b
+CD11c
dull m -like cells have recently
been shown to induce the differentiation of FoxP3
+ T regulatory cells in  vitro (235).45
Moreover, mice lacking F4/80 do not develop oral tolerance after feeding protein antigens,
and this is associated with defective induction of CD8
+ T regulatory cells (236). Several
findings also indicate that intestinal m  can prevent intestinal inflammatory responses in an
active manner. Depletion of intestinal mononuclear phagocytes by clodronate liposomes or
using transgenic mice expressing a drug-inducible suicide gene under the control of the c-
fms (CD115) promoter, exacerbates DSS-induced colitis, possibly secondary to increased
chemokine-induced neutrophil infiltration (237). Colonic LP m  from schistosome-infected
mice also transfer protection against DSS-induced colitis (186).
Somewhat paradoxically, the anti-inflammatory effects of m  appear to require
commensal bacteria-dependent TLR signalling, as deletion of TLRs or MyD88 in BM-
derived cells exacerbates experimental colitis (238, 239). In addition, colitis induced by
infection with Citrobacter rodentium, is exacerbated in TLR2 null mice; this is associated
with  impaired  barrier  function,  suggesting  that  TLR2  on  m   may  be  involved  in
maintaining mucosal integrity (240).  The  principal  protective  role  of  m   in  these
circumstances may be to modulate the epithelial cell response to injury, with m  in the
peri-cryptal stem cell niche contacting epithelial progenitors, and increasing the local
concentration of cytoprotective factors such as cyclooxygenase (COX)-2-dependent PGE2
(241). These TLR-mediated protective effects of m  may be additional and/or overlapping
with a similar protective role for TLR signalling in epithelial cells (242, 243). Collectively,
these  results  suggest  that  TLR  signalling  in  intestinal  m   is important for actively
maintaining  mucosal  function  and/or  repair.  Although  this  is  most  apparent  during
inflammation, it could be that m  play similar roles in the resting state given the high46
numbers of bacteria present. This is paradoxical in view of the usual lack of TLR on these
cells and therefore it may be that such functions occur before newly arrived m  lose TLR
expression. Alternatively, the small CD14
+ subset found in the resting state, which are
likely to express TLRs, may play this role. However, this needs to be examined by more
detailed phenotypic and functional analyses of m  subsets in the resting intestine.
Protective Immunity
In addition to their role in homeostasis, intestinal m  are also central to protective
immunity and immunopathology when pathogens or inflammation are present. As I have
noted, intestinal m  have constitutive phagocytic activities even in the healthy state (188).
Intestinal m  phagocytose and kill pathogenic Salmonella typhimurium and Escherichia
coli in vitro (188), supporting the view that they may contribute to clearance of pathogens.
Indeed animals infected with Shigella and treated with antagonistic anti-CD14 antibodies
display higher levels of bacterial invasion and more severe tissue damage (244). In addition
to their  ability to kill bacteria directly, the fact that intestinal m  undergo apoptosis when
infected by some intestinal bacteria such as Salmonella, facilitates uptake and presentation
of bacterial antigen by the local DCs (245). This process is known to be crucial for
protective immunity in such infections. In parallel, like IEC, intestinal m  secrete CCL20
(246), the ligand for CCR6. This chemokine receptor is needed to recruit DCs into
Salmonella-infected PP, a process which is essential for specific immunity to develop
(247).  Human  intestinal  m   have  also  been  shown  to  produce  the  neutrophil
chemoattractant, IL-8, in response to LPS, albeit at low levels (188).47
In addition to these anticipated roles in protective immunity during classical Th1-
type responses, there is also a striking increase in the number of colonic m  in mice
infected with the helminth parasite, Trichuris  muris, which peaks at the time of Th2-
mediated worm expulsion (248). During infection with helminths and related pathogens,
intestinal m  exhibit the functional and phenotypic features of the AAM discussed earlier.
Although much remains to be discovered about the functional role of AAM in the gut and
of the factors driving their differentiation, these studies highlight the plasticity of intestinal
m , and their ability to adapt appropriately to local conditions. Alternatively, these
observations may suggest the presence of different subsets of m  in the gut in different
situations. However, studies using models of intestinal infection in m -deficient animals
are needed to provide definitive answers to the role these cells play during infection.
Pathological roles of macrophages in intestinal inflammation
During human and experimental IBD, the intestinal mucosa is massively disrupted,
with compromised epithelial barrier function and secondary invasion by commensal
bacteria. This is accompanied by an intense influx of leukocytes, including monocyte-
derived m  (249), presumably attracted by chemokines released by epithelial cells and
other inflammatory cells in the mucosa (15, 193). There is increased production of m -
derived NADPH oxidase and of pro-inflammatory cytokines and chemokines such as
TNF ,  IL-6,  IL-18  and  IL-8 (250-253). Moreover, treatment with TNF   depleting
antibodies is beneficial in IBD patients (254, 255) and in reducing tumour development in a48
mouse model of chronic colitis associated with colon carcinogenesis (256). In addition,
non-T cell-derived TNF  is essential for development of disease in the CD4
+CD45RB
hi T
cell transfer model of colitis in mice (257). The intestinal inflammation found during
Citrobacter rodentium  infection  in  mice  is  also  dependent  on  the  characteristic  m 
products, TNF  and IL-12 (258). Depletion of m  ameliorates colitis in IL-10KO mice
(259) and the fact that DSS colitis can be induced in the absence of lymphocytes in NK
cell-deficient SCID mice (260, 261), suggests that m  may play a direct pathogenic role in
this model. Depletion of m   also reduces mucosal damage in a model of intestinal
ischaemia reperfusion injury (262). Thus it is clear that m  activation is a major feature of
intestinal inflammation and plays a central pathogenic role under these conditions.
M  may contribute to tissue pathology in a number of ways, including the release of
pro-inflammatory chemoattractants, such as IL-8, which induce further recruitment of
mononuclear and granulocytic cells. These effects will be enhanced by TNF -induced
upregulation  of  adhesion  molecules  on  local  blood  vessels  (61).  Moreover,  IL-12
production by activated m  drives IFN  production from T cells, which then increases
epithelial permeability (263, 264) and further m  activation (265). TNF  and IL-1 from
activated m  drive epithelial cell apoptosis and barrier dysfunction, vascular damage, and
necrosis  (266-268).  These  m -derived  mediators  also  drive  production  of  matrix
metalloproteinases (MMP) by fibroblasts, leading to the degradation of collagen and other
components of the extracellular matrix (269). Expression of tissue-degrading cathepsins by
intestinal m  is also seen in IBD (270), and increased release of aggressive metabolites49
such as NO, and oxygen radicals which attack and destroy DNA, all contribute further to
the m -dependent tissue damage (271).
Colonic m  in clinical colitis show increased expression of CD14, TLR2 and 4
(199, 201, 272), as well as of co-stimulatory molecules, scavenger receptors such as
CD163, pro-inflammatory cytokines, and greater respiratory burst activity (195, 273-278).
Most  available  evidence  suggests  that  these  inflammatory  cells  represent  a  distinct
population of m  which have recently arrived in the mucosa, rather than a change in the
resident population. As noted above, human blood monocytes are recruited very efficiently
into the inflamed gut (208). Moreover, blockade of chemokine receptors CCR2, CCR5 and
CXCR3 ameliorates DSS colitis by inhibiting the recruitment of inflammatory cells into the
mucosa  (279).  Thus  it  may  be  that  m -dependent intestinal inflammation requires
replacement of the environmentally conditioned resident population by newly recruited,
fully responsive monocyte-derived cells. These recently recruited monocytes may not be in
the local milieu for a long enough period of time for adaptive differentiation to occur, or it
may be that there are heightened levels of immunostimulatory signals, which overcome the
usual inhibitory processes.
Thus,  intestinal  m   behave  very  differently  during  inflammation  and  in
physiological conditions, but it is not known whether the inflammatory m  in pathology are
resident cells that have altered their behaviour, or if they are newly recruited cells. If the
latter  is  true,  it  may  be  possible  to  ameliorate  intestinal  inflammation  by  blocking
inflammatory monocyte infiltration into the gut. However if resident m  can alter their50
properties in situ, a greater understanding of the control of gut m  function must be gained
in order to manipulate m  behaviour in vivo.
1.22 Animal models of inflammatory bowel disease
Several animals models have been developed to study the pathogenesis of human
IBD. These include the administration of exogenous agents such as DSS, trinitrobenzene
sulphonic acid (TNBS) or oxazalone (280-282). Models of intestinal inflammation caused
by defects in epithelial barrier function include the DSS model, and the multi-drug resistant
(mdr)1a-deficient mouse model (283). In addition, disruption of genes such as IL-10, IL-
2/R , TGF  and TCR /  in mice results in the spontaneous development of intestinal
inflammation (232, 284-287), while transfer of CD4
+CD45RB
hi T cells drives colitis in
SCID or RAG-deficient recipients (288). Some of these models are caused by primary
abnormalities in immune function or regulation, while others are caused by defects in
barrier function and both specific and innate effector mechanisms are involved.
One model which is used widely is the DSS-induced model. DSS can be administered
in the drinking water and is thought to be directly toxic to the colonic epithelium (289),
inhibiting epithelial cell proliferation (290) and impairing barrier function and repair. This
allows the translocation of commensal bacteria into the underlying submucosa, driving a
rapid inflammatory response and ultimately loss of intestinal architecture, rectal bleeding,
diarrhoea and weight loss usually within 5 days. The inflammatory cell infiltrate in DSS
colitis, primarily m , neutrophils and eosinophils (291),  focuses  in  the  distal  colon,51
culminating  in  upregulation  of  pro-inflammatory  cytokines  (292),  oedema,  mucosal
ulceration, epithelial disruption and crypt necrosis.
That  bacterial invasion  may  be  critical  for  the  development of  DSS  colitis  is
supported by the fact that germ-free mice have reduced inflammation compared with their
conventionally reared counterparts (293). The TLR5 ligand, flagellin, can also exacerbate
DSS colitis (294). However, two other reports have indicated that DSS colitis can develop
under germ-free conditions (295, 296), indicating that the role of bacteria and/or their
products remains contentious. In addition, as discussed above, TLR-mediated recognition
of commensal bacteria by m  may be critical for maintaining intestinal homeostasis and
this has been shown to be required for restoring epithelial homeostasis and recovery from
DSS-induced injury (238).
DSS colitis has several advantages as a model. It can be induced in normal mice by a
readily available exogenous agent. It develops rapidly, follows a relatively well-defined
pattern and produces a consistent and characteristic form of colitis (281). In addition,
cessation of DSS administration allows recovery, thus providing a model for investigation
of tissue repair. In addition to this acute form of inflammation, cyclical administration of
DSS allows the induction of a more chronic form of colonic inflammation. Therefore this is
the model I decided to use to study intestinal m  during inflammation.
1.23 Modulation of macrophage inflammatory activity and immune responses by
helminths and their products52
One of the most potent examples of how intestinal pathogens can modulate the host
immune response is that of helminths. These produce chronic infection in most mammalian
species by virtue of their ability to inhibit host inflammation and tissue pathology. For
example, the presence of the gastrointestinal nematode, Nippostrongylus brasiliensis, is
prolonged  in  mice  previously  infected  with  Nematospiroides  dubius  (297),  and
Nippostrongylus infection can prolong the survival of kidney allografts in rats (298).
Remarkably, although the trematode, Schistosoma mansoni, activates Langerhans cells, it
also retains them in the epidermas via parasite-derived prostaglandin D2 (299), thus
inhibiting subsequent T cell activation. The ability of helminths and their products to
modulate immune responses has been shown to be associated with the development of
regulatory T cells and the production of IL-10 and/or TGF  (300, 301).
These immunomodulatory effects reflect a number of properties, but one of the most
important  is  the  secretion  of  regulatory  products.  One  such  molecule  is  ES-62,  a
phosphorylcholine (PC)-containing glycoprotein secreted by the rodent filarial nematode,
Acanthocheilonema  viteae (302). Homologues of ES-62 have also been discovered in
human filarial nematodes (303, 304). As ES-62 is a parasite-derived glycoprotein, it would
be predicted that the host’s immune system would recognise it as foreign. However, PC-
containing molecules of this kind persist for long periods in the bloodstream of patients
with filariasis (305).53
Recent studies have attempted to exploit the availability of purified ES-62 for use as a
therapeutic agent. As a result, ES-62 has been shown to suppress the development of
collagen-induced arthritis (CIA), a mouse model of rheumatoid arthritis, with associated
inhibition of collagen-specific TNF , IL-6, IFN  and IgG2a antibody production (306). In
parallel, ES-62 can suppress pro-inflammatory cytokine production by synovial cells from
human RA patients in vitro. Importantly, ES-62 has also been shown to suppress a Th2-like
response in a murine model of airway inflammation, where it reduced airway eosinophilia
and IL-4 production (307). The exact mechanism(s) of action of ES-62 is unclear, but it has
effects on a range of cell types including B cells, T cells, mast cells, DCs and m . PC is
considered the active moiety, as it mimics many of the effects of ES-62 on a range of cell
types (308-310) and it skews the antibody response to a T helper (Th2)-type, generating
anti-ES-62 IgG1 responses, but not IgG2a responses, via an IL-10-dependant mechanism
(311).
The effects of ES-62 on T cells have been demonstrated using Jurkat T cells, where it
suppressed anti-CD3 induced proliferation by modulating the activation of tyrosine kinases
such as ZAP-70, and so disrupting signalling downstream of the T cell receptor (305). ES-
62 has also been demonstrated to modulate a specific immune response to a heterologous
antigen, ovalbumin (OVA), in vivo, where ES-62-treated OVA-specific T cells produced
lower levels of IL-2 and proliferated less upon antigen rechallenge ex vivo (312). Pre-
exposure to ES-62 also suppressed antigen-specific production of IFN , IL-13 and IL-4,
and inhibited clonal expansion of transferred OVA-specific T cells, as well as reducing
follicular migration of T cells. In conventional B2 B cells, ES-62 inhibits B cell receptor54
(BCR)-driven proliferation by targeting key signalling events such as downregulating
protein kinase C (309, 313), and renders them hyporesponsive to stimulation (314). In
contrast, ES-62 activates peritoneal B1 B cells in vivo and induces them to produce the anti-
inflammatory cytokine, IL-10 (314). Together these findings indicate that ES-62 may
suppress conventional lymphocyte activation and proliferation, whilst enhancing the
production of anti-inflammatory mediators.
ES-62 induces a low and transient production of IL-12, IL-6 and TNF  by m  and
DCs, but these cells are then rendered refractory to stimulation by LPS and IFN  (315).
Furthermore, BM-DC and BMM derived ex vivo from BM precursors exposed to ES-62 in
vivo have an anti-inflammatory phenotype upon maturation, even in the presence of LPS,
indicating such effects are long-lived (310). ES-62 inhibits IL-12, IL-6 and TNF , but not
NO production by m  in response to stimulation (315), and decreases co-stimulatory
molecule expression by DCs, imparting on them a phenotype that drives the development
of Th2 cells (316). The low level cytokine induction and suppression of subsequent
activation by DCs and m  requires TLR4 and MyD88, perhaps reflecting the ability of ES-
62 to complex with TLR4 (317-319). ES-62 also prevents Fc  receptor I (Fc RI)-induced
release of allergic mediators from human mast cells and can prevent mast cell-dependent
hypersensitivity in the skin and airways (319).
By modulating pro-inflammatory cytokine production and co-stimulatory molecule
expression  by  APCs  in  response  to  bacterial  products,  as  well  as  lymphocyte
responsiveness and production of anti-inflammatory mediators, ES-62 can induce an anti-55
inflammatory/Th2-like response. However, the fact that ES-62 can suppress both a Th1-
and Th2-model of in vivo inflammation indicates that ES-62 does not simply reverse the
polarisation of the immune response, but rather acts to regulate inflammation in general and
suggests that it may induce a Th3/regulatory-type response, although this possibility has not
yet been formally determined. Because of this general ability to suppress a range of specific
and non-specific effector cells including m , one part of my project aimed to examine how
ES-62 might modulate m -dependent pathology seen in the murine model of DSS colitis.
1.24 Thesis Aims
Regulation  of  m   function  is  clearly  essential  for  intestinal  immunity  and
maintenance of homeostasis. Studies on humans thus far suggest that monocytes arrive in
the resting gut mucosa and differentiate into non-inflammatory cells to prevent aberrant
responses against innocuous commensal bacteria. However, although the existence of
different monocyte/m  subsets has been described in other tissues, this has not been studied
extensively during intestinal inflammation. Furthermore, although m  from the human
intestine have been shown to lack expression of activating receptors such as TLRs, there
are contradictory reports. In addition, all previous work has failed to look at a large number
of TLR family members, and has not compared expression both at the protein and mRNA
levels. There has also been a paucity of studies examining m  in the resting versus the
inflamed intestine in experimental models of colitis, where it is possible to conduct a more
detailed characterisation of these cells at different timepoints of disease in vivo. 56
The main aims of this thesis therefore, were to characterise murine colonic m  both
phenotypically and functionally under resting conditions. Using inbred mice under SPF
conditions allows steady-state in vivo experimentation, and there are mutant mice lacking
immunomodulatory genes available along with a multitude of immunological cell markers.
As  described  in  this  introductory  chapter,  small  intestinal  m   in humans are non-
inflammatory, but retain some of the hallmark functions of m , such as phagocytosis. If a
similar altered phenotype was observed in murine colonic m , I planned to explore the
reasons behind this hyporesponsiveness, by examining the expression of PRRs, particularly
TLRs, and assessing what factors might modulate their expression.
Furthermore,  by  employing  an  experimental  model  of  colitis  by  DSS
administration,  I  sought  to  investigate  how  m   from  the  inflamed  colon  differed
phenotypically  and  functionally  from  those  found  under  physiological  conditions.  I
anticipated that my studies would shed further light on the role m , and possibly distinct
m  subsets, play during the course of intestinal inflammation. Finally, I wished to use a
parasite-derived  immunomodulator,  which  has  known  effects  on  m -dependent
inflammation, to try to inhibit DSS colitis.
Chapter 3 of this thesis provides information about the phenotypic heterogeneity of
the  resident  m   population  in  the  normal  colon,  and  describes  how  these  differ
phenotypically and functionally from other m  populations in the body. These initial
studies suggested that colonic m  had many distinctive properties, and Chapter 4 describes
how I then explored the reasons for these unusual phenotypic and functional properties.57
Chapter 5 describes my studies of how intestinal m  may differ during inflammation, and
provides an insight into the role these cells play in the disease process. In Chapter 6, the
origin of the m  in the resting and inflamed gut is explored by investigating the differences
in cell turnover kinetics of distinct m  subsets, as well as differences in the expression of
chemokine receptors which could be involved in recruitment of these cells into the
intestine. Finally, Chapter 7 investigates the effects of ES-62, the immunomodulatory
parasite product that dampens pro-inflammatory m  functions, on the severity of intestinal
inflammation.58
Chapter 2
Materials and Methods59
2.1 Mice
C57Bl/6 (B6 mice) mice were obtained from Harlan Olac (Bicester, Oxfordshire)
and maintained on conventional diets under SPF conditions in the Central Research Facility
at the University of Glasgow, Scotland, until use. Ly5.1 mice were bred in the veterinary
research facility at the University of Glasgow. TLR2 (C57Bl/6 background) and IL-10
(BALB/c background) null mice were kindly provided by Professor F. Y. Liew (University
of Glasgow), and Professor Fiona Powrie (University of Oxford), respectively. All mice
were first used at 6 to 8 weeks of age, unless stated otherwise.
2.2 Generation of bone marrow-derived dendritic cells and macrophages
Bone marrow (BM) was flushed out of the femurs and tibias of adult C57Bl/6 mice
in RPMI 1640 (Gibco BRL, Paisley, Scotland) using a syringe and a 21G needle. The BM
cells were passed through Nitex mesh (Cadisch and Sons, London, UK) into a sterile 15ml
tube and counted using a haemocytometer and phase contrast microscope. To generate BM-
derived dendritic cells (BMDC), 1ml of cells were transferred into 90cm Petri dishes
(Sterilin, UK) at 3x10
6  cells/ml  with  8ml  complete  medium  (RPMI  1640,  2mM  L-
glutamine, 100µg/ml penicillin, 100µg/ml streptomycin, 1.25µg/ml Fungizone, and 10%
foetal calf serum (FCS)- all Gibco), and 10% GM-CSF (supernatant from the X-63 cell
line) and incubated at 37
oC in 5% CO2. After 3 and 6 days, the medium was supplemented
with 5ml complete medium and 0.5ml GM-CSF. The BM cells were used after 7-9 days
and were typically >75% CD11c
+ as assessed by flow cytometry. For generation of BM-60
derived macrophages (BMM), BM cells were obtained as above and cultured in complete
medium RPMI 1640 containing 1mM sodium pyruvate and 20% FCS- all Gibco), and 20%
M-CSF (supernatant from the L929 cell line) at 37
oC in 5% CO2. After 3 days, the medium
was supplemented with 5ml complete medium and 20% M-CSF and the cells were used on
day 6 of culture. Non-adherent cells were removed by washing with RPMI 1640 and the
adherent cells were then collected by adding ice cold 1mM EDTA/PBS for 5 minutes and
then displacing them with cell scrapers (Costar). The purity of BM cells was assessed by
flow cytometry and was typically >90% F4/80
 positive.
2.3 Activation of macrophages and DC in vitro
In most cases, single cell suspensions were resuspended at a final concentration of
5x10
5/ml cells and cultured overnight in 1ml aliquots in ultra low attachment, 24-well
tissue culture plates (Costar). For macrophages purified from the colonic lamina propria,
cells were plated at 1x10
5 cells/200µl. Cells were incubated either in medium alone, or with
varying concentrations of lipopolysaccharide (LPS) from Salmonella typhimurium (Sigma),
10µg/ml flagellin (Autogen Bioclear UK Ltd), 25µg/ml polyinosinic-polycytidylic acid
(poly I:C) (Sigma), 1µg/ml bacterial lipoprotein (BLP; Pam3CSK4) (Alexis Biochemicals,
Axxora LTD, Nottingham, UK), 3.2µg/ml CpG oligonucleotide (ODN 1826) (Autogen
Bioclear UK Ltd), 10µg/ml MDP (Invivogen), 100nM retinoic acid (Sigma), 40ng/ml IL-4
(Biosource International, CA, USA) or 10
-8M vasoactive intestinal peptide  (Calbiochem,
San Diego, CA) at 37
oC in 5% CO2. In some experiments, macrophages were cultured with
TLR ligands together with 100U/ml recombinant mouse interferon   (IFN ) (BioSource).61
2.4 Isolation of resting peritoneal macrophages (PEC m )
To  obtain  resting  peritoneal  macrophages,  euthanased  mice  were  injected
intraperitoneally with 10ml 1mM ice cold EDTA/PBS and peritoneal exudate cells (PEC)
were retrieved by harvesting the solution from the peritoneal cavity.
2.5 Adoptive transfer of macrophages
BMM from Ly5.1 mice were derived as described above, counted and washed twice
in RPMI. 1x10
6 cells in a volume of 0.2ml RPMI were injected intravenously into congenic
C57Bl/6 Ly5.2 recipients. Organs were then harvested from recipient mice at various
timepoints and transferred cells were identified by expression of Ly5.1 by flow cytometry.
2.6 Isolation of lymph node and spleen cells
Lymph nodes and spleens from C57Bl/6 mice were removed, mashed through
100µm  Nitex  mesh  in  5ml  RPMI  1640,  washed  twice,  counted  by  phase  contrast
microscopy and resuspended at 1x10
6 cells/ml. For spleen cell preparations, red blood cells
were removed by resuspending the cell pellet with 1ml Red Blood Cell Lysing Buffer
Hybri-Max (Sigma), gently mixing for 1 minute, washing, and resuspending in complete
medium.62
2.7 Isolation of colonic lamina propria cells
The large intestines of mice were removed and placed on paper towels soaked in
PBS (Gibco), and the fat was removed. The intestines were opened longitudinally, washed
in Hank’s balanced salt solution (HBSS) 2% FCS, and cut into 0.5cm sections. The tissue
was then shaken vigorously in 10 ml HBSS 2% FCS, and the supernatant was discarded. To
remove the epithelial layer, 10 ml fresh CMF HBSS (Gibco) containing 2mM EDTA
(Sigma) was then added, the tube placed in a shaking water bath for 15mins at 37
oC, before
being shaken vigorously and the supernatant discarded. 10ml fresh CMF HBSS was then
added, the tube shaken again and the supernatant discarded. After a second incubation in
2mM EDTA CMF HBSS, the washes were repeated and the remaining tissue was digested
with pre-warmed 1.25mg/ml collagenase D (Roche), 0.85mg/ml collagenase V (Sigma),
1mg  dispase  (Gibco),  and  30U/ml  DNase  (Roche  Diagnostics  GmbH,  Mannheim,
Germany) in complete medium for 30-40 minutes in a shaking water bath at 37
0C until
complete digestion of the tissue. At the start of the incubation, and at 5-10 minute intervals
thereafter, the tube was shaken vigorously and finally the supernatant (containing lamina
propria  cells)  was  removed  and  passed  through  Nitex.  The  cells  were  spun  down,
resuspended in complete medium, passed through Nitex, counted, and kept on ice until use.
In Chapter 7 a different method for the isolation of colonic LP cells was used and
details are as follows: The tissue was placed in 50ml tubes containing 20ml PBS and
incubated in a shaker for 15mins at 37
oC, shaken gently, and the supernatant discarded. 20
ml fresh CMF HBSS containing 2mM EDTA was then added, the tube placed in the shaker63
for 15mins at 37
oC, and the supernatant discarded. 10-15ml CMF HBSS (pre-warmed to
37
oC) was added and the tube was shaken vigorously and the supernatant discarded. This
step was repeated once before a further 20-30ml EDTA-containing CMF HBSS was added
and the tube returned to the shaker for 15mins at 37
oC. The last three steps were repeated
four times. The excess EDTA was removed by washing the tissue with 30-40ml sterile PBS
and  the  remaining  tissue  was  digested  with  100U/ml  collagenase  Type  VIII  from
Clostridium histolyticum (Sigma), 30U/ml Dnase (Roche Diagnostics GmbH, Mannheim,
Germany) and 20% FCS (Gibco) in CMF HBSS for three 45min incubations at 37
oC.
Following each incubation, the tube was shaken gently and the supernatant (containing the
cells) removed and passed through Nitex. The cells were spun down, resuspended in CMF
HBSS, passed through Nitex, counted, and kept on ice until use.
2.8 Purification of macrophages from the colon and peritoneum
Macrophages were purified from the colon lamina propria (LP) and peritoneal cell
preparations by positive selection, by MACS according to the manufacturer’s instructions.
Single cell suspensions of colonic LP and peritoneal cells were prepared, resuspended at
1x10
6 cells/100µl PBS 2% FCS and incubated for 15mins at 4
0C with purified anti-mouse
CD16/CD32 (Fc block), and then with an allophycocyanin (APC)-conjugated antibody to
F4/80 (Caltag Laboratories) (1 in 100 dilution) for 30 minutes at 4
0C. The cells were then
washed in ice cold sterile MACS medium (PBS, 2 mM EDTA, 0.5% BSA (Sigma) in PBS)
and incubated with 20µl anti-APC microbeads (Miltenyi Biotec, UK) per 10
7 total cells for
15 minutes at 4
0C in the dark. Cells were then washed and resuspended in 500µl MACS64
buffer and passed through a Large Cell Separation column, and then an MS column
previously equilibrated by adding 3 aliquots of 500µl of cold MACS medium in the
magnetic field of a MACS separator. Unbound cells were then eluted by washing with three
aliquots of 500µl MACS buffer, the column removed from the magnetic field and the
positively selected cells eluted. The purity of the cells was assessed by flow cytometry and
was typically >90% F4/80 positive. In some experiments, macrophages were positively
selected on the FACS Aria (BD Biosciences). Cells were incubated with Fc block and
APC-conjugated anti-F4/80 antibody for 30mins as before, passed through Nitex and
10x10
6cells/ml run through the FACS aria. Isotype controls were used to set up gates for
positive APC staining and purity was typically >90% F4/80 positive.
2.9 Flow Cytometry
200µl aliquots containing 1x10
5 cells in 12 x 75mm polystyrene tubes (Falcon BD,
Oxford, UK) were washed in FACS buffer (PBS/2mM EDTA/2% FCS) and incubated for
15mins at 4
0C in the dark with purified anti-mouse CD16/CD32 (Fc block) to prevent non-
specific binding via Fc receptors. The cells were washed and incubated with the appropriate
fluorochrome-conjugated or biotinylated primary antibodies for 30mins at 4
oC in the dark.
All antibodies and appropriate isotype controls were used at a 1:200 dilution and their
details are shown in Table 2.1. The cells were washed and resuspended in FACS buffer
and, where appropriate, biotinylated antibodies were detected by fluorochrome-conjugated
streptavidin for a further 15 minutes. Cells were then washed in FACS buffer and analysed
on a FACScalibur Flow Cytometer (Becton Dickinson) using Flowjo software. In most65
experiments, 10ng/ml propidium iodide (PI; Sigma-Aldrich) or 0.25µg/sample 7-amino-
actinomycin D (7-AAD; BD Pharmingen) was added to the cells a few minutes before
acquisition to enable exclusion of dead cells from the analyses. FSC (forward scatter) and
SSC (side scatter) were adjusted to allow gating on relevant cell types. Unstained samples
were  used  as  controls  for  auto-fluorescence.  For  detection  of  chemokine  receptor
expression, cells were incubated with 10% mouse serum (Biosera) in FACS buffer for 1
hour at 4
0C, and washed three times with FACS buffer. Cells were then incubated with
5µg/ml monoclonal antibody against CCR2 (MC-21) (a kind gift from Professor M. Mack,
Dept of Internal Medicine, Ludwig-Maximilians University, Munich, Germany) or isotype
control (purified rat IgG2b) for 1 hour at 4
oC, followed by three washes. Staining with
biotinylated polyclonal anti-rat Ig (BD Pharmingen) for 30 minutes at 4
oC was then
conducted, followed by a further set of three washes. Cells were then incubated with SA-
FITC for 15-20 minutes at 4
oC, and then washed. Cells were then incubated with Fc block
and stained for other markers as before.
2.10 Assessment of endocytosis by macrophages
To measure endocytosis, single cell suspensions were resuspended at a final
concentration of 5x10
5/ml cells and cultured in 1ml aliquots in ultra low attachment, 24-
well tissue culture plates (Costar) with 1mg/ml FITC-dextran (MW 4400; Sigma) at either
4
0C or 37
0C in 5% CO2. The cells were harvested and the uptake of FITC-dextran by
F4/80
+ m  was assessed by flow cytometry. The results are expressed as the  MFI (mean66
fluorescent intensity calculated by subtracting the MFI obtained after incubation at 4
0C
from that obtained at 37
0C).
2.11 Assessment of phagocytosis by macrophages
Cells were plated out at 2.5x10
5/ml (BMM and purified PEC m ) and 1x10
6/ml
(unpurified colonic m ) in complete medium and allowed to adhere to a 24-well plate for 2
hours at 37
0C in 5% CO2. The adherent cells were washed once with complete medium and
then  incubated with  2.5x10
7  3µm FITC-conjugated zymosan bioparticles (Molecular
Probes/Invitrogen) per well for 1.5hr at 37
0C in 5% CO2, or at 4
oC in the presence of 5mM
NaN3. Phagocytosis was arrested by washing twice in ice cold PBS/5mM NaN3 and the
phagocytic index was measured by calculating the percentage of F4/80
+ cells that were
FITC positive under both conditions. Phagocytosis was also visualised using fluorescence
microscopy (see below) and here, FACS-sorted F4/80
+ colonic m  were used.
2.12 Fluorescence microscopy
To image phagocytosis of fluorescent bioparticles, single cell fluorescence staining
was  conducted  using  FACS-sorted  F4/80
+  colonic  macrophages.  1ml  aliquots  of
5x10
5cells/ml complete medium
 were added to a circular glass cover slip (VWR) placed in
a flat bottomed 24-well plate. After culture, the cells were fixed with 4% formaldehyde in
PBS for 15 mins, washed with PBS for 5 mins and then incubated with permeabilisation
buffer (2% FCS, 2mM EDTA, 0.1% saponin in PBS), to allow phalloidin to enter the cell67
for 5 mins. The samples were then blocked in PBS/3% BSA/0.1% saponin for 10 mins,
before  0.12µg/ml Phalloidin-Alexa Fluor® 594 (Molecular Probes,  Eugene, OR)  in
PBS/3% BSA/0.1% saponin was added for 30 mins. The cells were then washed three
times in TNT buffer (100mM TRIZMA base, 150mM NaCl and 0.05% Tween-20 in dH2O)
for 3 mins, and incubated with 300nM DAPI (Invitrogen) for 5 mins. After 3 more washes
in TNT buffer, the cover slips were removed and allowed to air dry for 5 mins before being
mounted in Vectashield (Vector Labs), sealed with clear nail varnish and stored in the dark
at  4
oC. Samples were kept in a darkened, humidified chamber at room temperature
throughout staining, and all staining steps were performed in PBS/3% BSA/0.1% saponin.
Fluorescent images were captured using a 3CCD colour vision camera (regulated by a
Hamamatsu and Orbit controller) and analysed using Openlab version 3.0.9 digital imaging
programme (Improvision, Warwick, UK) connected to an Olympus BX50 microscope.
2.13 Immunofluorescence microscopy of tissue sections
To visualise F4/80
+ macrophages in the intestine, colons were removed, opened
longitudinally and rolled around a needle, before being snap-frozen in liquid nitrogen in
O.C.T. (Tissue-Tek, Sakura Finetek Europe) and stored at -80
oC. 6µm sections were cut on
a cryostat (ThermoShandon, Cheshire, UK) and stored in a sealed box at -20
oC until used
for immunofluorescence staining. All staining was performed in a darkened, humidified
chamber at room temperature. The sections were fixed in acetone for 10 mins, re-hydrated
in PBS for 15min and endogenous peroxidase activity was quenched with three washes of
PBS/0.1%  sodium  azide/3%  hydrogen  peroxide  for  10  min.  Avidin  (Avidin/Biotin68
Blocking Kit, Vector Laboratories, Burlingame, CA) was then added in PBS/3% BSA for
12min to block endogenous biotin, followed by another wash in PBS for 5min. Biotin was
then added in PBS/3% BSA for 12min to block excess avidin, followed by another wash
step.  The  sections  were  then  incubated  with  1:200  biotinylated  anti-F4/80  (Caltag
Laboratories) for 30 min, washed in TNT buffer and then incubated with streptavidin-HRP
(diluted 1:100 in PBS/3% BSA) for 25 min. After washing, the sections were treated with
biotinylated-tyramide (diluted 1:50 in amplification buffer; Perkin Elmer Life Sciences,
Boston, MA) for 10 min, washed and then incubated with Streptavidin-Alexa Fluor 647 (2
mg/ml in PBS/3% BSA; Molecular Probes) for 30 min. Details of the tyramide-based
amplification are provided in Fig 2.1. The sections were then washed twice in TNT buffer,
permeabilised in PBS/3% BSA/0.1% Triton X for 30min to optimise staining, washed, and
then incubated with 300nM DAPI for 5min. After three washes in TNT buffer, the sections
were air dried for 10 mins before being mounted in Vectashield and a coverslip sealed onto
the slide with clear nail varnish and stored in the dark at 4
0C. Fluorescent images were
captured as before.
2.14 Induction of DSS colitis
To induce acute colitis, C57Bl/6 mice received between 1.5 and 2.5% dextran
sodium sulphate (DSS) salt (reagent grade; MW 36,000-50,000 kDa; MP Biomedicals,
Ohio), ad libitum in sterile drinking water for up to 10 days. For the induction of chronic
DSS colitis, animals were given three cycles of DSS for 5-7 days, with rest periods of 7
days on sterile water alone in between. Water intake was measured daily for each group and69
the volume of water consumed per day per mouse was estimated by dividing the total
volume of water consumed per cage by the number of animals in the cage. Mice were also
monitored daily for weight change, diarrhoea and rectal bleeding, and the clinical score for
each mouse calculated based on the presence of weight loss, rectal bleeding and diarrhoea
was as follows:
Points Weight Loss (%) Rectal bleeding Diarrhoea
0 no weight loss no blood well-formed pellet
1 1-5
2 5-10 blood stain around anus pasty/semi-formed pellets
that did not adhere to anus
3 10-20
4 >20 gross bleeding diarrhoea that adhered to
anus
Total clinical disease score was determined by adding all the individual scores.
Immediately following sacrifice, each colon length was measured to assess the extent of
colon shortening. Furthermore, H&E histology of colons was conducted to assess the extent
of tissue pathology.
2.15 Colon organ culture
1cm segments of the proximal and distal colon were opened longitudinally, washed
in PBS supplemented with penicillin and streptomycin and cultured in 24-well flat bottom
culture plates in 1ml RPMI 1640 medium supplemented with penicillin and streptomycin
for 24 hours at 37
0C in 5% CO2. The cultures were then centrifuged at 13,000 rpm and the
supernatants were harvested and stored at –20
0C until assayed.70
2.16 Detection of intracellular cytokines and TLRs by flow cytometry
Aliquots containing 1x10
5 cells were washed in FACS buffer and intracellular
expression of cytokines or TLR determined after permeabilisation. Cells were washed and
incubated in 200 l for 15mins at 4
oC with purified anti-mouse CD16/CD32 (Fc block),
washed, and then stained for cell surface markers for 30mins at 4
oC. After washing, the
cells were fixed in 1% formaldehyde (BDH Laboratory Supplies, Poole, England) in PBS
for 10 minutes at 4
oC. Cells were then washed with FACS buffer and permeabilised with
Perm stain (PBS/0.1% NaN3 (Sigma)/0.1% BSA/1% FCS/0.1% saponin (Sigma)) and
stained with Fc block as before, to block antibody binding to intracellular Fc receptors. The
cells were washed in Perm wash (PBS/0.1% NaN3/0.1% BSA/0.2% FCS/0.1% saponin)
and fluorochrome-conjugated anti-cytokine or anti-TLR antibodies, or appropriate isotype
controls, were added at 1:200 dilutions in Perm stain at 4
oC in the dark for 30mins. The
cells were washed and resuspended in FACS buffer for flow cytometric analysis as before.
To allow dead cells to be excluded, cells were treated with 0.11µg/ml ethidium monoazide
(EMA; Molecular Probes) prior to permeabilisation. Cells were incubated with EMA in the
dark at RT for 10 minutes, and then exposed to bright light for a further 10 minutes. To
detect intracellular cytokines, cells were first activated in vitro by TLR ligands in the
presence of 10µg/ml Brefeldin A (Sigma) for 4.5 hours before being washed and stained.
2.17 Assessment of cell turnover in vivo71
Mice were injected i.p. with 1mg BrdU (BD Pharmingen) in PBS, culled 24hrs
later, and the uptake of BrdU by cells isolated from the colon was measured using the BrdU
Flow Kit (BD Pharmingen) as per the manufacturer’s instructions. Briefly, dead cells were
stained with EMA and cell surface antigen expression as described above. The cells were
then  fixed  and  permeablised  twice,  and  treated  with  30µg  DNase/tube  to  expose
incorporated BrdU, and stained with FITC-conjugated anti-BrdU monoclonal antibody.
Mice receiving long-term BrdU administration were injected with 1mg BrdU i.p. and then
0.8mg/ml BrdU was administered in the drinking water and this was kept in the dark and
changed daily. Cells in cell division were detected by permeabilisation and staining with
PE-conjugated anti-Ki-67 antigen (BD Pharmingen), using the same method as used for the
detection of intracellular cytokines.
2.18 Measurement of cytokine production by ELISA
Supernatants from cell cultures were harvested and stored at –20
oC until cytokine
production was quantified using sandwich ELISA. Immulon-4 plates (Corning) were coated
with anti-IL-1 (4 g/ml, R&D systems), anti-IL-6 (1 g/ml, BD Biosciences), anti-IL-12p70
(2 g/ml, BD Biosciences) or anti-TNF  (2 g/ml, BD Biosciences) detection antibodies
overnight at 4
0C. The plates were washed 3 times with PBS/0.05% Tween (Sigma), before
being blocked with PBS/10% FCS for 1hr at 37
0C. The plates were then washed and
incubated with serially diluted recombinant cytokine standards (BD Biosciences), and with
undiluted  samples  for  2hrs  at  37
0C, before being washed again and incubated with
biotinylated anti-IL-1 (300ng/ml, R&D systems), anti-IL-6 (1 g/ml, BD Biosciences), anti-72
IL-12p40/70 (1 g/ml, BD Biosciences), anti-TNF  (2 g/ml, BD Biosciences) for 1hr at
37
0C. Plates were washed and incubated with extravidin-peroxidase (1/1000, Sigma) for
1hr. Finally, following washing, the plates were developed using tetramethylbenzidine
(TMB) substrate (KPL) and read at 630nm on a MRX II microplate plate reader (Dynex).
2.19 Measurement of chemokine and cytokine production by Luminex
Supernatants from cell cultures were harvested and stored at –20
0C until assayed.
CCL2, CCL3, CCL4, CCL5, CCL19, CXCL10, FGF, GM-CSF, IFN , IL-1 , IL-1 , IL-2,
IL-4,  IL-5,  IL-6,  IL-10,  IL-12  (p40  and  p70),  IL-13,  IL-17,  KC,  MIG,  and  TNF 
production was quantified simultaneously using the Multiplex Bead Assay (Biosource, UK)
according to the manufacturer’s instructions. This assay uses specific antibodies for the
cytokines/chemokines of interest that have been coated on the surface of fluorescently
encoded microspheres. Each microsphere is labelled with a distinct fluorophore, which can
be recognised individually by the scanner. The microspheres were incubated in a 96-well
Luminex plate with test samples or standards and, after washing, biotinylated detection
antibodies are added for 1hr. After incubation the plate was washed and the samples
incubated  with  SA-PE  for  30mins.  After  washing,  the  fluorescence  bound  to  the
microspheres was analysed using a Luminex XMAP system with the intensity of the
fluorescence being directly proportional to the concentration of cytokine/chemokine
present.
2.20 RNA extraction73
Single  cell  suspensions  were  washed  twice  with  PBS,  spun  down  and  the
supernatant was completely removed by aspiration. RNA was then isolated using the
RNeasy  Micro  or  Mini  Kit  (Qiagen)  (depending  on  cell  number)  according  to  the
manufacturer’s instructions. Contaminating genomic DNA was removed on-column during
RNA isolation with the RNase-free DNase Set (Qiagen) according to the manufacturer’s
instructions and the amounts of RNA were measured using the BioPhotometer (Eppendorf,
Germany). Samples were stored at –80
0C until use.
2.21 cDNA synthesis from RNA
cDNA was reverse transcribed from DNAse-treated RNA using Superscript II
Reverse Transcriptase (RT) (Invitrogen) according to the manufacturer’s instructions.
Briefly, 5 g of RNA, 1 l Oligo(dT)12-18 (500 g/ml; Invitrogen), 1 l dNTP mix (25mM
each;  Invitrogen),  and  nuclease-free  water  (Ambion)  were  added  to  a  nuclease-free
microcentrifuge tube (ABgene, Surrey, UK) in a total volume of 12 l. The mixture was
heated at 65
0C for 5 minutes, and then quick-chilled on ice. 4 l 5X First-Strand Buffer
(Invitrogen), 2 l 0.1M DTT (Invitrogen), and 1 l RNaseOUT (40 units/ml; Invitrogen)
were added and incubated at 42
0C for 2 minutes. 1 l (200 units) Superscript II RT was then
added and the RNA was reverse transcribed at 42
0C for 50 minutes. Superscript II RT was
then inactivated by heating at 70
0C for 15 minutes. Negative control samples were
incubated in the absence of Superscript II, and cDNA was stored at –20
0C until use.74
2.22 End-product polymerase chain reaction (PCR)
A 1 in 5 dilution of cDNA was added to a 1.1x Pre-Aliquoted ReddyMix PCR
Master  Mix,  50 l  Reaction  (ABgene)  and  used  according  to  the  manufacturer’s
instructions. Briefly, 2 l cDNA (1 in 5 dilution), 2 l of forward and reverse primer mix
(primers at a final concentration of 1µM), and 1 l nuclease-free water was added to the
Master Mix. For end-product PCR, amplications were performed using the FTGENE5D
thermocycler (Techne (Cambridge) Ltd; Duxford, Cambridge, UK) using the primers,
annealing temperatures and cycle numbers shown in Table 2.2.
The PCR products were then run on a 2% agarose gel (2% ultra pure agarose
electrophoresis grade (Gibco) containing 800ng/ml ethidium bromide (Sigma)) in 0.5x TBE
buffer in a Horizon 58 (Life Technologies) gel tank. Gels were run at 90V powered by a
Pharmacia Electrophoresis Constant Power Supply ECPS 3000/150, and analysed using the
Gel Logic 200 imaging system.
2.23 Quantitative/real time PCR
Relative levels of mRNA were quantified by RT-PCR using the Taqman system,
using the primers and fluorogenic probes described in Table 2.3. RNA was extracted and
cDNA synthesised as before, and cDNA was used at a 1 in 5 dilution. The fluorogenic
probes contained a reporter dye (FAM) covalently attached at the 5’ end and a quencher
dye (TAMRA) covalently attached at the 3’ end. PCR reactions were performed in a 96-75
well plate in the ABI-prism 7900 Sequence Detector (ABI). PCR reactions contained 2µl of
the diluted cDNA sample, 10µl Taqman Real-Time PCR Universal Master Mix (2X)
(ABI), 900nM of each primer, 200nM of the detection probe, and nuclease-free water
(Ambion) to a total volume of 20µl. Each PCR reaction was performed in triplicate using
the following cycle conditions: 2 min at 50
0C and 10 min at 94
0C, followed by a total of 40
cycles of 15 sec at 94
0C and 1 min at 60
0C. Threshold cycle (CT) values were calculated
and data analysed using RQ Manager software (ABI) and samples were normalised by
reference to the hypoxyanthine-guanine phosphoribosyltransferase (HPRT) as a reporter
gene.
2.24 Statistical Analysis
Results are shown as means ± 1 standard deviation unless stated otherwise, and
groups were compared using a Student’s two tailed unpaired t-test. When comparing
multiple groups, a one-way ANOVA was performed (see specific figure legends for
repeated measures examples), followed by a Bonferroni multiple comparison test. Values
of p<0.05 were considered to be statistically significant. The daily rate of macrophage
turnover in Chapter 6 was calculated using linear regression analysis, where best-fit values
were used to calculate the difference between slopes.76
Antigen
CD4
CD8
CD11b
CD11c
CD40
B220
CD80
CD86
CD103
CD115
Class II MHC (I-A
b)
Ly6G
F4/80
Gr-1
TLR2
TLR3
TLR4
TLR9
TNF 
Ly5.1
Ki-67
Clone
GK1.5
53-6.7
M1/70
HL3
3/23
RA3-6B2
16-10A1
GL1
M290
AFS98
25-9-17
1A8
BM8
RB6-8C5
6C2
TLR3.7
MTS510
M9.D6
MP6-XT22
A20
B56
Isotype
Rat IgG2b
Rat IgG2a
Rat IgG2b
Hamster IgG1
Rat IgG2a
Rat IgG2a
Hamster IgG2a
Rat IgG2a
Rat IgG2a
Rat IgG2a
Murine IgG2a
Rat IgG2a
Rat IgG2b
Rat IgG2b
Rat IgG2b
Murine IgG1
Rat IgG2a
Rat IgG2a
Rat IgG1
Murine IgG2a
Murine IgG1
Company
BD Pharmingen
BD Pharmingen
BD Pharmingen
BD Pharmingen
BD Pharmingen
BD Pharmingen
BD Pharmingen
BD Pharmingen
BD Pharmingen
Ebioscience
BD Pharmingen
BD Pharmingen
Caltag Laboratories
BD Pharmingen
Ebioscience
Ebioscience
Ebioscience
Ebioscience
BD Pharmingen
BD Pharmingen
BD Pharmingen
Table 2.1 Monoclonal antibodies and isotype controls used for flow cytometry 
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Figure 2.1 Tyramide signal amplification
Tyramide signal amplification is an enzyme-based system that enhances fluorescent
labelling of target proteins. Biotinylated anti-mouse F4/80 or isotype control antibody is
used to detect the target protein. Steptavidin-horse radish peroxidase (SA-HRP) then binds
via biotin and catalyses the oxidation of tyramide and deposition of multiple biotin labels in
the immediate vicinity of the target protein. Biotin labels were then detected by SA-Alexa
Fluor 647.S
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Chapter 3
Phenotypic and functional characterisation of macrophages in the resting colonic
lamina propria82
Introduction
Tissue m  play a number of essential roles in the body. In addition to characteristic
inflammatory functions, such as phagocytosis and the production of pro-inflammatory
cytokines and chemokines, and presentation of antigen to T cells, m  are also involved in
tissue homeostasis, tissue repair, and in clearing senescent cells. M  are abundant in the
healthy human intestine, but unlike most other m  populations in the body, human small
intestinal m  fail to produce pro-inflammatory cytokines in response to a variety of stimuli,
despite exhibiting some other properties normally associated with m , such as phagocytic
and bactericidal functions (188). As a result, it has been suggested that m  may play a
central role in regulating intestinal immune responses, possibly by maintaining the level of
the resident microbiota without initiating inflammation. In addition, local m  are thought to
play a critical role in protection from intestinal infection and contribute to inflammation
during IBD. It is not known how these functions of intestinal m  are controlled, nor has the
biology of intestinal m   been compared directly in inflamed or resting colon under
controlled experimental conditions. In addition, their relationship to other myeloid cells is
not well characterised, partly because of difficulties in isolating them, nor is it known if m 
in the colon constitute a homogeneous population, or if there are individual subsets with
distinct functions. No detailed experiments of this kind have been carried out using murine
colonic m , and so the aim of my project was to examine the properties of resident and
inflammatory murine colonic m .83
To characterise this population, I explored their location, phenotype, function and
lineage in normal mice, before investigating their properties in mice with colitis. In this
chapter, I examined the location of m  in the resting intestine in situ, before establishing
and optimising methods for isolating them by tissue digestion. Having established an
appropriate method, I used it to conduct a detailed phenotypic analysis of resident myeloid
cells in the normal mouse colon, before comparing their functions with those of m  in other
tissues, by examining the production of pro-inflammatory cytokines and chemokines,
upregulation of co-stimulatory molecules, endocytosis and phagocytosis.84
3.1 Macrophages are abundant in the healthy mouse colon
As others have shown in mice and humans, the distal colon of healthy C57Bl/6 mice
contained large numbers of m  as defined by the expression of F4/80 (Fig 3.1). These m 
were found mainly in the LP underlying the epithelium. In order to conduct a more detailed
characterisation, I established methods for isolating and phenotyping these cells. I first
compared several previously described isolation methods to assess which method provided
the best and most consistent yields with optimal cell viability. The percentage of F4/80
+
cells obtained and the levels of F4/80 expression varied markedly depending on the
isolation method, and many techniques produced wide variations from experiment to
experiment. As a result of these experiments, I finally devised a protocol using two types of
collagenase, dispase and DNase which allowed effective tissue digestion with high cell
viability, and good yields of F4/80-expressing cells which were consistent from experiment
to experiment. This protocol is described in the Materials and Methods on p62.
Using this procedure, a heterogeneous population of cells was obtained with varying
FSC and SSC properties (Fig 3.2a) and to begin my phenotypic analyses, I selected a gate
which was likely to include as wide a range of mononuclear cells as possible. Dead cells
were excluded on the basis of 7-AAD uptake (Fig 3.2b) and approximately 40% of the
resulting, live-gated cells expressed CD45, indicating they were of haematopoietic origin
(Fig 3.2c). 10.9±1.9% of the total cells expressed the F4/80 marker of mature mouse m 
(Fig 3.2d). The CD45
- population was not characterised, but is likely to contain stromal,
epithelial and other mesenchymal cells.85
To gain an insight into the phenotypic heterogeneity of the resident m  population, I
first assessed the expression of myeloid cell markers, which display different patterns of
expression in m  and DC subsets in mice. Classical tissue m  are F4/80
+CD11b
+CD11c
-,
while mature classical DCs express high levels of CD11c and although some co-express
CD11b, they are usually negative for the expression of F4/80 (43).
Throughout  my  experiments  I  used  BMM  as  a  representative  population  of
immature m , whilst resident PEC m  were used as representative mature tissue m . As
expected and as reported by others, 86.2±6.8% and 96.9±1.6% of BMM and PEC m 
respectively had the F4/80
+CD11b
+CD11c
- phenotype of conventional m 
 (Fig 3.3a). Just
over 10% of F4/80
+ BMM expressed the DC marker, CD11c, but this was absent from PEC
m  (Fig 3.3a).
As expected, the majority (75.5±6.3%) of F4/80
+ cells in the colon expressed
CD11b; this was at slightly higher levels than BMM, but much less than that of PEC m 
(Fig 3.3b). 35.4±10.5% of colonic F4/80
+ cells also expressed the DC marker, CD11c (Fig
3.3+3.4b). These ‘triple positive’ cells expressed slightly lower levels of CD11c compared
with the small (2-3%) subset of CD11c
+ F4/80
- cells present in the same preparations,
which are likely to be conventional DCs (Fig 3.4b). There was also a smaller population
(22.4±8.5%) of F4/80
+ CD11b
- cells, most of which were also negative for CD11c (Figure
3.4a), as well as some F4/80
-CD11b
+ cells. 48.6±4.2% of these latter cells were also
CD11c
+, and are also likely to be a subset of DCs. Together these data show that there are a86
number  of  different  myeloid  cell  populations  present  in  the  healthy  intestine,  with
overlapping characteristics of m  and DCs.
Despite their phenotypic heterogeneity, there was little evidence of morphological
heterogeneity among colonic F4/80
+ subsets, as revealed by FSC/SSC analysis, apart from
the presence of cells with slightly higher granularity among the F4/80
+CD11b
+CD11c
-
subset (Fig 3.5b). These may include eosinophils, which have been shown to express these
markers at low levels (48). I carried out a more detailed morphological comparison of
BMM, PEC m  and FACS-sorted F4/80
+ colonic m . After being allowed to adhere to
plastic for 2 hrs, the cells were stained with DAPI and with phalloidin to visualise actin
filaments. All these F4/80
+ populations were large cells with several cytoplasmic processes,
typical of the m  lineage and no granular cells were evident (Fig 3.6). In general, PEC m 
and colonic m  exhibited a rounder morphology with more numerous processes compared
with BMM, which seemed to exhibit a more irregular morphology.
 Due to the fact the F4/80
+CD11c
+ cells expressed lower levels of CD11c compared
with F4/80
-CD11c
+ classical DCs, I considered the total F4/80
+ population of myeloid cells
as colonic m  for the remainder of this thesis. However, the possible relationships between
these different subsets is discussed in detail in Chapter 8.
I next attempted to characterise colonic m  in more detail by examining the
expression of other myeloid cell markers. Consistent with previous findings (320), all
BMM expressed high levels of intracellular CD68 (macrosialin), a scavenger receptor for87
oxidised low density lipoprotein (LDL), and also had moderate surface expression of this
marker (Fig 3.7a). In contrast, although PEC m  and colonic m  both expressed CD68
intracellularly, this was at a lower level than that of BMM and a small population of
colonic F4/80
+ cells lacked any expression of intracellular CD68. A proportion of this
population were larger than the cells present within the F4/80
+CD68
+ population (Fig 3.7b).
There  was  little  or  no  surface  expression  of  CD68  by  PEC  m  or colonic m . As
anticipated, the immature m  found in BM expressed uniformly high levels of the M-CSF
receptor,  CSF1R  (CD115)  and  this  was  also  present  on  all  PEC  m ,  although  at
substantially lower levels (Fig 3.7c). In contrast, colonic F4/80
+ cells expressed little or no
CD115.
Almost all BMM and PEC m  were negative for the granulocytic marker Gr-1, but
around 30% of F4/80
+ cells in the colon expressed this marker (Fig 3.8). There was also a
substantial population of F4/80
- Gr-1
+ cells in the colon, indicating the presence of a
granulocytic cell population in the colon under resting conditions (Fig 3.8b).
Finally, I examined the expression of CD103, the  E 7 integrin expressed on a high
proportion of small intestinal DCs and on CD11c
hi class II MHC
hi DCs in the colon (321).
A small proportion (2%) of total colonic LP cells expressed CD103, of which ~27%
expressed CD11c, indicating that these may be DCs, an idea supported by the fact they
were F4/80
-. The remainder of the CD103
+ cells lacked CD11c expression and had the
FSC/SSC properties of lymphocytes, consistent with the known expression of CD103 by
mucosal T cells (322). None of the F4/80
+ cells in the colon expressed CD103, although a88
small subset of BMM and around 40% of PEC m  expressed low levels of this marker (Fig
3.9a+b).
3.2 Expression of class II MHC and co-stimulatory molecules by colonic m 
Previous findings have shown that human colonic m  express low levels of co-
stimulatory molecules and class II MHC (187). To examine if this also applied to m  in the
mouse colon, F4/80
+ cells were analysed for the expression of CD40, CD80, CD86 and
class II MHC. Freshly isolated BMM expressed only low levels of CD80 and CD86 and no
CD40, while PEC m  expressed higher levels of these markers, especially CD40 and CD86
(Fig 3.10). Both BMM and PEC m  lacked expression of class II MHC. In stark contrast,
the vast majority of colonic m  expressed high levels of class II MHC, but had little or no
CD40, CD80 or CD86.
When the different subsets of colonic F4/80
+ cells were analysed for the expression
of class II MHC, almost all of the F4/80
+CD11b
- population were found to lack class II
expression, whereas >80% of the F4/80
+CD11b
+ subset expressed high levels of class II
MHC  (Fig  3.11a).  Expression  of  class  II  MHC  by  the  F4/80
-CD11b
+  cells  was
heterogeneous,  with  most  of  these  being  negative  and  the  remainder  expressing
intermediate levels. All the F4/80
+CD11b
+CD11c
int cells expressed high levels of class II
MHC, whereas most of the cells with the phenotype of classical DCs (F4/80
-CD11c
+)
expressed intermediate levels (Fig 3.11b). The F4/80
+CD11c
- cells show bimodal levels of
class II MHC, with ~60% being class II MHC
hi and the others being class II MHC
-.89
These findings allow three major phenotypic subsets of F4/80
+ cells to be identified
in the colon of normal mice (Fig 3.12). These are an F4/80
+CD11b
+CD11c
int subset, an
F4/80
+CD11b
+CD11c
- subset and a smaller F4/80
+CD11b
-CD11c
- subset. These subsets are
not present in PEC m  or BMM and are therefore unique to the intestine. In addition, there
is an F4/80
- CD11c
hi population, some of which expressed CD11b or CD103, which are
likely to be classical mucosal DCs.
3.3 Upregulation of co-stimulatory molecules and class II MHC following activation of
m 
I next set out to analyse the functional capabilities of colonic m . To do this, I first
purified F4/80
+ cells from PEC and colon by MACS or FACS and examined the expression
of CD40, CD80, CD86 and class II MHC after stimulation with LPS ± IFN  for 8hrs. 40-
50% of freshly isolated PEC were F4/80
+, and following MACS or FACS-based positive
selection (see figure legends), this was increased to almost 95% (Fig 3.13b). F4/80
+ m 
constituted approximately 10% of the total colonic LP cell population and following
MACS or FACS-based purification, this was increased to >90% F4/80
+ (Fig 3.13c). Cells
harvested from in-vitro BM cultures were >90% F4/80
+ and therefore further purification
was not necessary (Fig 3.13a).
As described above, freshly harvested BMM expressed low levels of CD40, CD80,
CD86 and class II MHC, and these markers were increased slightly following stimulation90
with LPS, especially CD40 and CD86 (Fig 3.14). These changes were even greater after
stimulation with LPS + IFN . As described above, freshly isolated PEC m  expressed
intermediate levels of all the co-stimulatory molecules, but failed to express any class II
MHC. None of these molecules were upregulated markedly on PEC m  by stimulation with
LPS (Fig 3.14a-d). However, CD86 expression by PEC m  was upregulated after culture in
medium alone. The addition of IFN  induced a greater upregulation of co-stimulatory
molecules by PEC m  in the presence of LPS, but there was still little effect on class II
MHC expression. As shown earlier, freshly isolated colonic m  expressed high levels of
class II MHC, but failed to express any co-stimulatory molecules. Stimulation with LPS or
with LPS + IFN  had no effect on CD40, CD80 and CD86 expression by colonic m , while
class II MHC expression was slightly lower than on unstimulated colonic m  (Fig 3.14).
3.4 Production of pro-inflammatory cytokines and chemokines following stimulation
of colonic macrophages
To examine if murine colonic m  produced pro-inflammatory cytokines in a similar
manner to other m  populations in the body, BMM and MACS-purified PEC or colonic m 
were examined for the production of TNF , IL-6 and IL-1  after culture in medium, LPS,
IFN , or LPS + IFN . Following stimulation with LPS or IFN  alone, BMM produced
moderate amounts of TNF  as assessed by ELISA and there was a synergistic effect of
adding both stimuli together (Fig 3.15a). Although TNF  production by PEC m  was
lower compared with BMM under all conditions, a similar pattern was observed, with some
production in response to either stimulus alone and higher levels being observed following91
culture with LPS + IFN  together (Fig 3.15a). In stark contrast, colonic m  produced little
or no TNF  under any conditions (Fig 3.15a).
A similar pattern was seen for the production of IL-6, with BMM producing high
levels of cytokine following culture with LPS + IFN  together, and some IL-6 after
stimulation with LPS alone (Fig 3.15b). Unlike TNF  production, treatment of BMM with
IFN  alone failed to induce production of IL-6. Treatment of PEC m  with either LPS or
IFN  alone induced moderate production of IL-6, which was increased further after culture
with LPS + IFN . As with TNF  production, colonic m  produced negligible levels of IL-6
under any conditions (Fig 3.15b). Consistent with previous findings (323, 324),  the
production of IL-12p70 by BMM was only observed following stimulation with both LPS +
IFN  (Fig 3.15c). However, PEC m  produced small but detectable amounts of IL-12p70 in
response to either IFN  alone, or with LPS + IFN .  Again  there  was  no  IL-12p70
production by colonic m  under any conditions (Fig 3.15c).
I next set out to confirm and extend the findings of functional unresponsiveness of
colonic m  by examining this at the cellular level using intracellular cytokine analysis and
by employing additional innate stimuli. These included the TLR2 ligand, BLP, and MDP,
the  ligand  for  intracellular  NOD2.  As  before,  LPS  stimulation  of  BMM  induced
intracellular TNF  production, with 95.6% of cells being positive for this cytokine (Fig
3.16). BLP and MDP also induced significant TNF  production when used alone (67.7%
and 51.4% cells positive, respectively) and this was increased further when these agents
were used together (82.6%). In contrast to BMM and consistent with the results shown in92
Fig 3.15, colonic m  were almost completely unresponsive to LPS, with only 3.2%
expressing TNF , compared with 3.7% when cultured in medium alone. A somewhat
larger proportion of colonic m  expressed TNF  following culture with the TLR2 ligand,
BLP (14.2%), but very few cells responded to MDP (6.5%) and these numbers were
markedly less than BMM under the same conditions (Fig 3.16).
Next I compared the ability of BMM, PEC m  and colonic m  to produce pro-
inflammatory chemokines, namely IP-10 (CXCL10), KC (CXCL1), MCP-1 (CCL2), MIG
(CXCL9), MIP-1  (CCL3), RANTES (CCL5) and MIP-1  (CCL4) following stimulation
with LPS, IFN  or LPS + IFN  using Luminex. Stimulation of BMM and PEC m  with
LPS, IFN , or LPS + IFN  induced similar levels of IP-10, although these were always
lower for PEC m  compared with BMM (Fig 3.17a). Overall, BMM produced little or no
KC except after culture with LPS alone, whereas PEC m  produced higher amounts of KC
under all conditions, especially when LPS was used alone (Fig 3.17b). High levels of MCP-
1 production by BMM and even higher levels by PEC m   were  observed  following
stimulation with LPS alone, or with LPS + IFN  (Fig 3.17c). In contrast, treatment with
IFN  and LPS + IFN  induced higher levels of MIG production by BMM than by PEC m 
(Fig 3.17d). High levels of MIP-1  production by BMM and PEC m  were induced by
treatment with LPS alone (Fig 3.18a). Both BMM and PEC m  produced RANTES after
treatment with LPS or with LPS + IFN , with higher levels seen with BMM (Fig 3.18b).
High levels of MIP-1  production were induced by treatment of BMM and PEC m  with
LPS alone (Fig 3.18c). In stark contrast to these active responses by BMM and PEC m ,93
colonic m  produced virtually none of the inflammatory chemokines under any condition,
the only exception being that some KC was found after stimulation with LPS (Fig 3.17b).
Together these results show that colonic m  are virtually incapable of producing
pro-inflammatory mediators in response to any stimulus.
3.5 Endocytic and phagocytic activities of colonic macrophages
As human small intestinal m  have been shown to phagocytose FITC-labelled beads
despite their impaired functional responses in other respects, I assessed the abilities of
murine colonic m  to phagocytose particles and to endocytose soluble material. I first
optimised an endocytosis assay using FITC-dextran and BMM. BMM were cultured with
FITC-labelled dextran for 10, 30 or 60 minutes either at 37
0C in 5% CO2, or at 4
0C as a
negative control. As shown in Fig 3.19a, temperature-dependent dextran uptake increased
with time, with active endocytosis peaking at 60mins and there was little background
uptake at 4
0C at this time. Therefore I used this timepoint in subsequent experiments. Under
these conditions, BMM endocytosed higher levels of dextran than PEC m , which showed
little activity above background (MFI = 136.2±9.1 vs 8.3±0.8; Fig 3.19b). Colonic m 
exhibited significantly higher endocytic activity than PEC m , but lower than that of BMM
(MFI = 35.8±2.4).
I next assessed the ability of colonic m  to phagocytose FITC-labelled zymosan-
coated bioparticles in vitro. Zymosan is a yeast cell wall component that can interact with94
TLR2 and TLR6, thus providing an innate immune stimulus to trigger phagocytic activity
(70). As negative controls for passive adhesion of particles, I used non-phagocytic L929
cells and m  cultured at 4
oC in the presence of sodium azide. As shown in Fig 3.20,
42.9±0.7% and 52.8±2.5% of BMM and PEC m  phagocytosed particles in a temperature-
dependent manner, respectively. Colonic m  exhibited similar levels of phagocytosis to
BMM, but these were slightly but significantly lower than that of PEC m  (37.3±3.9%). I
confirmed these findings at the cellular level by fluorescence microscopy and as shown in
Fig 3.21, BMM, PEC m  and colonic m , but not L929 cells, all internalised large numbers
of zymosan-coated beads per cell, indicating that all three populations exhibit avid
phagocytic capacity.
Summary
In this chapter, I demonstrated that there is a large resident population of F4/80
+ m 
in  the  colon  that  is  located  predominantly  in  the  LP  just  under  the  epithelium.
Comprehensive phenotypic analysis of this myeloid cell population in the healthy colon
demonstrated that it is extremely heterogeneous, with three main subsets being identifiable
on the basis of the expression of F4/80, CD11b and CD11c. There were also cells with the
phenotype of classical DCs and such heterogeneity was not apparent in other tissues such as
BM or the resting peritoneum. In addition, unlike other m , the majority of resident colonic
m  expressed high levels of class II MHC, particularly the F4/80
+CD11b
+ subset, some of
which also expressed intermediate levels of CD11c. However colonic m  failed to express95
the CD40, CD80 or CD86 co-stimulatory molecules, even after stimulation with LPS
and/or IFN , which induced increased expression of these molecules on other m .
Furthermore, following culture with a variety of innate immune stimuli, colonic m 
failed to produce the pro-inflammatory mediators, TNF , IL-6, IL-12p70, IP-10, MCP-1,
MIG, MIP-1 , RANTES and MIP-1  in response to stimuli which induced their secretion
by the other m . However, colonic m  produced low levels of the chemokine, KC, in
response to LPS, and a small proportion retained responsiveness to the TLR2 ligand, BLP.
In contrast to their inability to produce pro-inflammatory mediators, colonic m  showed
strong endocytic and phagocytic activities, both hallmark functions of m . Together these
results support the idea that resident colonic m  are in a partially refractory state, with
some functions being retained, but other, pro-inflammatory functions being impaired. This
suggests that colonic m  may be able to take up and possibly clear commensal bacteria, but
importantly, this does not result in upregulation of co-stimulatory molecules or the
production of pro-inflammatory cytokines and chemokines. Therefore I next sought to
investigate how these pro-inflammatory functions were regulated in colonic m  and these
studies are described in the next chapter.  96 
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Figure 3.1 Immunofluorescence staining of macrophages in the healthy intestine  
 
Immunofluorescence images show staining for F4/80
+ m  (red) (A) and the nuclear stain 
DAPI (blue), and staining with isotype control antibody (B), on sections of distal colon 
from C57Bl/6 mice.  
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Figure 3.2 Colonic LP cell preparations from mice
A) Colons pooled from 3 C57Bl/6 mice were digested and the cell
preparations were examined for granularity (SSC) and size (FSC). B) To
assess dead cell content, gated cells were stained with 7-AAD and the
resulting, live-gated cells were assessed for the expression of CD45 (C)
and F4/80 (D). Numbers in plots represent percentages of the total
population and the results are representative of at least five experiments.
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97Figure 3.3 Comparative expression of myeloid markers by m  populations
F4/80
+ BMM, PEC m  and colonic m  from C57Bl/6 mice were assessed for
the expression of F4/80, CD11b and CD11c by flow cytometry (A). Results are
shown as the mean percentage of F4/80
+cells in each subset ± SD for 3
individual mice. B) Histograms show marker expression on live-gated F4/80
+
cells, and the filled histograms represent staining with isotype controls. Data are
representative of at least three individual experiments.
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Figure 3.4 Populations of myeloid cells in the colonic LP of mice
Colons pooled from 3 C57Bl/6 mice were digested and live-gated LP cells were
analysed for the expression of F4/80, CD11b and CD11c by flow cytometry. The
histograms are gated on live cells and show the levels of CD11c (A), CD11b (B)
and F4/80 (C) expression by the different subsets. The filled histograms represent
staining with isotype controls. Numbers in quadrants represent percentages of the
total population and the plots are representative of at least four individual
experiments.
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Figure 3.5 FSC/SSC properties of colonic F4/80
+ subsets
F4/80
+ colonic LP cells pooled from 3 C57Bl/6 mice were analysed for the
expression of CD11b and CD11c by flow cytometry. A representative dot plot
of CD11b and CD11c expression by live-gated F4/80
+ cells (A) and FSC and
SSC properties of the individual subsets are shown (B). Results are
representative of at least three experiments.
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Figure 3.6 Immunofluorescence images of purified macrophages 
 
Representative images of adherent BMM (A), and MACS-purified F4/80
+ PEC m  (B) and 
colonic F4/80
+ m  (C). Cells were allowed to adhere for 2.5hrs and stained for phalloidin 
(red) and DAPI, before being visualised by fluorescence microscopy. CD115
CD68
Colonic LP m 
PEC m 
BMM
Figure 3.7 Expression of myeloid markers by different macrophage
populations
Live-gated F4/80
+ BMM, PEC m  and colonic m  from C57Bl/6 mice were
assessed for the expression of surface (blue) and cytoplasmic (red) CD68 (A).
The FSC/SSC properties of colonic F4/80
+CD68
- and F4/80
+CD68
+ cells are
shown in B. C) Surface expression of CD115 by live-gated F4/80
+ BMM, PEC
m  and colonic m . Histograms are gated on live F4/80
+cells and filled
histograms represent staining with isotype controls.
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Figure 3.8 Expression of Gr-1 by different macrophage populations
Live-gated F4/80
+ BMM, PEC and colonic LP cells from C57Bl/6 mice were
analysed for the expression of F4/80 and Gr-1 by flow cytometry. A) The histogram
shows the level of Gr-1 expression on live-gated F4/80
+ cells and the shaded
histogram represents staining with the isotype control. B) Representative dot plot of
colonic LP cells stained for F4/80 and Gr-1 expression. Numbers in quadrants
represent percentages of the total population. C) Results shown are the mean
percentage ± SD of F4/80
+ cells positive for Gr-1 expression for 3 mice/group. A
one-way ANOVA revealed a significant difference, F(2,6) = 32.38, p<0.001. Planned
comparisons which were significant showed that a higher proportion of colonic m 
expressed Gr-1 compared with BMM (**p<0.01) and PEC m  (   p<0.001),
Bonferroni's multiple comparison test.
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Figure 3.9 Expression of CD103 by different macrophage populations
Live-gated BMM (A), PEC m  (B) and colonic m  (C) were assessed for the
expression of CD103 by flow cytometry. Numbers in quadrants represent
percentages of the total population. D) Expression of CD11c by colonic
CD103
+ cells and FSC/SSC properties of CD103
+CD11c
- and
CD103
+CD11c
+cells (E). The shaded histogram represents staining with the
isotype control antibody.
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Figure 3.10 Expression of class II MHC and co-stimulatory molecules by
resting m  populations
BMM, PEC m  and colonic m  pooled from 3 C57Bl/6 mice were assessed
for the expression of CD40 (A), CD80 (B), CD86 (C) and class II MHC (D)
by flow cytometry. The histograms show the expression of each marker by
live-gated F4/80
+ cells, with the filled histograms representing staining with
isotype control antibodies.
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Figure 3.11 Expression of class II MHC by colonic m  subsets
Colonic LP cells pooled from 3 C57Bl/6 mice were analysed for the
expression of F4/80, class II MHC, and CD11b (A) or CD11c (B). Numbers
in quadrants represent percentages of the total population. Histograms show
the levels of class II MHC expression by live-gated subsets, with the shaded
histograms representing staining with the isotype control antibody. Data are
representative of at least two individual experiments.
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Figure 3.12 F4/80
+ subsets in the resting colonic LP 
 
A summary of the F4/80
+ subsets present in the resting colon and their relative contribution 
to the total F4/80
+ population. F4/80
Figure 3.13 Purification of macrophage populations by positive
selection
Following isolation, PEC and colonic LP cells were positively selected
for F4/80
+cells by MACS or FACS-based purification (see figure
legends). The purity of fresh BMM (A), or PEC m  (B) and colonic m 
(C) was assessed before and after purification. Histograms show the
percentage of F4/80
+ cells among total live-gated cells.
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108Figure 3.14 Expression of co-stimulatory molecules and class II MHC by
different macrophage populations after stimulation
BMM, MACS-purified F4/80
+ PEC m  and FACS-purified F4/80
+ colonic m 
were cultured in medium, 1µg/ml LPS or LPS + IFN  for 8hrs and assessed for
the expression of CD40, CD80, CD86 and class II MHC by flow cytometry.
Histograms show marker expression by live-gated F4/80
+ cells and shaded
histograms represent staining with isotype control antibodies.
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109Figure 3.15 Production of pro-inflammatory cytokines by macrophages
BMM and MACS-purified F4/80
+ m  from PEC and colon were cultured for 20hrs
in medium, 1µg/ml LPS, 100U/ml IFN  or LPS and IFN , and TNF  (A), IL-6 (B)
and IL-12p70 (C) production was assessed by ELISA. Results are shown as the
mean cytokine concentration ± SD for 3 replicates/group. One-way ANOVAs to
compare cells within each condition revealed significant differences, Bonferroni's
multiple comparison test. ns=not significant; **p<0.01; ***p<0.001.
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110Figure 3.16 Production of TNF  by BMM and colonic m  in response to
LPS, BLP and MDP
BMM and colonic LP cells were cultured in medium, 1µg/ml LPS, 1µg/ml
BLP, 10µg/ml MDP or BLP + MDP together for 4.5hrs in the presence of
Brefeldin-A and intracellular TNF  expression was assessed by flow
cytometry. Histograms are gated on live F4/80
+cells and the shaded
histograms represent staining with isotype control antibody. The numbers
represent the percentages of F4/80
+ cells that were positive for TNF .
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Figure 3.17 Production of pro-inflammatory chemokines by m 
populations
BMM and MACS-purified F4/80
+ m  from PEC or colon were cultured
for 20hrs in medium, 1µg/ml LPS, 100U/ml IFN  or LPS + IFN . The
production of IP-10 (A), KC (B), MCP-1 (C) and MIG (D) was assessed
by Luminex and the results are pg/ml for single cultures.
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Figure 3.18 Production of pro-inflammatory chemokines by m 
populations
BMM and MACS-purified F4/80
+ m  from PEC or colon were
cultured for 20hrs in medium, 1µg/ml LPS, 100U/ml IFN  or LPS +
IFN . The production of MIP-1  (A), RANTES (B) and MIP-1  (C)
was assessed by Luminex and the results are pg/ml for single cultures.
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113Figure 3.19 Endocytic activity of macrophage populations
A) BMM were assessed for their capacity to endocytose 1mg/ml FITC dextran (Mol.
Wt 40kD) after culture at 4
0C or 37
0C. Results are shown as the MFI ± SD for FITC at
the different points at 4
0C or 37
0C. A two-way ANOVA (repeated measures) revealed
a significant difference, F(2,2)=378.1, p<0.0001. B) BMM, PEC and colonic LP
cells were incubated with 1mg/ml FITC-dextran for 60 minutes and the uptake by
live-gated F4/80
+cells was assessed by flow cytometry. The results are expressed as
the differences in mean fluorescence intensity ( MFI) calculated by subtracting the
uptake at 4
0C from that at 37
0C for 3 replicates/group. A one-way ANOVA revealed a
significant difference, F(2,6)=458.1, p<0.0001. Planned comparisons which were
significant showed that a higher proportion of BMM were FITC
+ compared with PEC
m  and colonic m  (***p<0.01), and colonic m  compared with PEC m 
(**p<0.01), Bonferroni's multiple comparison test.
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114Figure 3.20 Phagocytosis activity of macrophage populations
L929 cells, BMM, PEC and colon LP cells were cultured for 1.5hr with
FITC-labelled, zymosan-coated beads at 37
0C or 4
0C in azide as a control and
enumerated by flow cytometry. Results shown are the mean percentage ± SD of
live-gated F4/80
+ cells positive for FITC for 3 replicates/group. Results are
representative of two individual experiments. A one-way ANOVA revealed a
significant difference, F(3,8) = 249.1, p<0.0001. Planned comparisons which were
significant showed that a higher proportion of PEC m  were FITC
+ compared with
BMM (**p<0.01) and colonic m  (***p<0.001), Bonferroni's multiple
comparison test.
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Figure 3.21 Phagocytic activity of macrophage populations 
 
L929 cells, BMM, adherance-separated PEC m  and FACS-purified F4/80
+ colonic m  
were  assessed  for  their  capacity  to  phagocytose  FITC-labelled,  zymosan-coated  beads 
(green). Cells were incubated with beads for 1.5hr, washed, and stained for phalloidin (red) 
and DAPI (blue) using fluorescence microscopy. Results shown are representative images 
of the four cell populations.  117
Chapter 4
Mechanisms of TLR hyporesponsiveness in colonic macrophages118
Introduction
The  experiments  in  Chapter  3  showed  that  colonic  m   exhibit  a  profound
refractoriness to stimulation and one way this could occur is via modulation of PRR
expression. In humans, m  from resting intestine have been shown to lack expression of
TLR1-5 mRNA, but there are also contradictory reports suggesting that these cells can
express TLR mRNA. In addition, similar analysis has not been carried out in the murine
system and it is unclear at what level expression of TLR may be modulated. Thus to try and
understand the cause of the hyporesponsiveness of resident colonic m , in this Chapter I
assessed the expression of TLR protein compared with m  from other tissues in the body,
and tried to determine at what level this was regulated in colonic m . In addition, I have
explored whether intestinal m  arrive in the mucosa as fully responsive cells which are
subsequently conditioned to become refractory by the local microenvironment, and have
investigated some of the possible factors involved.119
4.1 Expression of surface and intracellular TLR proteins by colonic macrophages
To examine the cause of the hyporesponsiveness of intestinal m , I first carried out
a detailed study of the expression of a number of TLR proteins using BMM and PEC m  as
examples  of  m   from other sites. 93.0±1.2%  of  BMM  and  98.6±1.4%  of  PEC  m 
expressed surface TLR2, but in stark contrast, only 29.1±5.1% of colonic m  expressed
TLR2 (Fig 4.1a). Similarly, 94.1±4.8% of BMM and 95.8±1.4% of PEC m  expressed
surface TLR4, but only 3.4±0.9% of colonic m  were positive for TLR4 (Fig 4.1c). As
expected from their predominantly intracellular expression, all three m  populations failed
to express TLR3 or TLR9 on the cell surface (Fig 4.1b+d), with the exception of a small
number of colonic m  that expressed surface TLR3 (Fig 4.1b).
I  next  assessed  the  expression  of  intracellular  TLR3  and  TLR9  after  cell
permeabilisation and found that 94.4±2.4% of BMM and 97.3±1.2% of PEC m  expressed
TLR3,  while  94.2±5.9%  of  BMM  and  97.7±1.8%  of  PEC  m   expressed  TLR9
intracellularly (Fig 4.2a+b). In contrast, virtually no colonic m  were positive for either
TLR3 or 9 (0.3±0.4% and 0.8±0.7%, respectively; Fig 4.2a+b). I also examined whether
TLR2 and TLR4 could be detected intracellularly in colonic m , as this could indicate there
was active internalisation of the receptors. However, the proportions of colonic m 
expressing TLR2 or TLR4 after permeabilisation were identical to those found when
surface TLR was examined, suggesting there had not been significant internalisation of
these proteins (Fig 4.2c+d). As expected, virtually all BMM and PEC m  were positive for120
TLR2 and TLR4 after permeabilisation, but it was not possible to determine whether this
was surface or intracellular (data not shown).
One trivial explanation for the apparent failure of colonic m  to express TLR could
be the enzymatic digestion protocol used to obtain colonic m . To investigate this, I treated
PEC m  in exactly the same way as colonic m  before examining them for the expression
of F4/80, CD11b, CD11c, TLR and class II MHC by flow cytometry. Enzyme treatment
did not affect the expression of any of the myeloid markers by PEC m  (Fig 4.3a), nor did
it affect the expression of surface TLR2, TLR4 or class II MHC (Fig 4.3b+c). Thus, the
unusual phenotype of colonic m  appears to be an inherent property of these cells and is
not due to the extraction protocol.
4.2 Expression of TLR2 by phenotypic subsets of colonic macrophages
As I had found there were different phenotypic subsets of F4/80
+ cells, I thought it
important to investigate whether the expression of TLR differed between the subsets I had
identified on the basis of F4/80, CD11b and CD11c expression. Due to the fact that a
proportion of colonic m  retained expression of TLR2, I analysed its expression by
different subsets. As shown in Fig 4.4a, ~57% of the cells with the F4/80
+CD11b
+
phenotype typical of classical m   expressed TLR2 at intermediate levels. A higher
proportion of the F4/80
+CD11c
int cells expressed TLR2 (~73%), whereas the F4/80
+CD11c
-
cells showed biphasic expression of TLR2 (Fig 4.4b). Only 23% of the F4/80
-CD11c
+ cells
with the phenotype of classical DC, and ~20% of CD11b
+ F4/80
- cells expressed TLR2 (Fig121
4.4a+b. In contrast, almost none (5%) of the F4/80
+CD11b
- cells expressed TLR2 (Fig
4.4a).
To investigate how TLR expression might correlate with maturation status of the
cells, I examined the presence of class II MHC on TLR2
+ and TLR2
- subsets, reasoning
that immature m  would express class II MHC at low levels. Interestingly, almost all
(>93%) TLR2-expressing m  in the resting colon expressed high levels of class II MHC,
whereas only ~38% of TLR2
- m  expressed class II MHC (Fig 4.4c).
4.3 Expression of mRNA for TLRs by colonic macrophages
Given the low TLR protein expression by colonic m , I sought to investigate the
level at which TLR protein expression is regulated. Therefore, I first performed end-
product PCR analysis to assess if colonic m  expressed mRNA for TLR1-9. BMM and
PEC m  expressed mRNA for all these TLRs, although TLR5 expression appeared low,
especially in PEC m  (Fig 4.5). Colonic m  showed a similar pattern of TLR expression,
with the possible exception of TLR7, which was virtually absent (Fig 4.5). All three m 
populations appeared not to express mRNA for TLR8, but I could not draw conclusions
from this analysis, as I was unable to obtain a positive control for this TLR, despite using a
variety of different cell populations and three different TLR8 primer pairs. Overall, these
results demonstrated that colonic m  expressed mRNA for most TLRs, and I went on to
explore this further by quantitative PCR analysis using Taqman.122
I used this approach to assess the levels of TLR2, 4 and 9 as representative surface
and intracellular TLRs. BMM expressed high levels of mRNA for all these TLRs, and PEC
m  also expressed mRNA for these receptors, but at lower levels (Fig 4.6). In contrast,
colonic m  expressed virtually no TLR2 or TLR4 mRNA, but expressed high levels of
TLR9 mRNA, similar to those found in BMM. Thus TLR expression appears to be
regulated at the transcriptional level for TLR2 and TLR4, but at a post-transcriptional level
for TLR9.
4.4 Irreversible downregulation of TLR expression by colonic macrophages
As discussed earlier, intestinal m  are thought to arise from the monocyte pool
which normally expresses a wide range of TLRs, suggesting that downregulation of these
receptors might occur following their arrival in the gut microenvironment. To assess
whether constant exposure to immunomodulatory factors in the local microenvironment is
necessary for maintenance of this altered phenotype, F4/80
+ colonic m  were FACS-sorted,
cultured overnight in medium and examined for TLR expression. As shown in Fig 4.7a,
there was no upregulation of TLR2 expression on colonic m  after overnight culture, with
only a small proportion (~11%) being TLR2 positive in these experiments. Similarly,
colonic m  failed to re-express TLR4 following 24hr culture in medium (Fig 4.7b). Thus
TLR expression cannot be re-induced on colonic m  simply by short-term withdrawal from
the local environment of the gut.
4.5 Effects of TLR ligands on TLR expression and responsiveness by macrophages123
Given the large numbers of commensal bacteria located in the colon which express
numerous TLR ligands, I hypothesised that constant ligation of TLRs by these materials
might result in downregulation of the cognate or non-cognate receptors. This process has
been described in the phenomenon known as endotoxin tolerance, where LPS-treated cells
are refractory to subsequent stimulation with LPS (102). To try and replicate these
conditions in vitro, BMM were cultured overnight with various TLR ligands and then
assessed for the expression of TLR2, 3, 4 and 9 by flow cytometry. As shown in Figs 4.8
and 4.9, treatment with BLP, poly I:C, LPS or CpG had no effect on the expression of
surface TLR2 or intracellular TLR3 and 9 compared with medium-treated BMM. Similarly,
treatment with BLP or CpG did not affect surface TLR4 expression by BMM (Fig 4.8b).
However treatment with LPS completely downregulated surface expression of TLR4 on
virtually all BMM (Fig 4.8b), consistent with previous data on PEC m  treated with LPS.
Interestingly, treatment with poly I:C also resulted in a partial downregulation of TLR4
from the surface of BMM, but around 60% of cells remained TLR4
+. Thus LPS was the
only stimulus that markedly affected expression of any of the TLRs, and this was specific
to its corresponding receptor. To examine this profound effect of LPS in more detail, I
carried out a dose response study. BMM were cultured with 20ng/ml, 200ng/ml or 2µg/ml
of LPS overnight before assessing the level of TLR4 expression. All of the concentrations
of LPS completely downregulated surface TLR4 expression (Fig 4.10a). To examine
whether the downregulation from the cell surface was due to receptor internalisation, I
assessed intracellular TLR4 expression after treatment with 2µg/ml LPS. In contrast to the
complete absence of TLR4 when surface expression was examined, when the intracellular124
staining protocol was used, intermediate levels of TLR4 could be detected intracellularly
following treatment with LPS, suggesting that TLR4 may indeed be internalised after
ligand treatment (Fig 4.10b).
Next I explored at what level TLR expression might be regulated by TLR ligation,
by carrying out quantitative PCR to determine mRNA levels in BMM treated overnight
with medium, BLP or LPS. I used these stimuli as BLP failed to affect TLR protein
expression, whereas LPS downregulated TLR4 protein expression. Culture of BMM in
medium alone increased the expression of mRNA for TLR2, 4 and 9 compared with freshly
harvested BMM (Fig 4.11). Treatment of BMM with BLP or LPS abrogated this increase in
TLR4 mRNA expression, but had no effect on the induction of TLR2 mRNA (Fig
4.11a+b). BLP also reduced TLR9 mRNA levels to below the baseline found in freshly
harvested BMM, but LPS had no effect on TLR9 mRNA expression after overnight culture
(Fig 4.11c). Thus BLP specifically targeted the transcription of TLR9 mRNA, rather than at
the protein level where TLR9 may be more stable, suggesting different TLR ligands might
regulate TLR expression at distinct levels. In conclusion, LPS has a selective effect on the
expression of its own TLR protein and mRNA, while BLP appears to have somewhat more
wide ranging effects, especially at the mRNA level. However none of the TLR ligands
themselves can reproduce the global downregulation of TLRs seen in resident colonic m .
Finally, I thought it important to explore the functional consequences of prior
exposure to TLR ligands on the responsiveness of BMM to subsequent stimulation with the
same or different TLR ligands. Thus BMM were cultured for 20hrs in medium alone, or125
with BLP, poly I:C or LPS, washed and re-stimulated with the same or different TLR
ligands. All three stimuli induced TNF  and IL-6 production by freshly isolated BMM
after the initial overnight culture, with the weakest stimulus being BLP (Fig 4.12).
Interestingly, overnight culture in medium alone led to significantly increased subsequent
cytokine responses to all stimuli, which corresponds with the increase in TLR mRNA
levels I found in BMM cultured overnight in medium. In addition, consistent with the
dramatic reduction in TLR4 protein expression found under the same conditions, BMM
pre-treated with LPS and re-stimulated with the same ligand failed to produce any TNF 
and IL-6 at all, despite the higher levels seen after culture in medium (Fig 4.12). Although
BLP had failed to affect the expression of TLR2 protein, BMM cultured with BLP
produced significantly lower levels of TNF  and IL-6 upon subsequent BLP stimulation
compared with control BMM cultured in medium overnight (Fig 4.12). Similarly, poly I:C
treatment abrogated subsequent TLR3-mediated stimulation, even though it did not affect
TLR3 protein expression (Fig 4.12). Thus all three ligands profoundly inhibit subsequent
responsiveness via their own TLR.
To investigate whether these effects extended to responsiveness to other ligands, I
also examined cytokine production by pre-treated BMM after re-stimulation with different
TLR ligands. As shown in Fig 4.13, BMM cultured initially with poly I:C or LPS failed to
produce TNF  or IL-6 after re-stimulation with BLP. BMM treated with BLP also showed
a significantly reduced TNF   response upon re-stimulation with poly I:C,  but  IL-6
responses were normal. However, poly I:C-induced TNF  and IL-6 production by BMM
was completely abrogated by pre-treatment with LPS. Pre-treatment with BLP reduced the126
subsequent TNF  response to LPS, but did not affect the production of IL-6 significantly.
In contrast, pre-treatment of BMM with poly I:C completely abrogated the subsequent
LPS-induced production of both TNF  and IL-6. These data demonstrate that treatment of
BMM with poly I:C or LPS prevents subsequent TNF  and IL-6 responses to the other
ligands. However, BLP has a similar, if somewhat lesser effect, as culture with it only
decreased the production of TNF , not IL-6, in response to subsequent stimulation with
poly I:C or LPS.
4.6 Effects of in  vivo TLR2 and TLR4 signalling on TLR expression by colonic
macrophages
The data thus far indicated that ligation of individual TLR in vivo may not provide
the explanation for the global downregulation of TLRs observed in colonic m . To examine
this in vivo, the expression of TLR3, 4 and 9 by colonic m  from TLR2- and TLR4-
unresponsive mice was examined. As shown in Fig 4.14a-c, colonic m  from both WT and
TLR2KO animals expressed no surface TLR4 or 9 and had similarly low levels of surface
TLR3. TLR2 KO m  also expressed the same low levels of intracellular TLR3 and TLR9
as found in WT m  and appeared to express even lower levels of intracellular TLR4 than
WT controls.
I next examined the expression of TLRs by colonic m  from C3H/HeJ mice, which
have a point mutation in the cytoplasmic tail of TLR4, and thus cannot respond to TLR4
ligation (76). This is confirmed by the fact that BMM from C3H/HeJ mice produced TNF 127
after stimulation with BLP and poly I:C, but not with LPS (Fig 4.15). Although no
C3H/HeN mice were available as WT controls, the expression of surface TLR2 and 4, and
intracellular TLR3 and 9 by C3H/HeJ colonic m  were at the same low levels as I normally
found on control C57Bl/6 m  (Fig 4.16). Together these results indicate that TLR2 or
TLR4 signalling in vivo is not required for the lack of TLR expression by colonic m .
4.7  Effects  of  candidate  immunomodulatory  factors  on  TLR  expression  by
macrophages
As TLR signalling itself does not seem to account for the lack of TLR expression by
colonic  m , I went on to explore some of the factors which could be present in the
intestinal microenvironment and have the potential to downregulate pro-inflammatory
functions by m .  The first mediator I investigated was vasoactive intestinal peptide (VIP),
which has been shown to modulate DC function and downregulate TLR4 expression by
murine m  (217, 218). To confirm these previous findings on TLR4 expression and to
assess whether VIP affected expression of other TLRs by m ,  BMM  were  cultured
overnight with a dose of VIP others in the laboratory had used to treat DCs. However this
did not affect the surface expression of TLR2 or TLR4 (Fig 4.17a). I also included IL-4 in
this experiment, as IL-4 has been shown to decrease the expression of TLR in human IEC
(325). However IL-4 had no effects on TLR expression by BMM (Fig 4.17b).
As described previously, retinoic acid has been shown to be critical for the ability of
intestinal CD103
+ DCs to drive FoxP3
+ regulatory T cells and to impart T cells with gut-128
homing properties (30, 211). Retinoic acid also downregulates TLR2 expression in human
monocytes (326). For these reasons, I cultured BMM with retinoic acid at the same dose as
found to be optimal for driving T cells to express FoxP3, for 7 or 24hrs to assess any short
and longer term effects, and examined the expression of TLR2, 3, 4 and 9. As shown in Fig
4.18,  retinoic  acid  had  no  effect  on  the  expression  of  surface  TLR2  or  TLR4,  or
intracellular TLR3 or TLR9 after 7hrs (left panel) or 24hrs (right panel). Together these
preliminary results suggest that VIP, IL-4 and retinoic acid may not contribute to the
phenotype of colonic m , but time did not permit me to perform more detailed experiments
using different concentrations, combinations and time courses to confirm these conclusions.
4.8 Effects of IL-10 on TLR expression and function by colonic macrophages in vivo
I decided to concentrate the remainder of these studies on IL-10. IL-10 is a potent
immunomodulatory cytokine that downregulates pro-inflammatory m  functions. IL-10KO
mice develop colitis spontaneously (232), as do mice with a myeloid-specific defect in the
IL-10R signalling molecule, STAT-3 (233). As intestinal m  from IL-10KO mice have
been shown to produce increased IL-12p70 following stimulation with whole bacteria
(195), I assessed whether intestinal m  from these mice were hyperresponsive to purified
TLR ligands and if this heightened responsiveness was associated with an increased
expression of TLRs. I examined the expression of TLRs by colonic m  from 2 and 4
month-old IL-10KO mice, first assessing whether either of these groups had colitis. Neither
group of IL-10KO mice had blood in their faeces as assessed by the Haemoccult test.
Furthermore, 2 month-old IL-10KO mice also had no histological signs of colitis, but one129
of the two 4 month-old KO mice examined had early signs of inflammatory cell infiltrates
in the colon (Fig 4.19). For these reasons, I used 2 month-old mice as a pre-colitic group
and 4 month old mice as animals with early signs of inflammation.
The total number of m  in the colon was not significantly different between KO and
WT  animals  of  either  age  (Fig  4.20a-c)  and  there  were  also  no  differences  in  the
proportions of F4/80
+ subsets between KO and WT animals (Fig 4.21a). It should be noted
that in this experiment, the F4/80
+CD11b
+CD11c
int subset constituted a lower proportion of
the F4/80
+ fraction compared with the C57Bl/6 mice described in Chapter 3, producing
concomitant increases in the other two subsets. There was also no difference in the
proportion of Gr-1-expressing F4/80
+ cells between KO and WT mice (Fig 4.21b).
 As shown in Fig 4.22a, significantly higher percentages of colonic m  from 2 and 4
month-old IL-10KO mice expressed surface TLR2 (70.7±3.7% and 61.1±1.8% compared
with 26.2±11.2% and 30.1±5.8% in WT controls, respectively). Similarly, a significantly
higher proportion of colonic m  from 2 and 4 month-old IL-10KO mice expressed surface
TLR4 compared with WT controls (51.2±8.2% and 42.5±11.2% compared with 15.2±3.3%
and 12.1±1.9%, respectively; Fig 4.22b). There were no differences in the expression of
intracellular TLR3 or TLR9 between IL-10KO and WT mice with virtually no expression
in any group (Fig 4.22c+d).
As shown in Fig 4.23a, the increased expression of TLR2 and TLR4 correlated with
increased responsiveness of colonic m  from IL-10KO mice to stimulation with LPS. In130
contrast to the experiments described in Chapter 3 using C57Bl/6 mice, a small proportion
(~15%)  of  colonic  m   from  Balb/c  WT  mice  in  this  experiment  produced  TNF 
spontaneously, but this was not increased further by TLR stimulation (Fig 4.23b+c). In
contrast, significantly higher proportions of colonic m  from pre-colitic IL-10KO mice
produced  TNF   spontaneously  (28.0±1.0%) and this was increased even further by
stimulation with BLP or LPS (44.4±4.3% and 59.5±5.7%, respectively). An identical
pattern of results was seen when colonic m  from 4 month-old IL-10KO mice were
analysed, with 29.20±2.26% producing TNF  spontaneously, increasing to 39.4±5.4% and
36.3±3.6% after BLP and LPS stimulation, respectively. To try and assess whether
enhanced pro-inflammatory cytokine production was an intrinsic property of m  from IL-
10KO mice, I examined the capacity of BMM from these mice to produce cytokines.
Although there was no difference in TNF  or IL-6 production, in vitro-differentiated BMM
derived from IL-10KO mice displayed a significantly heightened IL-12p70 response to
stimulation compared with BMM from WT mice (Fig 4.24).
To examine the activation status of colonic m  from IL-10KO mice further, the
expression of co-stimulatory molecules and class II MHC was assessed. The levels of these
molecules were low, but colonic m  from IL-10KO mice expressed lower levels of CD40
and this was significantly different from WT in 4 month-old mice (Fig 4.25a). Colonic m 
from IL-10KO mice also expressed significantly lower levels of CD80 (Fig 4.25b), but had
a small but significant increase in CD86 expression at 4 months (Fig 4.25c). Class II MHC
expression was significantly higher in IL-10KO colonic m  compared with WT controls at
both ages (Fig 4.25d).131
Summary
The results of this chapter demonstrate that the hyporesponsiveness of colonic m 
to TLR ligation is associated with a lack of TLR protein expression. However, colonic m 
do express mRNA for TLRs, albeit at reduced levels for some TLRs when compared with
other m  populations and removal of m  from the intestinal microenvironment failed to
allow expression of TLRs by gut m . However a small proportion of colonic m  retained
expression of TLR2 in the resting intestine and it is possible that these represent recently
recruited  monocytes,  which  have  not  yet  acquired  the  refractory  phenotype which
characterises the resident population. Alternatively, these m  may represent a distinct
subset of monocyte-derived cells, which are present in lower numbers under resting
conditions.
Further experiments suggested that continuous TLR ligation is probably not the full
explanation for the global defect in TLR expression by colonic m , as exogenous TLR
ligands such as BLP, poly I:C, LPS and CpG did not reproduce the phenotype in BMM and
colonic m  from TLR2KO or C3H/HeJ mice still showed no expression of TLRs. The
immunomodulatory mediators IL-4, VIP or retinoic acid did not seem to account for the
TLR phenotype of colonic m . However, IL-10 may be involved in the regulation of TLR
expression by m  in the intestine, as colonic m  from IL-10KO mice, which had no signs
of inflammation, expressed higher levels of TLR2 and TLR4 compared with WT controls.
Importantly,  colonic  m   from IL-10KO animals also displayed a heightened TNF 132
response to TLR ligation. Whether the role for IL-10 is in the regulation of m  function or
in the recruitment of monocyte subsets into the intestine, it represents a crucial checkpoint
in preventing excessive inflammatory responses to commensal bacteria in the gut.Figure 4.1 Surface TLR protein expression by macrophage populations
BMM, PEC m  and colonic m  were examined for the expression of surface
TLR2 (A), TLR3 (B), TLR4 (C) and TLR9 (D) by flow cytometry. The results
shown are the mean percentages ± SD of live-gated F4/80
+ cells for 3 mice/group
and the results are representative of at least 3 individual experiments. A one-way
ANOVA revealed a significant difference; (A) F(2,6) = 454.9, p<0.0001; (B)
F(2,6)=723.4, p<0.0001; (C) F(2,6)=952.3, p<0.0001. Planned comparisons
were significant (***p<0.001), Bonferroni's multiple comparison test.
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133Figure 4.2 Intracellular TLR protein expression by macrophage
populations
BMM, PEC m  and colonic m  were examined for intracellular expression of
TLR3 (A) and TLR9 (B), and colonic m  were examined for intracellular
expression of TLR2 (C) and TLR4 (D) by flow cytometry. The results shown are
the means ± SD of live-gated F4/80
+cells for 3 mice/group and are
representative of at least three individual experiments. A one-way ANOVA
revealed a significant difference; (A) F(2,6) = 3603, p<0.0001; (B)
F(2,6)=696.6, p<0.0001; Planned comparisons were significant (***p<0.001),
Bonferroni's multiple comparison test.
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134TLR2
Figure 4.3 Effects of enzyme treatment on the expression of myeloid
markers, TLRs and class II MHC by PEC m 
PEC m  were isolated by wash out and some were treated with the same
enzyme mixture and isolation protocol as colonic LP cells, before being
examined for the expression of F4/80, CD11b, CD11c (A), surface TLR2
and TLR4 (B) and class II MHC (C) by flow cytometry. The results shown
are the mean percentages ± SD for 3 mice/group. The histograms show
marker expression levels on live-gated F4/80
+ cells and the shaded
histograms represent staining with isotype control antibodies.
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Figure 4.4 Expression of TLR2 by colonic macrophage subsets
Colon LP cells from C57Bl/6 mice were analysed for the expression of
F4/80, TLR2, CD11b (A), CD11c (B) and class II MHC (C) by flow
cytometry. Numbers in quadrants represent the percentages of the total
population positive for each marker. Shaded histograms represent staining
with isotype controls and the data are representative of two individual
experiments.
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Figure 4.5 Expression of TLR mRNA by macrophages
mRNA was extracted from BMM or from MACS-purified F4/80
+ PEC m 
and colonic m  before being examined for the expression of TLR1-9 by
end-product PCR, using the primer sequences detailed in Table 2.2.
137Figure 4.6 Quantitative analysis of TLR mRNA expression by macrophages
mRNA from freshly isolated BMM, and from FACS-sorted F4/80
+ PEC or
colonic m  was isolated and mRNA levels for TLR2 (A), TLR4 (B) and TLR9
(C) were analysed by Taqman real-time PCR. Levels of mRNA are expressed as
the percentage expression relative to HPRT and the data are representative of
two individual experiments. Primer and probe sequences are detailed in Table
2.3.
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138Freshly isolated
24 hour culture
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Figure 4.7 Expression of TLR2 and TLR4 by colonic m  following ex vivo
culture
F4/80
+ cells from colonic LP were FACS-sorted and examined for the
expression of surface TLR2 (A) and TLR4 (B) by flow cytometry before or
after culture in medium for 24 hrs. The histograms show marker expression
levels on live-gated F4/80
+ cells and the shaded histograms represent staining
with isotype controls.
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139Figure 4.8 Effects of TLR ligands on surface TLR expression by BMM
Freshly isolated BMM or BMM that had been cultured overnight in medium,
1µg/ml BLP, 25µg/ml poly I:C or 1µg/ml LPS were analysed for surface
expression of TLR2 (A) and TLR4 (B) by flow cytometry. The results shown
are the percentage of live-gated F4/80
+ cells positive for each TLR.
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140Figure 4.9 Effects of TLR ligands on intracellular TLR expression by BMM
Freshly isolated BMM or BMM that had been cultured overnight in medium,
1µg/ml BLP, 25µg/ml poly I:C or 1µg/ml LPS were analysed for intracellular
expression of TLR3 (A) and TLR9 (B) by flow cytometry. The results shown are
the percentage of live-gated F4/80
+ cells positive for each TLR.
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Figure 4.10 Effects of LPS concentration on TLR4 expression by BMM
Freshly harvested BMM or BMM cultured overnight in medium or 2µg/ml,
200ng/ml or 20ng/ml LPS were assessed for surface TLR4 expression. A)
The results shown are the MFI for TLR4 expression by live-gated F4/80
+
cells. B) Intracellular TLR4 expression by live-gated F4/80
+ cells following
culture with or without 2µg/ml LPS. The shaded histogram represents staining
with isotype control antibody.
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142Figure 4.11 Effects of TLR ligands on TLR mRNA expression by BMM
Freshly harvested BMM or BMM cultured in medium, 1µg/ml BLP or 1µg/ml
LPS for 18hrs were analysed for the levels of expression of mRNA for TLR2
(A), TLR4 (B) and TLR9 (C) by Taqman real-time PCR. The levels of mRNA
are shown as the percentage expression relative to HPRT ± SEM of triplicate
wells.
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Figure 4.12 Induction of functional tolerance to TLR ligation in BMM
BMM were cultured in medium, 1µg/ml LPS, 1µg/ml BLP or 25µg/ml poly I:C
overnight and the supernatants were analysed for the production of TNF  and
IL-6 by ELISA. BMM were then re-stimulated with the homologous TLR ligand
for a further 24hrs. The results shown are the mean cytokine concentration ± SD
for triplicate wells. Two-way ANOVAs revealed significant differences,
Bonferroni-corrected. ns=not significant; ***p<0.001.
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Figure 4.13 Induction of functional tolerance to TLR ligation in BMM
BMM were cultured in medium, 1µg/ml LPS, 1µg/ml BLP or 25µg/ml poly
I:C overnight and the supernatants were analysed for the production of TNF 
and IL-6 by ELISA. BMM were then re-stimulated with the heterologous TLR
ligands for a further 24hrs. The results shown are the mean cytokine
concentration ± SD for triplicate wells. Two-way ANOVAs revealed significant
differences, Bonferroni-corrected. ns=not significant; ***p<0.001.
145Figure 4.14 TLR expression by colonic macrophages from TLR2 KO
mice
Colonic LP cells from TLR2 KO and control mice were assessed for the
expression of surface (left panels) and intracellular (right panels) TLR4 (A),
TLR3 (B) and TLR9 (C). Histograms show the level of marker expression on
live-gated F4/80
+ cells and the shaded histograms represent staining with
isotype control antibodies.
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Figure 4.15 Responsiveness of C3H/HeJ bone marrow macrophages
to TLR ligands
BMM from C3H/HeJ mice were cultured in medium (A), 1µg/ml BLP (B),
25µg/ml poly I:C (C) or 1µg/ml LPS (D) in the presence of brefeldin-A
for 4.5hrs. The cells were then assessed for the expression of intracellular
TNF  by flow cytometry. Numbers in quadrants represent the percentages
of the total live-gated population.
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Figure 4.16 TLR expression by colonic macrophages from C3H/HeJ mice
Colonic LP cells from C3H/HeJ mice were assessed for the expression of
surface TLR2 (A) and TLR4 (B), or intracellular TLR3 (C) and TLR9 (D) by
flow cytometry. The histograms show the levels of marker expression on
live-gated F4/80
+ cells and the shaded histograms represent staining with
isotype controls. Numbers represent the percentages of live-gated F4/80
+ cells
positive for each TLR.
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Figure 4.17 Effects of VIP and IL-4 on TLR expression by macrophages
BMM were cultured overnight in medium, 10
-8M VIP (A) or 40ng/ml IL-4
(B) and examined for the expression of TLR2 (left panels) and TLR4 (right
panels) by flow cytometry. The histograms show the levels of marker
expression on live-gated F4/80
+ cells and the shaded histograms represent
staining with isotype control antibodies.
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Figure 4.18 Effects of retinoic acid on TLR expression by macrophages
BMM were cultured in medium alone or with 100nM RA for 7hrs (left
panels) or 24hrs (right panels) and assessed for the expression of surface
TLR2 (A) and TLR4 (B), or intracellular TLR3 (C) and TLR9 (D) by flow
cytometry. The histograms show the levels of marker expression on
live-gated F4/80
+ cells and the shaded histograms represent staining with
isotype control antibodies.
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Figure 4.19 Histology of the distal colon from IL-10KO mice
The distal colons from 4 month-old WT (A), or 2 month-old (B) and 4
month-old (C) IL-10KO mice were excised and fixed in 10% formalin,
embedded in paraffin, and stained with haematoxylin and eosin (final
magnification x100).
cellular infiltration
151Figure 4.20 Total cellularity, proportion and absolute numbers of
macrophages in the colon of IL-10KO mice
Colonic LP cells from IL-10KO and WT control mice were isolated
and enumerated. Results shown are the mean total cell numbers (A),
percentage F4/80 positive (B) and absolute numbers of F4/80
+ cells
(C) ± SD for 3 mice/group. ns=not significant; *p<0.05.
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152Figure 4.21 Macrophage subsets in the colon of IL-10KO mice
Colonic LP cells from 4 month-old IL-10KO and WT mice were analysed for the
expression of F4/80, CD11b and CD11c (A) and Gr-1 (B) by flow cytometry.
Results show the mean percentage ± SD of F4/80
+ cells in each subset (A) or the
proportion of F4/80
+ cells that co-express Gr-1 (B) for 3 mice/group. ns=not
significant.
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153Figure 4.22 Expression of TLRs by colonic macrophages from IL-10KO
mice
Colonic m  from IL-10KO mice and control mice were assessed for the
expression of surface TLR2 (A) and TLR4 (B), or intracellular TLR3 (C) and
TLR9 (D) by flow cytometry. The results shown are the mean percentages ±
SD of F4/80
+ cells positive for each TLR for 3-4 mice/group. **p<0.01;
***p<0.001.
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Figure 4.23 TNF  production by colonic macrophages from IL-10KO mice
Colonic LP cells from IL-10KO and WT mice were cultured for 4.5hrs in
medium, 1µg/ml BLP or 1µg/ml LPS in the presence of brefeldin-A. A)
Representative dot plots of TNF  expression by cells cultured with LPS. B) and
C) show the mean percentage ± SD of F4/80
+ cells positive for TNF  in 2
month- (B) and 4 month-old (C) mice for 3 mice/group. **p<0.01; ***p<0.001.
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Figure 4.24 Production of pro-inflammatory cytokines by BMM from
IL-10KO mice
BMM from WT and IL-10KO mice were cultured in medium, 1µg/ml LPS,
100U/ml IFN  or LPS + IFN  for 18hrs and the supernatants assessed for the
production of TNF  (A), IL-6 (B) and IL-12p70 (C) by ELISA. The results
shown are the mean cytokine concentration or OD ± SD for triplicate wells.
ns=not significant; ***p<0.001.
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Figure 4.25 Expression of co-stimulatory molecules and class II MHC
by colonic macrophages from IL-10KO mice
Colonic LP cells from IL-10KO and WT mice were analysed for the
expression of F4/80 and CD40 (A), CD80 (B), CD86 (C) and class II MHC
(D) by flow cytometry. Results shown are the mean MFI of marker
expression on live-gated F4/80
+ cells ± SD for 3 mice/group. ns=not
significant; *p<0.05; **p<0.01.
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Chapter 5
Phenotypic and functional characterisation of macrophages in the inflamed gut159
Introduction
It has been demonstrated that during intestinal inflammation, there is an increase in
the number of m  present in the colon. In addition, these m  have been shown to exhibit
distinct functional properties compared with the resident population present in the healthy
gut. In humans with active IBD, intestinal m  exhibit heightened inflammatory and
bactericidal  functions,  producing  pro-inflammatory  cytokines  and  chemokines,  and
expressing higher levels of NADPH oxidase, compared with m  under resting conditions.
Furthermore, m  from IBD biopsies express higher levels of TLR2 and TLR4, and higher
levels of costimulatory molecules. For these reasons, intestinal m  are considered to be one
of  the  main  contributors  to  ongoing  tissue  pathology,  possibly  via  production  of
inflammatory mediators such as TNF . To obtain a more detailed insight into how m 
might  contribute  to  intestinal  inflammation,  I  performed  a  detailed  phenotypic  and
functional analysis of m  from the colon of mice with DSS-induced colitis. Thus, I
quantified these cells, examined their location in situ, and investigated their expression of
TLRs, as well as the production of pro-inflammatory mediators.160
5.1 Induction of intestinal inflammation and tissue pathology
Following administration of 2% DSS in drinking water, C57Bl/6 mice began to lose
body weight after 5 days, which continued to fall rapidly in the days thereafter (Fig 5.1a).
Weight loss was accompanied by severe, fibrotic shortening of the colon, which is one of
the standard parameters of disease severity in this model. As shown in Fig 5.1b, following
administration of 2% DSS for 7 days, the length of the colon decreased by almost 50% in
the majority of animals, from 9.85±0.75cm in water fed control mice to 6.2±0.45cm. The
clinical severity of disease was assessed by monitoring diarrhoea and rectal bleeding, which
were evident in some animals as early as 4-5 days after beginning DSS administration (Fig
5.2b+c). As shown in Fig 5.2d, the total clinical disease score continued to increase steadily
up to day 7, although there was marked variability between individual animals. Histological
analysis showed that following 7 days of DSS administration, there was severe intestinal
pathology with oedema, crypt lengthening, epithelial damage, areas of ulceration and
complete crypt loss, as well as an influx of inflammatory cells into the mucosa and
submucosa (Fig 5.3). To assess the contribution m  make to intestinal pathology, I next
performed  immunofluorescence  staining  for  F4/80-expressing  cells  in  the  inflamed
intestine. As shown in Fig 5.4, there were numerous F4/80
+ cells in the normal distal colon,
mainly scattered throughout the LP and around the crypts. By day 7 of colitis, there was a
large increase in the numbers of F4/80
+ cells in the inflamed colon, and these were now
found throughout the mucosa and submucosa (Fig 5.4).161
I then isolated colonic LP cells in order to conduct detailed phenotypic and
functional analyses of the infiltrating m . The total number of cells obtained following
tissue  digestion  increased  significantly  from  5.7x10
6±0.9  per  colon  under  resting
conditions, to 10.5x10
6±3.4 and 15x10
6±2.3 cells following administration of DSS for 4 or
7 days, respectively (Fig 5.5a). As shown in Fig 5.5b, morphometric analysis by flow
cytometry showed increased populations of mononuclear and granulocytic cells during
colitis compared with resting conditions. This was confirmed by a signifcant increase in the
proportion of F4/80-expressing cells, with 16.9±1.6% and 21.6±3.8% cells being F4/80
+
after 4 and 7 days of DSS administration respectively, compared with 11.7±2.3% in the
resting colon (Fig 5.6a). This corresponded to increases in the absolute number of m  from
0.61x10
6±0.3  per  colon  under  resting  conditions,  to  1.38x10
6±0.2 and 3.44x10
6±0.4
following 4 and 7 days of DSS administration, respectively (Fig 5.6b).
To  extend  the  phenotypic  characterisation  of  the  inflammatory  infiltrates,  I
examined the expression of Ly6C, a non-specific marker present on some monocyte/m 
populations, including the ‘inflammatory’ subset of blood monocytes which express Gr-1, a
shared epitope on Ly6C and Ly6G. Unlike the Ly6C
bright population which did not change,
there was a rapid and substantial increase in the percentage of Ly6C
int cells in the DSS
inflamed colon, from 10.5±4.4% of total colonic LP cells under resting conditions to
26.7±5.6%  (Fig 5.7a+c). This occurred as early as 3 days after DSS administration was
commenced and most of the cells were mononuclear in terms of size and granularity,
suggesting they were of myeloid origin (Fig 5.7b). However, the majority of these cells
failed to express F4/80 or CD11b both in normal mice and in colitis (Fig 5.7a+d),162
suggesting that these may be an unusual population of mononuclear cells. This was
supported by the fact that they did not express the Ly6G marker of neutrophils, which were
completely absent in the healthy gut and on day3 of colitis (0.1±0.1% and 0.2±0.1%,
respectively), and constituted only 1.5±0.3% of total live-gated cells by d7 of colitis (Fig
5.8a+b).  As  shown  above  in  the  morphometric  analyses,  there  was  an  increase  in
granulocytic  cells  by  day  3  of  colitis,  suggesting  that  these  may  represent  another
population of granulocytes, such as eosinophils.
5.2 TLR-expressing macrophages become dominant in the inflamed colon
To assess further how m  present in the inflamed colon differed from those present
under  resting  conditions,  I  next  conducted  a  detailed  phenotypic  analysis  of  TLR
expression by m  during colitis. In stark contrast to the healthy colon, large numbers of
TLR2
+  F4/80
+  cells were observed during colitis (Fig 5.9a). This TLR2
+ population
accounted for 29.3±5.0% of F4/80
+ cells in the healthy colon, but it constituted the majority
of F4/80-expressing cells in the inflamed colon, increasing to 69.1±10.6% and 75.9±15.1%
on days 4 and 7 of DSS administration (Fig 5.9b). There was also an increase in the
proportion of F4/80
+ cells expressing surface TLR4 during colitis, but no intracellular
TLR3 and 9 expression could be detected in control or colitic intestine (Fig 5.10a-c).
Unfortunately, due to the unavailability of antibodies, I was unable to assess the expression
of these TLRs on the total TLR2
+ population. The high levels of surface TLR2 on these
cells during colitis allowed two clearly distinct populations to be identified and analysed on
the basis of TLR2 expression. Interestingly, although the majority (>85%) of the total TLR-163
expressing cells in colitis were CD11b
+ and these CD11b
+TLR
+ cells had the size and
granularity consistent with monocytic cells, around 50% of the TLR-expressing cells in
colitic mucosa had low or absent expression of F4/80 (Fig 5.11a+b). In contrast, the
majority of TLR2
+ cells in resting mucosa were F4/80
+ (Fig 5.11a). As blood monocytes
express  lower  levels  of  F4/80  than  tissue  m   (43),  this  suggests  that  these
F4/80
loTLR2
+CD11b
+ cells in the inflamed colon may be recently derived from blood
monocytes. However, to ensure that the cells I was characterising were definitely m , I
based  my  studies  strictly  on  the  F4/80
+  population.  A  greater  proportion  of  the
TLR2
+F4/80
+ cells expressed CD11c both under resting conditions and in colitis, compared
with the TLR negative subset (Fig 5.11d). Therefore this F4/80
+TLR
+CD11b
+CD11c
lo
population is somewhat similar to the minor population of triple positive F4/80
+ cells I
defined in the normal colon in Chapter 3, but they are now the dominant population in the
inflamed intestine.
To assess the activation status of the F4/80
+ cells present during colitis, total F4/80
+
cells were assessed for the expression of CD40, CD80, CD86 and class II MHC. As shown
in Fig 5.12a-c, F4/80
+ cells in the resting and inflamed colon expressed low levels of
costimulatory molecules. However a lower proportion of F4/80
+ cells expressed class II
MHC in the inflamed colon, compared with this population in the resting colon (Fig 5.12d).
As I had found that a significant proportion of m  in the inflamed colon expressed TLR2, I
next assessed the presence of activation markers directly on the TLR
-  and TLR
+ m 
subsets. Whereas the TLR2
- F4/80
+ cells from DSS inflamed colon expressed little or no
class  II  MHC,  no  CD40  or  CD86  and  only  low  levels  of  CD80,  the  majority  of164
TLR2
+F4/80
+ cells were strongly class II MHC
+ and expressed detectable amounts of
CD40, CD80 and CD86 (Fig 5.13). Interestingly a similar dichotomy based on TLR
expression was seen in resting colon, with the majority (>90%) TLR2
+F4/80
+ cells being
class II MHC
+ compared with <40% of TLR2
- cells and they also expressed higher levels
of the co-stimulatory molecules. Two marked differences were that a small subset (~20%)
of TLR2
+ class II MHC
- m  appeared for the first time in colitis and there were also very
few TLR2
- class II MHC
+ m  in colitis, whereas almost 40% of these cells are present in
resting colon.
Due to the fact that the inflammatory response in this disease model is focused at
the distal end of the colon, I conducted an anatomical analysis of TLR expression by m  in
the resting and inflamed colon. As shown in Fig 5.14, a significantly higher percentage of
m  expressed TLR2 in the proximal colon compared with the distal colon under resting
conditions (63.96±7.9% compared with 34.0±16.56%). On day 5 of colitis, the percentage
of TLR-expressing m  in the distal colon increased significantly to 78.06±6.47%, while the
proportion  of  TLR
+ m   in  the  proximal  colon  did  not  change  during  intestinal
inflammation. These results suggest that TLR expression by m  is anatomically determined
under resting conditions, but its increase during colitis may be driven locally by the
inflammatory process.
5.3 Production of pro-inflammatory TNF  by colonic macrophages during colitis165
To assess whether this expanded population of TLR-expressing m  may contribute
to the inflammation of the colon seen after administration of DSS, I examined spontaneous
production of TNF  by intracellular staining. Compared with the healthy colon, which
contained almost no TNF -producing cells, the inflamed colon contained a substantial
population of TNF -expressing cells (~12%), the majority of which were F4/80
+ (Fig
5.15a).  As before, colitis in this experiment was associated with an increased percentage of
F4/80
+ cells that expressed TLR2 and it was notable that the majority of TNF -expressing
cells were also TLR2
+  (Fig 5.15b+c). As I found with TLR expression, a substantial
proportion of the TNF 
+ cells expressed little or no F4/80, but all expressed CD11b
 at high
levels
 and resembled mononuclear cells in terms of size and granularity (Fig 5.15d), again
suggesting these may be derived from recently recruited blood monocytes. Notably, there
were very few TNF 
+ cells in the inflamed colon which were not CD11b
+, indicating that
these infiltrating myeloid cells account for most of the production of this cytokine during
colitis (Fig 5.15).
The results from replicate mice in these experiments are summarised in Fig 5.16.
This shows that in resting colon, there was minimal spontaneous production of TNF , with
no significant difference between the TLR
- and the TLR
+ m , although some TNF  could
be detected in the TLR
+ cells (4.9±4.2% vs 0.2±0.2%). In stark contrast, a substantial
percentage  (up  to  60%  on  d5  and  d7)  of  the  TLR2
+  F4/80
+  cells  produced  TNF 
spontaneously during colitis. However very few TLR2
- cells produced TNF  even in colitis
(4.1±1.8% and 6.1±6% on d5 and d7, respectively). Due to the fact that a large proportion
of F4/80
+ cells in the inflamed intestine expressed TLR2 and TLR4, I next assessed166
whether I could further increase TNF  expression via stimulation with the corresponding
ligands, BLP and LPS. Consistent with the presence of small numbers of TLR2-expressing
m  in the resting colon, up to 30% of these cells expressed TNF  after culture with BLP
(Fig 5.17). However this increased markedly to 60-70% of TLR2
+ cells on days 5 and 7 of
colitis. Stimulation of resting cells with LPS induced little production of TNF  by TLR2
+
cells, but again this was greatly increased in colitis, where similar proportions of TLR
+ m 
stimulated with LPS expressed TNF  as found after stimulation with BLP. TLR2
- m  from
resting colon produced little or no TNF  in response to BLP or LPS and this was not
significantly increased during colitis (Fig 5.17).
Summary
In this chapter, I have demonstrated that following administration of DSS, mice
begin to lose weight rapidly, along with shortening of the colon, diarrhoea and rectal
bleeding. The colon loses its architecture and becomes infiltrated by large numbers of
inflammatory cells, a large proportion of which are F4/80-expressing monocytic cells and
are now present throughout all layers of the colon. In addition there is a delayed increase in
both the proportion and absolute number of F4/80
+ cells. Furthermore, there is also a rapid
influx of Ly6C
int cells and a more delayed influx of Ly6G
+ neutrophils. The majority of the
former Ly6C
int cells were mononuclear in terms of FSC/SSC properties and a similar
population of Ly6C
int monocytes has been found in the inflamed peritoneum (173). In this
model, the monocytes are also CD11b
hi, but in contrast, the majority of Ly6C
int cells I
found in the inflamed colon failed to express F4/80 or CD11b, suggesting these are an167
unusual population of mononuclear cells. Furthermore, a large increase in the proportion of
granulocytic cells was apparent before the appearance of the Ly6G
+ neutrophil population,
suggesting the infiltration of another granulocytic population such as eosinophils.
A substantial proportion of the increased numbers of m  which appeared in the
inflamed gut now expressed TLR2 and TLR4 and this change was most obvious at the
distal end of the colon, where the inflammatory response is focused. The TLR
+  m 
expressed CD11b, class II MHC and low levels of CD11c, CD40, CD80 and CD86 and
accounted for virtually all the TNF  producing cells in the intestine of mice with DSS-
induced colitis. Interestingly, the smaller proportion of TLR2-expressing m  in the normal
colon were also capable of expressing TNF  in response to the corresponding ligand, BLP,
but unlike m  from the inflamed colon, these cells did not express TNF  spontaneously
and did not respond to TLR4 stimulation. The TLR2-expressing, TNF -producing m 
present in the inflamed colon are likely to represent a population of blood monocytes that
has been recruited to the inflamed intestine under the influence of pro-inflammatory
chemokines. However, to try and answer this question and gain a further insight into the
origin of these inflammatory m , I went on to carry out BrdU pulse-chase experiments
which would provide me with information regarding the turnover kinetics of the TLR
- and
TLR
+ m  subsets. These experiments are reported in the next Chapter.Figure 5.1 Weight loss and colon lengths in DSS colitis
C57Bl/6 mice were given water or 2% DSS for 7 days, starting on day 0, and
monitored daily for weight loss, calculated as % of initial body weight (A). A
one-way ANOVA revealed a significant difference, F(8,8)=34.86, p<0.0001,
Bonferroni-corrected. B) After 7 days, colons were excised and the lengths
were measured. The results shown are the means ± SD for 10 mice/group and
similar results were obtained in repeat experiments. ***p<0.001.
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168Figure 5.2 Clinical aspects of DSS-induced colitis
C57Bl/6 mice were given water or 2% DSS and were monitored daily for
weight change (A), diarrhoea (B), rectal bleeding (C), and total clinical
score (D), calculated as described in the Materials and Methods. The
results shown are the means ± SD for 10 mice/group and are
representative of at least five experiments.
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169Figure 5.3 Histology of the distal colon from control and colitic mice
Colons from control C57Bl/6 mice (A) or mice fed DSS for 7 days (B + C) were
excised and fixed in 10% formalin, embedded in paraffin, and stained with
haematoxylin and eosin. Results are representative histological images
(magnification x100).
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170Figure 5.4 Localisation of macrophages in the resting and inflamed colon
Immunofluorescence images show staining with anti-F4/80 (red) and the nuclear
stain DAPI (blue) on sections of distal colon from control C57Bl/6 mice (A) or
mice fed DSS for 7 days (B). High power images (x40) of inflamed colon were
taken after staining with anti-F4/80 (C) or isotype control antibody (D). Images
are representative of colons from three individual mice.
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171Figure 5.5 Total cellularity of the LP of control and inflamed colon
Live-gated colonic LP cells were isolated and enumerated from C57Bl/6 mice
given water or DSS for 4 and 7 days (A). The means ± SD of total numbers of cells
for 4 mice/group are shown and are representative of at least four individual
experiments. B) Representative FSC vs SSC analysis of LP cells taken on day 4
and 7 of colitis. A one-way ANOVA revealed a significant difference,
F(2,9)=13.91, p=0.0018. Planned comparisons which were significant showed a
higher number of cells on colitis d7 compared with control colon (**p<0.01),
Bonferroni's multiple comparison test. ns=not significant.
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Figure 5.6 Proportions and total number of macrophages in the
inflamed colon
Colonic LP cells from C57Bl/6 mice fed water or DSS for 4 or 7 days were
examined for the expression of F4/80 by flow cytometry. Percentages (A)
and absolute numbers of F4/80
+cells (B) are shown as the means ± SD for 4
mice/group. A one-way ANOVA revealed a significant difference; (A) F(2,9)
= 13.33, p<0.0020; (B) F(2,9)=108.7, p<0.0001; Planned comparisons
were significant (ns=not significant; *p<0.05; **p<0.01; ***p<0.001),
Bonferroni's multiple comparison test.
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Figure 5.7 Expression of Ly6C by cells in the normal and inflamed colon
Colonic LP cells from C57Bl/6 mice fed water or DSS for 3 days were
assessed for the expression of F4/80 and Ly6C by flow cytometry.
Representative dot plots obtained from the different groups (A) and FSC and
SSC properties (B) of the total Ly6C
intand Ly6C
brightcell population are
shown. C) The mean percentage ± SD of total Ly6C
int cells for 4 mice/group
and CD11b expression by total Ly6C
int cells (D). Data are representative of
two individual experiments. **p<0.01.
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174Figure 5.8 Infiltration of colon by Ly6G
hi cells during colitis
Colonic LP cells from C57Bl/6 mice fed water or DSS for 3 or 7 days were
assessed for the expression of Ly6G by flow cytometry. Representative dot plots
(A) and the mean percentages ± SD (B) of total Ly6G
hi cells for 4 mice/group.
Data are representative of two individual experiments. A one-way ANOVA
revealed a significant difference, F(2,9) = 69.91, p<0.0001. Planned comparisons
which were significant showed that there was a higher proportion of Ly6G
hi cells
on colitis d7 compared with colitis d3 or control colon  (***p<0.001),
Bonferroni's multiple comparison test.
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Figure 5.9 Infiltration of colon by TLR2
+ macrophages during colitis
Colonic F4/80
+ cells from C57Bl/6 mice fed water or DSS for 4 or 7 days were
assessed for the expression of TLR2 by flow cytometry. A) Levels of TLR2
expression on live-gated F4/80
+cells from control and colitic mice. B) The mean
percentages ± SD of F4/80
+ cells that express TLR2 for 4 mice/group. The data
are representative of at least three individual experiments. A one-way ANOVA
revealed a significant difference, F(2,8) = 15.62, p<0.0017. Planned comparisons
which were significant showed that there was a higher proportion of TLR
+ F4/80
+
cells on colitis d4 and d7 compared with control colon  (**p<0.01), Bonferroni's
multiple comparison test.
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Figure 5.10 Expression of TLRs by intestinal m  during colitis
Colonic LP cells from mice fed water or DSS for 5 days were assessed for
the expression of surface TLR4 (A), and intracellular TLR3 (B) and TLR9
(C). The data show the proportion of TLR positive cells among live-gated
F4/80
+ cells and are representative of three individual experiments. Shaded
histograms represent staining with isotype controls.
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Figure 5.11 Phenotype of TLR2
+ cells in the colon
Mice were fed water or DSS for 4 or 7 days and the co-expression of F4/80 (A) and
CD11b (B) by live-gated TLR2
+ cells was examined. Numbers in quadrants represent
the percentages of the total population. C) Forward and side scatter of total
CD11b
+TLR2
+ cells. D) Expression of CD11c by live-gated F4/80
+TLR2
+ and
F4/80
+TLR2
- cells. The shaded histograms represent isotype control staining. Results
are representative of at least three individual experiments.
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Figure 5.12 Expression of class II MHC and co-stimulatory molecules
by total F4/80
+cells
Colonic LP cells from C57Bl/6 mice fed water or DSS for 5 days were
assessed for the expression of F4/80 and CD40 (A), CD80 (B), CD86 (C)
and class II MHC (D) by flow cytometry. Histograms show the proportions
of live-gated F4/80
+ cells positive for each marker, and shaded histograms
represent staining with isotype controls. Data are representative of two
experiments.
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Figure 5.13 Expression of co-stimulatory molecules and class II MHC by
TLR2
- and TLR2
+ m  populations
Colonic LP cells from mice fed water or DSS for 5 days were analysed for the
expression of CD40, CD80, CD86 and class II MHC by flow cytometry.
Histograms show the proportions of live-gated F4/80
+ cells positive for each
marker, and shaded histograms represent staining with isotype controls. Data are
representative of two experiments.
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180Figure 5.14 Anatomical expression of TLR by m  in the resting and
inflamed colon
Proportions of TLR2
+ F4/80
+ cells in the proximal and distal colon of control
and mice fed DSS for 5 days. The data shown are the mean percentages ± SD
of live-gated F4/80
+ cells positive for TLR2 for 3 mice/group. Two-way
ANOVAs revealed significant differences, F(1,1)=6.101, p=0.0387 for
control proximal vs distal, F(1,1)=24.61, p=0.0011 for control vs colitis,
Bonferroni-corrected. *p<0.05; **p<0.01.
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Figure 5.15 Spontaneous TNF  expression by m  from the control and
inflamed colon
Control C57Bl/6 mice (left panel) or mice given DSS for 7 days (middle panel)
were examined for spontaneous expression of cytoplasmic TNF  by flow
cytometry. LP cells were cultured for 4.5 hours with Brefeldin-A before analysing
the expression of F4/80 vs TNF  ( ), F4/80 vs TLR2 (B) and TLR2 vs TNF  (C).
D) Cells were also stained for CD11b and TNF  following DSS administration for
7 days, and double positive cells (R1) were assessed for granularity and size.
Numbers in quadrants represent percentages of the total population and plots are
representative of at least three individual experiments.
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colitis
Colonic LP cells from control C57Bl/6 mice or mice given DSS for 5 or 7 days
were examined for spontaneous expression of cytoplasmic TNF  by flow
cytometry. Total LP cells were isolated and cultured for 4.5 hours in the presence
of Brefeldin-A before being stained for F4/80, TLR2 and TNF . The results shown
are the mean percentage ± SD for 4 mice/group and are representative of three
experiments. ns=not significant; **p<0.01.
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183Figure 5.17 TLR-induced TNF  expression by macrophage populations
during colitis
Colonic LP cells from control C57Bl/6 mice or mice given DSS for 5 or 7
days were examined for TLR-induced expression of cytoplasmic TNF  by
flow cytometry. Total LP cells were cultured in either 1µg/ml BLP or 1µg/ml
LPS for 4.5hrs in the presence of Brefeldin-A, before being stained for
F4/80, TLR2, and TNF . The results shown are the mean percentages ± SD
for 4 mice/group and are representative of two experiments. ns=not
significant; *p<0.05; **p<0.01.
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Chapter 6
Origin of F4/80-expressing cells in the inflamed intestine186
Introduction
The large increase in m  numbers in colitic mucosa could reflect rapid recruitment
of new inflammatory F4/80
+ monocytic cells into the colon, or could be due to local
proliferation and differentiation of the resident m  population. During human IBD, it has
been suggested that blood monocytes are recruited into the inflamed gut mucosa (208).
However, this is difficult to prove under clinical conditions and in particular, it is not
known exactly how the inflammatory cells which appear in colitis relate to the normal
resident population. In this chapter I have investigated the turnover and population
dynamics  of  the  different  subsets  of  F4/80
+  cells  in  the  healthy  and  inflamed  gut,
concentrating on the TLR
+ and TLR
- subsets I defined in previous chapters. In addition, I
investigated the expression of the CCR2 inflammatory chemokine receptor which could be
involved in recruitment of these cells and attempted to follow the recruitment of adoptively
transferred m  into the colon of healthy and colitic recipients.187
6.1 Turnover of macrophages in the resting and inflamed colon
To explore the relationship between the different subsets of m , I first examined the
turnover kinetics in normal and inflamed colon by measuring the uptake of BrdU in vivo.
Firstly, I assessed the turnover of monocyte precursors in the BM by injecting BrdU i.p.
and measuring its uptake by flow cytometry, as I postulated that this population would be
proliferating actively and thus allow me to assess the usefulness of the technique, and also
give me an idea about the dynamics of monocyte precursors. Within 2hrs after injection,
over 50% of F4/80-expressing cells in the BM incorporated BrdU and this increased
somewhat 24hrs after injection (Fig 6.1). Thus even under physiological conditions, there is
rapid turnover of myeloid cells and their precursors in the BM.
To  examine  intestinal  myeloid  cell  turnover  in  the  resting  state  and  during
inflammation, control and DSS-fed mice were injected i.p. with BrdU, and culled 24 hours
later. 4.1±0.6% of the total F4/80
+ m  population in the resting colonic LP had proliferated
in the 24-hour period (Fig 6.2a). As discussed in Chapter 4, a low percentage of F4/80
+
cells in the resting colon express TLR2 (Fig 6.2b) and interestingly, more of the TLR2
+
subset had proliferated than the TLR2
- subset, which represents the majority of the m  in
the resting state (6.0±0.8% BrdU
+ compared with 1.3±0.5% of the TLR2
- subset; Fig 6.3e).
Indeed, >70% of the F4/80
+BrdU
+ cells expressed TLR2. The proportions of recently
divided F4/80
+ m  increased dramatically during colitis to 16.8±5.1% and 18.9±4.7% of
the total F4/80
+ population after a 24-hour pulse with BrdU on days 3 4 and 5 6,
respectively (Fig 6.3). As in the control colon, the proportions of TLR2
+F4/80
+ cells188
incorporating BrdU were significantly higher than those among the TLR
- subset, with
21.0±5.7% and 21.9±2.4% of TLR2
+ cells being BrdU
+ on days 3 4 and 5 6 of colitis,
respectively (Fig 6.3e). Indeed >96% of the F4/80
+BrdU
+ cells present on day 5 6 of
colitis expressed TLR2. In contrast, BrdU uptake by the TLR2
- fraction from the same
animals increased very little in colitis, to 4.7±1.4% and 5.9±5.0% on days 3 4 and 5 6 of
colitis, respectively (Fig 6.3e).
A significant amount of BrdU incorporation occurred in the F4/80
- fraction of
colonic cells in control mice and approximately 70% of these cells were negative for CD45,
indicating they were of non-haematopoietic origin, possibly epithelial cells (Fig 6.2d).
During colitis, less than 30% of F4/80
- BrdU
+ cells were CD45
-, suggesting that there is a
decrease in proliferation of non-haematopoietic cells and/or a proportional increase in the
proliferation of CD45
+ F4/80
- cells (Fig 6.3d).
When  analysing  BrdU  incorporation  by  m  in colitic mice, I noticed that a
substantial number of BrdU
+ cells expressed lower levels of F4/80 compared with the
BrdU
+ cells in the control colon, which either expressed high levels of F4/80, or were
completely negative (Fig 6.4a+b). Thus the proportion of CD45
+F4/80
lo  cells almost
doubled from ~20% under resting conditions to ~40% during inflammation (Fig 6.4a). It
seems likely that these BrdU
+F4/80
lo cells represent the F4/80
loTLR2
+TNF 
+ cells I found
in colitis in Chapter 5. Despite their low levels of F4/80 expression, the majority (90%) of
these F4/80
lo  BrdU
+  cells  expressed  high  levels  of  CD11b  and  had  the  FSC/SSC
characteristics of mononuclear cells (Fig 6.4c+d). These are probably cells recently derived189
from blood monocytes/BM precursors, which are known to express lower levels of F4/80
than tissue m  (43).
To investigate whether there was in situ proliferation of F4/80
+ cells in the colon, I
assessed the expression of the nuclear antigen, Ki-67, in colonic m  from the resting and
inflamed intestine. Ki-67 protein is present during all active phases of cell cycle, so is an
ideal marker to examine when trying to identify cells within a population that are actively
dividing. As shown in Fig 6.5, Ki-67 expression was virtually undetectable among F4/80
+
cells from the resting colon (0.5±0.1%). Although this increased significantly on d5 of
colitis to 1.5±0.3% of the F4/80
+ population, this was much less than the number of
BrdU
+F4/80
+ cells at similar timepoints (~20%), indicating that local proliferation is
unlikely to account for either the BrdU uptake, or for the dramatic rise in m  numbers seen
during inflammation.
To gain a better idea of the turnover of m  subsets in the normal and inflamed
colon, I used a long-term BrdU administration protocol. Thus control and DSS-fed mice
received BrdU throughout the experiment starting with an i.p. injection on day 0, followed
by administration in the drinking water for 6 days. Mice were culled 1 day, 4 days and 6
days after the initiation of BrdU treatment. As shown in Fig 6.6a, the percentage of total
F4/80
+ BrdU
+ m  in normal colon rose steadily from 4.0±0.2% after 1 day of feeding, to
18.4±2.9% and 24.1±2.7% after 4 and 6 days, respectively. In the group receiving DSS, the
uptake of BrdU by F4/80
+ cells was similar to that in controls (4.6±0.8%) after 1 day, but
by d4 and d6 of colitis, 26.7±3.3% and 39.8±3.8% of F4/80
+ m  had incorporated BrdU.190
Linear  regression  analysis  of  these  data  showed  that  the  turnover  rate  of  m   rose
significantly from 4.1±0.4% m  per day under resting conditions, to 7.1±0.5% m  per day
during colitis (Fig 6.6b).
Dramatic differences were seen when BrdU incorporation by the F4/80
+ population
was compared on the basis of TLR2 expression. As with the total population of F4/80
+
cells, the uptake of BrdU by the TLR2
+ F4/80
+ subset from control mice rose from
7.8±0.8% on day 1, to 37.3±2.6% and 44.0±5.9% on days 4 and 6, respectively (Fig 6.7a).
However,  there  was  no  significant  increase  in  the  rate  of  proliferation  by  these
TLR2
+F4/80
+ cells during colitis, which showed identical values to those in control mice at
all times rising from 7.5±0.9% after 1 day, to 41.2±3.0% and 48.5±4.6% after 4 and 6 days,
respectively. Notably, although the levels of BrdU incorporation by the TLR2
- subset of
F4/80
+ cells also rose in control colon over time, from 1.9±0.3% after 1 day, to 8.8±3.3%
and 16.6±3.2% after 4 and 6 days, respectively (Fig 6.7a), these levels were significantly
lower than the equivalent values among the TLR2
+ cells at all times (p=0.0003). The TLR2
-
population also showed increased BrdU incorporation over time during colitis, rising from
2.5±0.7% after 1 day, to 5.0±1.0% and 15.5±3.3% after 4 and 6 days, respectively. Like the
TLR2
+ population, the overall turnover of the TLR2
- cells did not significantly change
during colitis compared with control mice, but at all times these levels were significantly
less  than  the  TLR2
+  subset  in colitic mice (p=<0.0001). Linear regression analysis
confirmed these differences between TLR2
+ and TLR2
- m , with overall turnover rates of
7.4±0.9% and 8.4±0.9% TLR2
+ m  per day in resting and inflamed colon versus 2.9±0.4%191
and 2.5±0.5% TLR2
- m  per day. These analyses also confirmed that the overall turnover
of the individual subsets was not different in the resting and inflamed intestine (Fig 6.7b).
To ensure that any differences in the levels of BrdU incorporation were not due to
differences in uptake of the BrdU-containing water between the groups, I measured daily
water consumption in water and DSS-fed groups. As shown in Fig 6.8, water intake in the
healthy group averaged around 4-6ml per mouse per day.  This decreased to <3ml by d3-4
of colitis and then increased again in subsequent days to similar levels consumed by the
water control group, suggesting increased BrdU intake did not account for the increased
level of BrdU incorporation observed in the DSS-fed group.
6.2 Expression of CCR2 and Gr-1 inflammatory markers by colonic m  in healthy
and inflamed intestine
As the lack of Ki-67 expression indicated that the F4/80
+ cells that had incorporated
BrdU had done so outside the intestine, I assessed whether these cells might express the
CCR2 chemokine receptor which is known to be involved in recruitment of inflammatory
m  to the intestine (327). Strikingly, 73.4±5.5% of the TLR2-expressing population of m 
in the resting intestine expressed high levels of CCR2, compared with only 22.6±4.5% of
the dominant TLR2
- population (Fig 6.9a). Similar differences concerning the CCR2
expression by each subset were seen during colitis, with 74.4±8.4% and 76.8±5.3% of the
TLR2
+ m  expressing CCR2 on days 3 and 7, respectively, compared with 27.5±3.0% and
16.6±4.3% of the TLR2
- population. The TLR2-expressing m  also expressed higher levels192
of the receptor than the TLR2
- subset under both resting and inflammatory conditions (Fig
6.9b). Thus TLR2
+ m  in the colon have constitutively higher levels of CCR2 expression
than their TLR2
- counterparts and this does not change during colitis.
As CCR2 and the Gr-1 granulocytic marker have been shown to be co-expressed on
the subset of inflammatory monocytes described in other studies, I examined if this applied
to the m  subpopulations in the inflamed intestine by assessing the expression of Gr-1. As
shown in Chapter 3, 29.6±7.8% of total F4/80
+ m  in the resting intestine expressed Gr-1
and this rose during colitis, particularly at later timepoints (Fig 6.10). Significantly higher
proportions of the TLR2
+ subset expressed Gr-1 at all timepoints compared with the TLR2
-
subset, and although the proportion of Gr-1-expressing F4/80
+TLR2
+ cells decreased
slightly on day 3 of colitis, this rose again by day 7. These results are further support for the
TLR2
+ subset being derived from inflammatory CCR2
+Gr-1
+ monocytes in both the resting
and inflamed colon.
6.3 Adoptive transfer of macrophages
I next set out to follow the recruitment of myeloid cell precursors into the intestine
by  more  direct  means,  with  the  ultimate  aims  of  determining  their  phenotype  and
monitoring their adaptation upon arrival in the normal or inflamed gut. To try and do this, I
transferred in vitro-differentiated BMM from Ly5.1
+ donors into normal Ly5.2
+ recipients
and analysed the appearance of donor cells in the BM, PLN, MLN, peritoneum, spleen and
colonic LP 24 and 48 hours later. However donor BMM could not be detected in any tissue193
apart from the peritoneum (Fig 6.11), where they were found in very low numbers at both
24 and 48 hours after transfer (Fig 6.12). I tried to repeat the experiment to obtain sufficient
cells in the intestine for analysis, but this was unsuccessful.
Summary
In this chapter, I have demonstrated that the appearance of increased numbers of
phenotypically  and  functionally  distinct  m   during  intestinal  inflammation  involves
substantial proliferation of myeloid cells, as measured by the incorporation of BrdU by total
F4/80
+ cells. However, there was minimal proliferation of m  in situ, suggesting that
colonic m  had proliferated outside the intestine before being recruited into the tissue.
Although there was a significantly increased rate of m  turnover throughout the course of
experimental colitis, this proliferation was restricted primarily to the TLR2-expressing
population of m . Interestingly, this population showed identical levels of turnover in the
resting and inflamed intestine, while the TLR2
- population had much lower turnover
kinetics  under  both  conditions.  A  substantial  population  of  the  BrdU
+  TLR2
+  cells
expressed low-intermediate levels of F4/80 and high levels of CD11b, suggesting these
may be recently derived from blood monocytes. In addition, these cells expressed high
levels of CCR2 and some Gr-1, markers of the inflammatory monocyte subset. Together
with my earlier finding that the TLR2
+ m  are the principal source of TNF  in colitis, these
results suggest that the functionally competent TLR2
+ m  that appear during inflammation
represent recruitment of recently divided inflammatory monocytes. As a small population
of TLR2
+ CCR2
+ BrdU
+ m  is also present in the resting colon, there may be constant194
turnover of these cells even in the absence of inflammation. Importantly, these cells are
quite distinct from their TLR2
- counterparts which are not turning over rapidly and are
CCR2
-.2 hours 24 hours
Figure 6.1 Turnover of monocyte precursors in the BM
Control C57Bl/6 mice were injected with PBS (left panel) or 1mg BrdU i.p.,
culled 2hrs (middle panel) or 24hrs later (right panel), and F4/80
+ BM cells
were analysed for BrdU incorporation by flow cytometry. Numbers in quadrants
represent percentages of the total, live-gated population.
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Figure 6.2 Macrophage turnover in the resting colon
Control C57Bl/6 mice were injected with 1mg BrdU i.p, and culled 24 hours
later, when colonic LP cells were harvested and stained for the expression of
F4/80, TLR2 and BrdU incorporation (A, B, C).  Numbers in quadrants
represent percentages of the total, live-gated population. D) The expression
of CD45 by live F4/80
- BrdU
+ cells. The results are representative of at least
three individual experiments.
13.1 3.9
3.2
29.6
196Figure 6.3 Macrophage turnover in the inflamed colon
C57Bl/6 mice were fed water or DSS and injected with 1mg BrdU i.p. on day 3 or
5, and culled a day later. A, B, and C show representative plots of colonic LP cells
from mice fed DSS for 6 days and stained for the expression of F4/80, TLR2 and
BrdU incorporation. D) The expression of CD45 by live F4/80
-BrdU
+ cells. E)
Mean percentages ± SD of F4/80
+ TLR2
+ and F4/80
+ TLR2
- cells which have
incorporated BrdU from 4 mice/group at different stages of colitis. ** p<0.01;
*** p<0.001.
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197Figure 6.4 Turnover and phenotype of F4/80
int m  in colon
C57Bl/6 mice were fed water or DSS for 4 days and colonic LP cells were
examined for the expression of CD45 and F4/80. A) Levels of F4/80
expression by live CD45
+ cells. B) Mice fed water or DSS for 4 days were
injected with 1mg BrdU i.p. on d3, culled 24 hours later and colonic LP
cells harvested. Live-gated F4/80
int BrdU
+ cells (R1) were examined for the
expression of CD11b (C) and for FSC and SSC properties (D).
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198Figure 6.5 In situ proliferation of m  in the resting and inflamed
intestine
Colonic LP cells fromC57Bl/6 mice fed water or DSS for 5 days were
stained for F4/80 and permeabilised for the detection of the nuclear antigen,
Ki-67, by flow cytometry. Results are shown as the mean percentages ± SD
of live F4/80
+ cells that are Ki-67
+ from 3 mice/group and are
representative of two individual experiments. *p=0.011.
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Figure 6.6 Turnover rates of colonic m  in the resting and inflamed colon
C57Bl/6 mice were given a single injection of 1mg BrdU i.p. on day 0 and drinking
water containing 0.8mg/ml BrdU was administered from day 0 onwards. Some mice
then had DSS added to the water, while controls received BrdU in water alone. Colon
LP cells were harvested 24 hrs, 4 days or 6 days later and analysed for the expression
of F4/80 and BrdU incorporation by flow cytometry. A) The mean percentages ± SD of
total, live-gated F4/80
+ cells positive for BrdU from 3 mice/group. B) Rate of
turnover of F4/80
+ cells calculated by linear regression analysis of BrdU
incorporation. ns=not significant; *p<0.05; **p<0.01.
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Figure 6.7 Turnover rates of colonic m  subsets in the resting and inflamed
colon
C57Bl/6 mice were given a single injection of 1mg BrdU i.p. on day 0 and drinking
water containing 0.8mg/ml BrdU was administered from day 0 onwards. Some mice
then had DSS added to the water, while controls received BrdU in water alone.
Colon LP cells were harvested 24 hrs, 4 days or 6 days later and analysed for the
expression of F4/80, TLR2 and BrdU incorporation by flow cytometry. A) The
mean percentages ± SD of total, live-gated F4/80
+TLR2
+ and F4/80
+TLR2
- cells
positive for BrdU from 3 mice/group. B) Rate of turnover of the two subsets
calculated by linear regression analysis of BrdU incorporation. **p<0.01;
***p<0.001; §§p<0.0001; §p=0.0003.
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201Figure 6.8 Consumption of BrdU-containing drinking water by
control and colitic mice
C57Bl/6 mice were given 0.8mg/ml BrdU in their drinking water and
some mice also received 2% DSS. Results are shown as the estimated
volume of water consumed per dayper mouse in each group calculated as
described in the Materials and Methods.
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202Figure 6.9 Expression of CCR2 by macrophages in the resting and
inflamed intestine
C57Bl/6 mice were fed water or DSS for 3 or 7 days, and total live-gated
colonic LP cells were analysed for the expression of F4/80, TLR2 and
CCR2 by flow cytometry. Results are shown as the mean percentages (A)
and mean MFI (B) ± SD of F4/80
+TLR2
-and F4/80
+TLR2
+ cells
expressing CCR2 from 4 mice/group. The results are representative of
two individual experiments. *p=0.031; ***p<0.001.
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Figure 6.10 Expression of Gr-1 by macrophages in the resting and inflamed
intestine
C57Bl/6 mice were fed water or DSS for 3 or 7 days and total live-gated colon LP
cells were analysed for the expression of F4/80, TLR2 and Gr-1 by flow cytometry
(A). B) The mean percentage ± SD of F4/80
+TLR2
- and F4/80
+TLR2
+ cells positive
for Gr-1 from 4 mice/group. The results are representative of two individual
experiments. ns=not significant; *p<0.05; **p<0.01; ***p<0.001.
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Figure 6.11 Analysis of recipient tissues after adoptive transfer of BMM
1x10
6 Ly5.1 BMM were transferred i.v. into congenic Ly5.2 recipients and BM (A),
pLN (B), mLN (C), spleen (D) and colon (E) cells were harvested from recipient mice
24 hrs later. The presence of Ly5.1
+ F4/80
+ cells was assessed by flow cytometry.
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Figure 6.12 Repopulation of PEC by adoptively transferred BMM
1x10
6 Ly5.1 BMM were transferred i.v. into congenic Ly5.2 recipients and
PEC were harvested from recipient mice 24 hrs (left panel) and 48 hrs
(right panel) later. The presence of Ly5.1
+F4/80
+ cells was assessed by
flow cytometry.
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Chapter 7
Effects of ES-62 on macrophage function and intestinal inflammation208
Introduction
The findings in my previous chapters, together with other published studies, have
demonstrated  the  critical  role  m   play  during  the  DSS-induced  model  of  intestinal
inflammation. DSS colitis does not require T or B cells and as I have shown, m  are the
principal producers of TNF  in this disease. As blockade of TNF  has already proven
beneficial in patients with Crohn’s disease (328), there is currently considerable interest in
targeting m  and their products as therapies for IBD. One molecule which is currently in
pre-clinical testing as a treatment for arthritis and other inflammatory disorders is ES-62
(306), a secreted phosphorylcholine (PC)-containing glycoprotein of the rodent filarial
nematode, Acanthocheilonema  viteae.  ES-62  modulates  pro-inflammatory  cytokine
production by m  in response to LPS and IFN  (315) and although it initially induces some
production of TNF  and IL-12 by m , it then renders these cells hyporesponsive to
subsequent stimulation with LPS and IFN . The low level cytokine induction by ES-62 is
abrogated in TLR4-deficient and MyD88-deficient mice (318), suggesting the effects are
TLR4/MyD88-dependent. However, the same study showed that LPS-unresponsive, TLR4-
mutant C3H/HeJ mice respond normally to ES-62, suggesting TLR4 must be present, but
does not need to be fully functional for ES-62 to exert its effects. Indeed it was recently
shown that binding of TLR4 by ES-62 prevents Fc RI-induced release of allergic mediators
from human mast cells and can prevent mast cell-dependent hypersensitivity in the skin and
airways (319).  ES-62 also suppresses the response of DCs and m  to other TLR ligands,
such as BLP and CpG (318), indicating that ES-62 may inhibit a signalling component
common to TLRs. Together these findings indicate that ES-62 can inhibit m  responses to209
bacterial products and other stimuli, and that this property may allow it to suppress
inflammatory disease in vivo. Therefore I examined whether the modulatory effects of ES-
62 on m  would influence DSS colitis in vivo.210
7.1 Effects of ES-62 on BMM function
I first wanted to confirm previous findings that ES-62 could modulate the pro-
inflammatory functions of m  and DCs. In these experiments, treatment of BMM with
LPS, but not BLP, increased the expression of CD40 and CD80 compared with medium
alone, but both LPS and BLP had little effect on the expression of CD86 or class II MHC
(Fig 7.1). In contrast, treatment with IFN  alone, or with LPS + IFN  or BLP + IFN 
markedly increased the expression of all co-stimulatory molecules, with IFN  treatment
alone inducing the highest levels of class II MHC expression. ES-62 alone had no effects
on the expression any of these molecules by BMM compared with medium alone. When
supernatants from these cultures were analysed for the production of pro-inflammatory
cytokines, treatment with either LPS or BLP alone induced production of intermediate
levels of TNF  and IL-6 (Fig 7.2a+b). However, treatment of BMM with BLP or LPS plus
IFN  induced high levels of TNF  and IL-6 production, and only these combined stimuli
induced any production of IL-12p70 (Fig 7.2c). No pro-inflammatory cytokines could be
detected after treatment of BMM with ES-62 alone.
These results indicated that ES-62 itself had no ability to induce a classical pattern
of m  activation, but as it has been suggested that helminths can induce polarisation of m 
toward the AAM subtype, I examined if ES-62 could affect the expression of markers
associated with this subtype. In this experiment, I used IL-4 as a positive control for
alternative activation of m , as well as LPS + IFN  to produce classical activation. PCR
was  used  to assess  the expression  of  mRNA  for  arginase and Ym-1  as  markers of211
alternative activation, and for iNOS as the marker for classical activation. BMM cultured
with medium showed induction of iNOS, and if anything LPS treatment seemed to decrease
this (Fig 7.3a). However, as expected, the strongest induction of iNOS was seen after
treatment with LPS + IFN . iNOS expression was also seen after treatment with ES-62 or
IL-4, but it is difficult to interpret this finding, as this was also seen with cells treated in
medium alone. Next, I examined the expression of the AAM marker, arginase, and found
that BMM expressed low levels of arginase mRNA when freshly isolated and this appeared
to increase following overnight culture in medium alone (Fig 7.3b). Interestingly, arginase
expression seemed to be downregulated when LPS or IFN  were present in the culture,
whereas culture with ES-62 or IL-4 induced levels similar to or even higher than those in
medium alone. The second AAM marker, Ym-1, was expressed by freshly isolated BMM,
and this expression was not affected by treatment with medium alone, ES-62 or IL-4.
However, Ym-1 expression seemed to be downregulated when LPS or IFN  were present.
Therefore, ES-62 seems to favour the development of an AMM rather than a CAM
phenotype, and it would be important to confirm these results by Q-PCR or at the protein
level.
7.2 Effects of ES-62 on responsiveness of DCs to re-stimulation
As ES-62 has also been reported to downregulate pro-inflammatory functions of
DCs, I used these cells to assess whether ES-62 would affect subsequent responsiveness to
stimulation. Thus BMDCs were cultured with ES-62 overnight, washed and re-stimulated
with  the  TLR  ligands,  BLP,  poly:IC,  LPS,  flagellin  and  CpG  and  assessed  for  the212
expression of co-stimulatory molecules and class II MHC, as well as for the production of
pro-inflammatory cytokines. As shown in Fig 7.4, ligation of all TLRs increased expression
of most co-stimulatory molecules and class II MHC, although the levels were somewhat
variable depending on the marker examined. Most importantly, none of these effects were
altered by pre-treatment with ES-62 in this experiment, although no formal statistical
analysis could be performed. When production of pro-inflammatory cytokines from the
same cultures was assessed, ligation of TLR2, 3, 4, 5 and 9 by their respective ligands
induced the production of TNF  and IL-6 above the levels seen with medium alone (Fig
7.5a+b). Although only duplicate wells were used and so no statistical analysis could be
carried out, pre-treatment of BMDC with ES-62 slightly reduced the subsequent TNF  and
IL-6 responses to BLP, but it had no effect on the responses to the other TLR ligands.
7.3 Effects of ES-62 on acute intestinal inflammation
To assess whether ES-62 is able to modulate acute intestinal inflammation, I
administered ES-62 i.p. to mice with DSS-induced colitis, beginning two days before DSS
was given (day-2) and every two days thereafter. The dose of ES-62 was based on previous
findings demonstrating the beneficial effect of ES-62 during CIA. As in the experiments
described  in  previous  chapters,  mice  began  to  lose  weight  after  4-5  days  of  DSS
administration and this was not significantly affected by treatment with ES-62 (Fig 7.6a).
Similarly, the colon shortening which occurred in colitis was not reduced by ES-62 (Fig
7.6b). However, when the individual components of clinical disease were evaluated
individually, ES-62 was seen to significantly reduce rectal bleeding on days 6 and 7 of213
colitis, as well as the total clinical score on day 5 (Fig 7.7). However it had no significant
effect on diarrhoea or on any of the other parameters at other times.
To assess the effects of ES-62 further, I measured pro-inflammatory cytokines in
supernatants of explants taken from the proximal and distal colon. Consistent with the
histological pattern of DSS colitis, explants of distal colon from PBS-treated colitic animals
produced significantly increased levels of TNF  and IL-6 compared with explants of
inflamed proximal or control colon, which both produced very little of either cytokine (Fig
7.8). ES-62 treatment had no significant effect on the enhanced production of cytokines
seen in the distal colon of colitic PBS-treated controls, although the levels were highly
variable and not significantly above control mice (Fig 7.8). I next assessed whether
treatment of colitic mice with ES-62 affected cellular infiltration into the colon, by
examining the expression of Ly6G, B220, CD4, CD8 and F4/80 to assess the presence of
neutrophils, B cells, CD4
+ T cells, CD8
+ T cells and m , respectively, among isolated LP
cells. As described in Chapter 5, the proportion of Ly6G
+ cells increased during colitis
compared with untreated control mice, and this was not affected by treatment with ES-62
(Fig 7.9). Consistent with the fact that SCID mice are susceptible to DSS-induced colitis,
the proportions of B cells, CD4
+ and CD8
+ T cells did not increase significantly during
colitis and none of these were affected by ES-62 treatment. ES-62 also did not affect m 
infiltration in colitis, but in contrast to the data shown in Chapter 5, the proportion of
F4/80
+ m  was not increased during colitis in this experiment. It should be noted that these
experiments were carried out much earlier and with a different enzymatic isolation
protocol, and thus are not directly comparable to results in previous chapters.214
To ensure that any differences between PBS- and ES-62-treated mice were not due
to the amount of water consumed and therefore DSS, water intake was monitored daily and
although DSS-fed animals consumed less water as the experiment progressed, there were
no differences between the PBS and ES-62 groups (Fig 7.10).
Due to the fact that ES-62 reduced the clinical aspects of colitis, but exerted little
effect on the other parameters measured, I postulated that this acute model of DSS colitis
might be too short-lived and severe for ES-62 to have had any effect. Therefore, I decided
to lower the dose of DSS from 2.5% to 2% to try and reduce the severity of disease. The
ES-62 dose used was the same as in the previous experiment, but ES-62 was injected s.c.
on this occasion to try and slow absorption into the bloodstream and maintain a more
constant level of ES-62 between injections. This was also the route used for ES-62
administration in the CIA experiments conducted by McInnes et  al (306). Under these
conditions, mice began to lose weight after 5-6 days of DSS administration and again ES-
62 had no effect (Fig 7.11a). However ES-62 did significantly reduce the colon shortening
(Fig 7.11b) found in this experiment and also reduced the diarrhoea and rectal bleeding on
day 8 (Fig 7.12). Overall these parameters were generally lower in ES-62-treated mice,
with the result that the total clinical score was significantly reduced on day 8 (Fig 7.12d).
As before there was increased pro-inflammatory cytokine production by explants of distal
colon from colitic mice compared with control mice, but ES-62 failed to reduce the levels
of these cytokines (Fig 7.13). Ly6G
hi neutrophils again infiltrated the inflamed intestine,
but ES-62 had no effect on this (Fig 7.14a). As before, the proportions of B cells and CD4
+215
T cells were unchanged during this model of colitis and were unaffected by treatment with
ES-62 (Fig 7.14). Although the numbers were extremely low, there was a small but
significant  increase  in  the  proportion  of  CD8
+  T  cells  in  the  ES-62-treated  group.
Unusually, the proportion of F4/80
+  cells  was  actually  lower  during  colitis  in  this
experiment, and this was not altered by ES-62 treatment (Fig 7.14).
As ES-62 seemed to have a variable and rather subtle ability to modify colitis in the
previous two experiments, I assessed whether a higher dose of ES-62 (10µg every two
days) could modulate the pathology more substantially. In addition, I used female mice,
which are considered to be less susceptible to DSS-induced colitis. However the disease
was not notably less severe in terms of time of onset or clinical aspects of disease, and even
at high doses, ES-62 had no significant effect on weight loss or colon shortening in this
experiment (Fig 7.15). Although there was significant reduction in rectal bleeding and the
total clinical scores on day 4 in the ES-62 treated animals, there were no effects at other
times or on other parameters of disease (Fig 7.16). Non-colitic control animals were not
used in this particular experiment due to lack of availability of ES-62.
7.4 Effects of ES-62 on chronic intestinal inflammation
As ES-62 had only minor and inconsistent effects on acute colitis, I next assessed its
effects in a chronic form of the disease which I postulated might allow any modulatory
effects of ES-62 to be observed more clearly. Thus, female mice received three 5-7 day
cycles of DSS administration with increasing DSS concentration in each cycle and a rest216
period of 7 days water administration in between each cycle. As shown in Fig 7.17, mice
began to lose weight after 5-6 days of the first cycle, but began to gain weight again 2-3
days after DSS was stopped on day 7. Thereafter they did not lose significant amounts of
weight when DSS administration was recommenced in the following cycles. In addition,
when measured on d33, colon shortening was less severe in the majority of colitic animals
(Fig 7.18) when compared with the acute colitis model (Fig 7.6+7.11+7.15). Clinical signs
of disease were also most apparent during the first cycle of DSS feeding and most animals
failed to show any signs of disease thereafter (Fig 7.19-7.22). ES-62 had little effect during
the first cycle of DSS treatment or at later timepoints when the disease was minimal. ES-62
also had no effect on colon shortening and it should be noted that three ES-62-treated mice
had to be culled on day 8 of the experiment due to severe disease, whereas all the DSS
treated control mice survived. Again the proportion of Ly6G
+ neutrophils in colonic LP
isolates was increased on d33 of disease compared with control animals (Fig 7.23a), but to
a lesser degree than in the acute model of colitis (Fig 7.9+7.14) and ES-62 treatment did
not affect this. The proportions of B cells, CD4
+ T cells, CD8
+ T cells and m  present in the
colon were not altered in chronic colitis and ES-62 did not affect these features (Fig 7.23).
Thus, ES-62 appeared to have no beneficial effect on chronic DSS colitis.
Summary
In this chapter, I found that ES-62 did not activate BMM either in terms of
upregulation  of  co-stimulatory  molecules  and  class  II  MHC,  or  production  of  pro-
inflammatory cytokines. Furthermore, in contrast to LPS + IFN , ES-62 favoured the217
expression of molecules expressed by the AAM subtype, such as Ym-1. However, I was
unable to confirm previous findings that pre-treatment with ES-62 could inhibit the
subsequent activation of BMDC in response to TLR ligation, although there may have been
slightly reduced pro-inflammatory cytokine production in response to the TLR2 ligand,
BLP. ES-62 had a subtle and rather variable effect on the development of acute DSS colitis,
chiefly by reducing some of the clinical signs of disease at earlier timepoints. However ES-
62 did not affect weight loss or colonic pro-inflammatory cytokine production, or the
cellular infiltrate during intestinal inflammation. Similarly, it had no effect clinical disease,
colon shortening or cellular infiltration during chronic intestinal inflammation. Therefore
ES-62 seems to provide some protection from the acute form of DSS colitis but not during
chronic intestinal inflammation.CD40
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Figure 7.1 Effects of ES-62 on class II MHC and co-stimulatory
molecule expression by BMM
BMM pooled from triplicate cultures were analysed immediately after
harvesting, or after culture in medium, 1µg/ml LPS, 100U/ml IFN , LPS +
IFN , 1µg/ml BLP, BLP + IFN  or 2µg/ml ES-62 for 18hrs and assessed for
the expression of CD40 (A), CD80 (B), CD86 (C) and class II MHC (D) by
flow cytometry. Results are shown as the MFI for each marker.
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Figure 7.2 Effects of ES-62 on pro-inflammatory cytokine production
by BMM
BMM were cultured in medium, 1µg/ml LPS, 100U/ml IFN , LPS + IFN ,
1µg/ml BLP, BLP + IFN  or 2µg/ml ES-62 for 18hrs and assessed for the
production of TNF  (A), IL-6 (B) and IL-12p70 (C) by ELISA. The results
shown are the mean concentration of cytokine ± SD for 3 replicates/group.
ns=not significant; *p<0.05; **p<0.01; ***p<0.001 versus medium
control.
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Figure 7.3 Effects of ES-62 on expression of iNOS, Arginase and Ym-1
mRNA
Freshly harvested BMM or BMM pooled from triplicate wells cultured in
medium, 1µg/ml LPS, 100U/ml IFN , LPS + IFN , 2µg/ml ES-62 or
40ng/ml IL-4 for 18hrs were assessed for the expression of iNOS (A),
arginase (B) and Ym-1 (C) mRNA by PCR.
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Figure 7.4 Effects of ES-62 on class II MHC and co-stimulatory
molecule expression by BMDC
BMDC were cultured in medium or 2µg/ml ES-62 for 24hrs, washed and
re-stimulated in medium or 1µg/ml BLP, 25µg/ml poly I:C, 2µg/ml LPS,
20 µg/ml flagellin or 3.2µg/ml CpG for a further 24hrs, before the
expression of CD40 (A), CD80 (B), CD86 (C) and class II MHC (D) was
assessed by flow cytometry. Results are shown as the MFI of expression
using BMDC pooled from duplicate wells.
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Figure 7.5 Effects of ES-62 on pro-inflammatory cytokine production by
BMDC
BMDC were cultured in medium or 2µg/ml ES-62 for 24hrs, washed and
re-stimulated in medium or 1µg/ml BLP, 25µg/ml poly I:C, 2µg/ml LPS, 20 µg/ml
flagellin or 3.2µg/ml CpG for a further 24hrs. The production of TNF  (A) and IL-6
(B) was then analysed by ELISA. Results are shown as the concentration of cytokine
for two replicates/group.
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Figure 7.6 Effects of ES-62 on weight loss and colon shortening
during acute colitis
Male C57Bl/6 mice received water or 2.5% DSS for 8 days and were
injected with PBS or 2µg ES-62 i.p. every second day starting two days
before DSS was given. Mice were weighed daily and the results in (A) are
the mean percentage ± SD change from initial weight. Colon lengths
were also recorded (B). ns=not significant.
A
B
223*Diarrhoea
1 2 3 4 5 6 7 8
0
1
2
3
4
Day
 
D
i
a
r
r
h
o
e
a
*Rectal bleeding
0 1 2 3 4 5 6 7 8 9
0
1
2
3
4
5 *
***
Day
 
R
e
c
t
a
l
 
b
l
e
e
d
i
n
g
Weight loss
1 2 3 4 5 6 7 8
0
1
2
3
4
Day
 
W
e
i
g
h
t
 
l
o
s
s
*Total clinical score
1 2 3 4 5 6 7 8
0
2
4
6
8
10
*
Day
 
T
o
t
a
l
 
c
l
i
n
i
c
a
l
 
s
c
o
r
e
Figure 7.7 Effects of ES-62 on clinical aspects of colitis
Male C57Bl/6 mice were given water or 2.5% DSS and injected with PBS or
2µg/ml ES-62 i.p. every second day (starting on day-2) and were monitored daily
for diarrhoea (A), rectal bleeding (B), weight loss (C) and total clinical score
(D), calculated as described in the Materials and Methods. n=6 for water control
groups and n=9 for colitis groups. Two-way ANOVAs revealed significant
differences, Bonferroni-corrected. *p<0.05; ***p<0.001.
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Figure 7.8 Effects of ES-62 on colonic pro-inflammatory cytokine
production during colitis
1cm segments of proximal or distal colon from male C57Bl/6 mice fed water or
2.5% DSS and injected with PBS or 2µg/ml ES-62 i.p. every second day were
cultured for 24hrs and the production of TNF  (A) and IL-6 (B) was measured by
ELISA. Results are shown as the mean OD ± SD for 3 mice/group. Two-way
ANOVAs revealed significant differences in distal control vs distal colitis for
TNF  and IL-6, but not PBS vs ES-62, Bonferroni-corrected. ns=not significant;
**p<0.01.
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Figure 7.9 Effects of ES-62 on the cellular composition of the inflamed
colon
Colons from male C57Bl/6 mice given water or 2.5% DSS for 7 days and
injected with PBS or 2µg/ml ES-62 i.p. every second day (starting on day-2)
were digested and the cells examined for the expression of Ly6G (A), B220
(B), CD4 (C), CD8 (D) and F4/80 (E) by flow cytometry. Results are shown
as the mean percentage ± SD for 3 mice/group. ns=not significant.
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Figure 7.10 Consumption of DSS-containing water during colitis
C57Bl/6 mice were given water or 2.5% DSS and injected with PBS or
2µg/ml ES-62 i.p. every second day (starting at day-2) and the volume of water
consumed per day per mouse in each group was calculated, as described in the
Material and Methods.
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Figure 7.11 Effects of ES-62 on severity of acute DSS colitis
Male C57Bl/6 mice received water or 2% DSS for 8 days and were
injected with PBS or 2µg ES-62 s.c. everysecond day starting two
days before DSS was given. Mice were weighed daily and the results
in (A) are the mean percentage ± SD change from initial weight for
10 mice/group. Colon lengths were also recorded (B). **p<0.01.
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Figure 7.12 Effects of ES-62 on clinical aspects of colitis
Male C57Bl/6 mice were given water or 2% DSS and injected with PBS
or 2µg/ml ES-62 s.c. every second day (starting on day-2) and were
monitored daily for diarrhoea (A), rectal bleeding (B), weight loss (C) and
total clinical score (D), calculated as described in the Materials and
Methods, for 10 mice/group. Two-way ANOVAs revealed significant
differences, Bonferroni-corrected. *p<0.05; ***p<0.001.
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Figure 7.13 Effects of ES-62 on colonic pro-inflammatory cytokine
production during colitis
1cm segments of proximal or distal colon from mice fed water or 2% DSS and
injected with PBS or 2µg/ml ES-62 s.c. every other day were cultured for 24hrs
and the production of TNF  (A), IL-6 (B) and IL-1  (C) was measured by
ELISA. Results are shown as the mean OD or cytokine concentration ± SD for 3
mice/group. Two-way ANOVAs revealed significant differences,
Bonferroni-corrected. ns=not significant; *p<0.05, **p<0.01; ***p<0.001.
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Figure 7.14 Effects of ES-62 on the cellular composition of the inflamed
colon
Colons from male C57Bl/6 mice given water or 2% DSS for 7 days and
injected with PBS or 2µg/ml ES-62 s.c. every second day (starting on day-2)
were digested and the cells examined for the expression of Ly6G (A), B220
(B), CD4 (C), CD8 (D) and F4/80 (E) by flow cytometry. Results are shown
as the mean percentage ± SD for 3 mice/group. ns=not significant;
***p<0.001.
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Figure 7.15 Effects of high dose ES-62 on weight loss and colon
shortening during acute colitis
Female C57Bl/6 mice received water or 2% DSS for 8 days and were
injected with PBS or 10µg ES-62 s.c. every second day starting two days
before DSS was given. Mice were weighed daily and the results in (A) are
shown as the mean percentage ± SD change from initial weight for 8
mice/group. Colon lengths were also recorded (B). ns=not significant.
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Figure 7.16 Effects of high dose ES-62 on clinical aspects of colitis
Female C57Bl/6 mice were given 2% DSS and injected with PBS or 10µg
ES-62 s.c. every second day (starting on day-2). Mice were monitored daily for
diarrhoea (A), rectal bleeding (B), weight loss (C) and total clinical score (D),
calculated as described in the Materials and Methods, for 8 mice/group.
Two-way ANOVAs revealed significant differences, Bonferroni-corrected.
**p<0.01.
233Figure 7.17 Effects of ES-62 on weight loss during chronic DSS colitis
Female C57Bl/6 mice were given three cycles of DSS for 5-7days, with a 7-day
rest period in between each cycle when they received water. The first cycle used
DSS at 1.5%, the second at 2% and the third at 2.5%. 2µg/ml ES-62 s.c was
administered every second day throughout the experiment commencing two days
before DSS administration began. Mice were weighed daily and results are
shown as the mean percentage ± SEM of change from initial body weight. n=4
for water control groups and n=10 for the colitis groups. Two-way ANOVA
(Bonferroni-corrected) revealed no significant difference between the PBS vs
ES-62 colitis groups.
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Figure 7.18 Effect of ES-62 on colon length during chronic colitis
Female C57Bl/6 mice were given three cycles of DSS for 5-7days, with a 7-day
rest period in between when they received water. The first cycle used DSS at
1.5%, the second at 2% and the third at 2.5%. 2µg/ml ES-62 s.c. was
administered every second day throughout the experiment commencing two
days before DSS administration began. Colon lengths were recorded on d33
(except from 3 mice in the DSS + ES-62 group which were measured on day 8)
and n=4 for water control groups and n=10 for the colitis groups. ns=not
significant.
236Figure 7.19 Effects of ES-62 on diarrhoea during chronic DSS colitis
Female C57Bl/6 mice were given three cycles of DSS for 5-7days, with a
7-day rest period in between each cycle when they received water. The first
cycle used DSS at 1.5%, the second at 2% and the third at 2.5%. 2µg/ml
ES-62 s.c. was administered every second day throughout the experiment
commencing two days before DSS administration began. Mice were
monitored daily for the presence of diarrhoea and results are shown as the
mean percentage ± SEM of diarrhoea score. n=4 for water control groups and
n=10 for the colitis groups. Two-way ANOVA (Bonferroni-corrected)
revealed no significant differences between the PBS and ES-62 colitis groups.
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238Figure 7.20 Effects of ES-62 on rectal bleeding during chronic DSS colitis
Female C57Bl/6 mice were given three cycles of DSS for 5-7days, with a 7-day
rest period in between each cycle when they received water. The first cycle used
DSS at 1.5%, the second at 2% and the third at 2.5%. 2µg/ml ES-62 s.c was
administered every second day throughout the experiment commencing two
days before DSS administration began. Mice were monitored daily for the
presence of rectal bleeding and results are shown as the mean percentage ±
SEM of bleeding score. n=4 for water control groups and n=10 for the colitis
groups. Two-way ANOVA (Bonferroni-corrected) revealed no significant
differences between the PBS and ES-62 colitis groups.
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240Figure 7.21 Effects of ES-62 on weight loss during chronic DSS colitis
Female C57Bl/6 mice were given three cycles of DSS for 5-7days, with a 7-day
rest period in between each cycle when they received water. The first cycle
used DSS at 1.5%, the second at 2% and the third at 2.5%. 2µg/ml ES-62 s.c.
was administered every second day throughout the experiment commencing
two days before DSS administration began. Mice were monitored daily for
weight loss and results are shown as the mean percentage ± SEM of weight loss
score. n=4 for water control groups and n=10 for the colitis groups. Two-way
ANOVA (Bonferroni-corrected) revealed no significant differences between
the PBS and ES-62 colitis groups.
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242Figure 7.22 Effects of ES-62 on total clinical score during chronic DSS
colitis
Female C57Bl/6 mice were given three cycles of DSS for 5-7days, with a 7-day
rest period in between each cycle when they received water. The first cycle
used DSS at 1.5%, the second at 2% and the third at 2.5%. 2µg/ml ES-62 s.c
was administered every second day throughout the experiment commencing
two days before DSS administration began. Mice were monitored daily for the
total clinical score and results are shown as the mean percentage ± SEM of
total clinical score. n=4 for water control groups and n=10 for the colitis
groups. Two-way ANOVA (Bonferroni-corrected) revealed no significant
differences between the PBS and ES-62 colitis groups.
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Figure 7.23 Effects of ES-62 on the cellular composition of the chronically
inflamed colon
Female C57Bl/6 mice were given three cycles of DSS for 5-7days, with a 7-day rest
period in between each cycle when they received water. The first cycle used DSS at
1.5%, the second at 2% and the third at 2.5%. 2µg/ml ES-62 s.c. was administered
every second day throughout the experiment commencing two days before DSS
administration began. Colons were digested on day 33 and the cells examined for
the expression of Ly6G (A), B220 (B), CD4 (C), CD8 (D) and F4/80 (E) by flow
cytometry. Results are shown as the mean percentage ± SD for 3 mice/group.
ns=not significant.
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Chapter 8
Discussion247
The intestinal immune system faces the onerous task of protecting the body against
pathogens whilst regulating responses directed at self-tissues, food antigens and the vast
number of commensal microbes that reside in this tissue. Thus, cellular immune responses
in the intestine have to be tightly regulated to ensure protection against infection without
immunopathology. It has long been known that m  contribute to tissue destruction in a
number of inflammatory diseases via the production of pro-inflammatory and tissue-
destroying  mediators.  This  is  particularly  true  in  the  gut,  where  m -derived  pro-
inflammatory cytokines are central mediators of disease and can be targeted therapeutically.
However, m  are also known to have apparently paradoxical roles in protective immunity
and tissue repair in the inflamed gut, stressing the need for further investigation into the
roles intestinal m  play in health and inflammation.
When I started my project, there was a paucity of information on m  biology in the
resting intestine, and the studies which had been published had focused primarily on small
bowel m  from human biopsies ex vivo. This work had suggested that small bowel m  had
dramatically downregulated pro-inflammatory functions, such as cytokine production, but
retained the ability to engulf and kill bacteria (188). Furthermore, despite their potent
phagocytic and bactericidal activity, human intestinal m  fail to show respiratory burst
activity (196), or NO production via iNOS (197, 198). The basis of this was relatively
unexplored, as was the possibility that different subsets of m  might account for these
distinct homeostatic and/or pathological roles. Phenotypic studies of human colonic m  had
demonstrated a similar phenotype, with low levels of the LPS co-receptor, CD14, class II
MHC and co-stimulatory molecules, and they are also phagocytic, but no further functional248
studies were carried out (187). Thus the aims of my thesis were to conduct a more thorough
characterisation of colonic m  in the resting and inflamed intestine using established
systems in inbred mice. In this way, I hoped to understand more clearly the role m , and
possibly distinct subsets of m , play in intestinal inflammation and homeostasis. In
particular, I sought to investigate whether there were m  subsets with different functions in
health and disease, to try to assess the origin of these cells and how they relate to the
resident m  found in the resting state. The studies described in this thesis have generated a
number of novel observations with regard to the function, regulation, origin and turnover of
m  subsets in the resting and inflamed intestine.
8.1 Phenotype of resident colonic macrophages in normal mice
My initial experiments, described in Chapter 3, examined the phenotypic and
functional characteristics of resident m  in the colon of normal mice. M  have been shown
to be abundant in the human intestine, suggesting an important role of these cells in
intestinal homeostasis, and I found a similarly large population of F4/80
+ m  in the resting
colonic LP of mice. Interestingly, during my studies in the IL-10KO model, I observed that
the proportion and absolute numbers of m  were slightly higher in older WT and KO mice,
but that the level of class II MHC expression was lower compared with their younger
counterparts. This could suggest that the colonic m  pool may expand with age and/or
exposure to microbes, but that this is associated with lower basal levels of class II MHC.249
I next set out to explore the phenotype of these cells in more detail as this had not
been done in mice to any extent. Although m  in the human small and large intestine have
been examined phenotypically, several differences were observed between these sites.
Human colonic m  express the human m  marker, macrosialin (CD68) and low levels of
CD11c, but unlike blood monocytes, express only low levels of class II MHC and CD11b
(187). In contrast, human small intestinal m  express the zinc metalloproteinase, CD13,
and high levels of class II MHC, but unlike blood monocytes, fail to express CD11b,
CD11c, and the integrin LFA-1 (CD11a/CD18) (188). Previous studies in mice have shown
that m  in the normal and helminth-infected colon express F4/80 and CD11b, but lack
CD11c expression (186).
In view of the discrepancies and the lack of information on murine intestinal m , I
first performed a detailed phenotypic characterisation of the myeloid cell population in the
colon of resting mice, using F4/80 to identify m  (44, 185). Like m  in other tissues,
isolated colonic F4/80
+ cells were large cells with cytoplasmic processes and the majority
(70%) expressed intracellular CD68. Identical F4/80
+CD68
+ cells were found in BMM and
PEC  m ,  and  all  had  FSC/SSC  properties  of  m .  However,  the  smaller  subset  of
F4/80
+CD68
- cells in the colon appeared heterogeneous in terms of FSC/SSC properties,
and included some large cells not seen in the F4/80
+CD68
+ gate. The identity of these cells
is unclear and I was unable to find a previous description of cells with a similar phenotype.
It would be interesting to examine whether these cells were included among the F4/80
+
population that was negative for CD11b expression (see below). One possibility is that they
are eosinophils, as these have been shown to express F4/80 (48) and this could be assessed250
by  histochemical  analysis  of  purified  F4/80
+CD68
-  cells.  However,  my  preliminary
assessment of the cytospins suggested that there were no granular cells of this kind in the
total colonic F4/80
+ population.
I also assessed the expression of CD115, the M-CSFR, which is critical for the
development of m  (158) and is commonly used as a marker for monocytes in the mouse.
In contrast to PEC m  and to an even greater extent BMM, colonic m  expressed very low
levels of CD115. This could reflect differentiation status, or could be due to ligand-induced
receptor internalisation (329), secondary to the high levels of M-CSF present in the colon
(195). To discriminate between these ideas, it would be interesting to examine if culture of
colonic F4/80
+ cells in the absence of M-CSF allowed expression of CD115, as this would
presumably reverse the effects of M-CSF. In addition, it would be important to assess the
expression of CD115 mRNA in normal colonic m . Alternatively, the c-fms (CSF-1R)-GFP
reporter mice could be used to determine if this receptor has been expressed at any time
during colonic m  development, as this may provide an insight into the requirement for
CD115 signalling in the survival and/or differentiation of colonic m .
Unlike BMM and PEC m , a significant proportion of colonic F4/80
+ cells (~30%)
expressed the granulocytic marker, Gr-1. As Gr-1 expression has been associated with the
‘inflammatory’ subset of blood monocytes (168), it could be that the Gr-1-expressing and
Gr-1
- F4/80
+ cells in the colon derive from distinct precursors. Adoptive transfer studies
using different monocyte subsets would be needed to resolve this issue fully, although
functional studies of the sorted subsets could also be useful. It is also possible that at least251
some of these Gr-1
+ cells in the colon are granulocytes such as eosinophils which are
known to express Gr-1 (330).
Compared  with  m  from the resting peritoneum and BMM, which almost all
exhibited the F4/80
+CD11b
+CD11c
- phenotype of conventional mouse m , colonic F4/80
+
cells showed a strikingly high degree of heterogeneity and could be separated into three
distinct subsets on the basis of these markers. These included an F4/80
+CD11b
+CD11c
int
subset, an F4/80
+CD11b
+CD11c
- subset and a smaller F4/80 single positive subset. There
were no consistent differences in SSC/FSC properties or in terms of morphology when the
subsets were examined in preparations of purified F4/80
+ cells from the colon. All the
F4/80
+ cells were large cells with cytoplasmic processes and no granular cells were
apparent. It would be useful to conduct more detailed histological staining and/or electron
microscopy on the different F4/80
+ subsets to explore any morphological differences such
as  numbers  of  lysosomes  or  granules,  as  this  may  indicate  functional  differences.
Importantly, the phenotypic characteristics of colonic m  appear not to be due to the
isolation procedure, as PEC m  treated with the same enzymes and protocol showed no
detectable differences in the expression of the myeloid markers.
I next assessed the activation status of colonic m  and found that in contrast to
BMM and PEC m , the majority of freshly isolated colonic m  expressed high levels of
class II MHC. These levels were higher than had been described in previous work (115),
but as the earlier study had examined CD11b-expressing cells in the mouse colon, the
findings may not be directly comparable. However in agreement with the previous study, I252
found low expression of the co-stimulatory molecules CD40, CD80 and CD86 on resting
colonic m . Freshly isolated BMM also expressed low levels of co-stimulatory molecules,
whereas PEC m  expressed higher levels of these markers, especially CD40 and CD86.
Although co-stimulatory molecule expression by the individual subsets was not examined,
the subsets differed in class II MHC expression, with the F4/80
+CD11b
-CD11c
- subset
being almost completely negative, while the other subsets expressed high levels. On the
basis of their conventional m  phenotype, I would conclude that the F4/80
+CD11b
+CD11c
-
cells in the colon are bone fide tissue m , but the nature of the other two subsets is less
clear. The identity of the F4/80
+CD11b
- cells I found in the colon is also unknown and I
have been unable to find any published evidence of cells with a similar phenotype. As
discussed above, they have a similar mononuclear morphology to the F4/80
+CD11b
+ cells,
which would argue against them being eosinophils that can express low levels of F4/80
(48). Nevertheless, it would be useful to examine this more directly by assessing the
expression of CCR3 or Siglec F, both of which are expressed preferentially by eosinophils
(331, 332).
The F4/80
+CD11b
+CD11c
int subset is particularly interesting, given the fact that
they co-express m  and DC markers. Similar cells have been seen in the small intestine
(Palendran, B and Agace, WW; personal communication), kidney (333), lung (229) and the
inflamed peritoneum (work in our laboratory by Bordon, Y). These are probably not
classical DCs, which are likely to be the F4/80
-CD11c
hi cells I found. These expressed
higher levels of CD11c, as well as class II MHC and were the only cells that expressed
CD103, the marker of small intestinal DC (30, 334). Nevertheless, epidermal LCs, which253
may represent an immature population of myeloid DCs, express F4/80 and therefore the
F4/80
+CD11b
+CD11c
int cells in the colon could also represent an early stage of myeloid
cell differentiation with the potential to develop into either m  or DCs. This is consistent
with the small number of F4/80
+CD11c
lo present in BMM, although I could find no formal
evidence that myeloid cell precursors co-express F4/80 and CD11c. Rather, it seems more
likely to be a mature cell of some kind, given the high levels of F4/80 and class II MHC
expression (335). Nevertheless, it should be noted that plasmacytoid DC-like cells in
melanoma-bearing mice have also been reported to be F4/80
+CD11c
+ (336), and therefore
the nature of these cells in the colon warrants further study.
Studies over the last 10-15 years have supported the idea that DC and m  are
distinct lineages of myeloid cell with separate progenitors and functions. However, there is
now increasing confusion over their exact relationship, with more and more overlap being
found between their markers and precursors. Thus, although it was thought initially that DC
development  occurred  independently  of  M-CSF  (160),  which  is  essential  for  m 
development, more recent studies suggest that all monocytes, DCs and m  derive from a
CX3CR1
+ CSF-1R
+ CD117
+ Lin
- common precursor (152). In addition, DC appear to have
expressed the c-fms (CSF-1R) promoter (337) and it has been shown that myeloid DC
numbers are dependent on CSF-1 in vivo (338).
Therefore  DCs  and  m   may share a common circulating precursor that may
differentiate separately once in tissues, under the control of the local environment. This is
supported by the ability to generate conventional DC from human and murine PBMC254
monocytes, and from findings from in vitro transendothelial migration and in vivo studies
(171, 339). Thus the unusual subset of F4/80
+CD11c
int cells in the colon could represent an
unusually activated form of either DC or m .
The best way to distinguish DCs and m  is probably functionally, by comparing
antigen-presenting capacity, CCR7-dependent LN migration or bactericidal capacity. DCs
are usually considered to be the only APC capable of priming naïve CD4
+ T cells in LN,
perhaps reflecting the presence of a less proteolytic environment within DC compared with
m , allowing sustained antigen presentation (340). In addition, tissue DCs upregulate
CCR7 after taking up antigen, and migrate to the draining LN under the influence of ELC
(CCL19) and SLC (CCL21) (341, 342). Although these are usually thought to be unique
properties of DCs, it has been shown that CD11c
- m  can upregulate class II MHC and may
be able to migrate to LN and present antigen to naïve CD8
+ T cells in vivo (40), suggesting
they can initiate antigen presentation in some situations. However, it has not been shown
that the migration of m  to LN is CCR7-dependent, nor if such m  can prime naïve CD4
+ T
cells in vivo. Therefore their APC activity may not be similar to, or as efficient as DCs, but
this needs to be addressed directly. Thus it would be interesting to examine the expression
of CCR7 on colonic m , test their ability to migrate in vitro in response to CCR7 ligands
and assess their ability to present antigen to naïve CD4
+ T cells.
On the other hand, m  are generally considered to be more bactericidal than DC,
being capable of producing high levels of toxic mediators such as ROI, NO and lysosomal
proteases. Although some DCs may produce TNF  and iNOS during microbial infection255
(343), this is an unusual feature and therefore the high bactericidal capacity of intestinal m 
(188) supports the idea that the colonic F4/80
+ cells may be m . It would be important to
determine if the F4/80
+CD11c
int subset show such properties.
8.2 Functional characterisation of macrophages in the resting colon
Although I did not have time to assess the functions of the individual F4/80
+
subsets, I did examine the whole population of F4/80
+ cells. Here, in contrast to BMM and
PEC m , which upregulated CD40, CD80 and CD86 to some extent following stimulation
with LPS or LPS + IFN , colonic F4/80
+ m  failed to upregulate these co-stimulatory
molecules. However, unlike BMM and PEC m  which failed to express class II MHC when
freshly isolated, or after stimulation with LPS + IFN , colonic m  expressed class II MHC
when freshly isolated and after overnight culture.
As expected, BMM and PEC m  stimulated with LPS + IFN  produced the pro-
inflammatory cytokines TNF , IL-6 and IL-12p70. In stark contrast and in agreement with
previous studies (188), there was negligible production of any of these cytokines by the
total colonic F4/80
+ population after overnight stimulation with LPS + IFN . However,
there was some response to BLP by colonic m . The hyporesponsive phenotype of colonic
m  extended to Nod2 stimulation via MDP, whereas BMM produced TNF  under the same
conditions. This is consistent with previous findings that human intestinal m  fail to make
pro-inflammatory cytokines in response to Nod2 ligation (106). My findings that MDP
induced TNF  production by BMM, especially when used together with BLP support some256
findings, but not others (344, 345). In contrast, TNF  production by colonic m  in response
to BLP was lower when MDP + BLP were used together. Although this could mean that the
interplay between the Nod/TLR pathways differs in colonic m  compared with other m 
populations, these experiments were only performed once and would thus have to be
repeated.
In  contrast  to  BMM  and  PEC  m ,  colonic  m   failed  to  produce  the  pro-
inflammatory chemokines IP-10, KC, MCP-1, MIG, MIP-1 ,  RANTES  and  MIP-1 
following  stimulation  with  LPS  +  IFN .  However,  low  levels  of  the  neutrophil
chemoattractant, KC, were produced. This suggests that m  resident in the normal colon
are profoundly impaired in their ability to influence the chemokine-mediated infiltration of
inflammatory cells. I was only able to do this experiment once and therefore it needs
repeated, but these results are consistent with the idea that colonic m  have a generalised
inability to react in a pro-inflammatory manner (Table 8.1). Nevertheless, it is important to
note that the viability of the F4/80
+ population decreased to 80-85% after overnight culture,
and thus the presence of dead or dying cells could influence my interpretation as the normal
function of the viable m  could be affected.257
Marker/Function F4/80
+ BMM F4/80
+ PEC m  F4/80
+ colonic m 
CD11b + +++ 75% (+)
CD11c - - 35% (+)
TLR2 ++ ++ 30% (+)
TLR3 ++ ++ -
TLR4 ++ ++ -
TLR9 ++ ++ -
Class II MHC - - 75% (+++)
CD40 - + -
CD80 +/- + +/-
CD86 +/- + +/-
TNF  production +++ ++ -
Chemokine
production
++ ++ -
Phagocytosis ++ +++ ++
Endocytosis +++ + ++
Table 8.1 Comparison of different macrophage populations
For markers:
-  - No expression; +/- very low; + low; ++ moderate; +++ high
-  % The proportion of the total F4/80
+ population expressing marker
For cytokines/chemokines:
-  - No production; ++ moderate production; +++ high production
For endocytosis/phagocytosis:
-  + Low uptake; ++ moderate uptake; +++ high uptake258
Despite their lack of pro-inflammatory functions, I found that colonic m  retained avid
endocytic and phagocytic activities comparable to the other m   populations. Similar
phagocytic activity has been demonstrated for human small bowel m , which were also
shown to kill internalised bacteria (188). It is unclear what mediators are used by human
small bowel m  to kill bacteria given that they lack iNOS expression and respiratory burst
activity (196-198). Thus it would be important to determine the bactericidal capacity of
colonic  m   and,  if  they  lack  these  anti-microbial  mechanisms,  to  investigate  what
mechanisms may be involved in this process, such as acidification, acid hydrolases,
lysozyme, and nutrient competitors such as lactoferrin.
In view of their non-inflammatory properties, I considered the possibility that
colonic m  may be alternatively activated m  (AAM). Like colonic m , IL-4 and/or IL-13
induced AAM do not produce pro-inflammatory cytokines or NO, but they express class II
MHC, are phagocytic and are involved in Th2-type anti-parasite responses (178). In
addition, co-infection of mice with Heligmosomoides polygyrus exacerbates C. rodentium
colitis and this is associated with the induction of AAM (346). It would be important to
examine the expression of other markers associated with AMM, such as the mannose
receptor and Ym-1, or the production of the AMM-associated chemokines, CCL17 and
CCL22,  in  colonic  m .  Due  to  time  constraints,  I  was  unable  to  carry  out  these
experiments.
Despite lacking the expression of CD40, CD80 or CD86, colonic m  retained class
II MHC expression, suggesting they could act as tolerogenic APCs, producing T cell259
anergy, or possibly the differentiation of regulatory T cells (347, 348). This would be
consistent with the recent finding that small intestinal F4/80
+CD11b
+CD11c
dull m -like
cells can induce the differentiation of FoxP3
+ T regulatory cells in vitro (235). In addition,
mice lacking F4/80 do not develop oral tolerance after feeding protein antigens, and this is
associated  with  defective  induction  of  CD8
+  T  regulatory  cells  (236).  To  test  the
tolerogenic capacity of colonic m , I could purify F4/80
+ cells from the resting colon, load
them in vitro with ovalbumin (OVA) and examine their ability to stimulate T cells by
culturing them with OVA-specific OT-II transgenic T cells and assessing the functional
profile of the responding T cells, such as proliferation, cytokine production and FoxP3
expression.
For all of these functional assays, it would be important to assess the properties of
the individual subsets I had identified, by first FACS-sorting the cells into individual
subsets to define whether they differ in these functions.
8.3 Regulation of colonic macrophage responsiveness
In Chapter 4, I went on to examine the mechanisms of hyporesponsiveness in
colonic m  by examining their expression of the TLRs, which mediate the recognition of
microbial stimuli. Colonic m  showed a complete lack of surface TLR4 and intracellular
TLR3 and 9 protein expression, in contrast to BMM and PEC m  which all expressed these
TLRs. However, a small proportion of F4/80
+ cells in the resting colon retained the
expression of surface TLR2, consistent with their partial responsiveness to the TLR2260
ligand, BLP. The only previous study examining the expression of TLR proteins on m 
from the normal human intestinal mucosa found no expression of TLR4 or TLR2, and did
not examine surface or intracellular TLR3 or 9 (199). Although contested, some workers
have reported that TLR4 is also absent on mucosal DC (203, 349). In that work, it was also
suggested that small bowel DCs express TLR5 and respond to its ligand, flagellin. However
I was unable to examine the expression of TLR5 on F4/80
+ colonic m  due to a lack of an
effective antibody, and due to time constraints, was unable to examine the colonic m 
response to flagellin stimulation.
Unusually, I found that a small proportion of F4/80
+ cells in the colon (~8%)
expressed TLR3 on their surface. Surface TLR3 expression has been shown on human
endothelial cells (350), and experiments culturing colonic m  with TLR3 ligand would be
required to assess if this expression is functionally significant. Thus, the overall TLR
hyporesponsiveness of intestinal m  is associated with a lack of most of the relevant
receptor proteins confirming previous studies showing the lack of CD14 expression (194).
As with their other characteristics, the lack of TLR proteins in colonic m  was not
due to the isolation procedure, as PEC m  treated with the same enzymes and protocol
showed no detectable differences in the expression of TLRs. It would be useful to confirm
my results from isolated m  by using immunohistochemistry to assess TLR expression by
colonic m  in situ, and by measuring TLR proteins by Western blotting. However it should
be noted that the absence of CD14 and CD89 on isolated human small bowel m  was261
confirmed with immunohistological analysis, and was also not a function of the isolation
procedure (194), supporting the idea that these cells genuinely lack TLR expression in vivo.
Due to the fact that a proportion of colonic m  retained expression of TLR2, I
assessed whether this was associated with one or other of the phenotypic subsets I had
previously identified. As a result, I found that the unusual F4/80
+CD11b
+CD11c
intclass II
MHC
+ subset contained the highest proportion of TLR2-expressing cells (73%). In contrast,
the F4/80
+CD11b
- cells, which failed to express class II MHC, also failed to express any
TLR2. As I will discuss later, it appears that this pattern of TLR2 expression may define a
functionally distinct lineage of m  in the resting and inflamed colon.
Several mechanisms of TLR hyporesponsiveness have been described, including
inhibition of TLR transcription, synthesis and signalling (114-116). I therefore tried to
assess the level at which TLR expression was modulated in colonic m . Although there was
no previous evidence to suggest it might occur, I hypothesised that enhanced internalisation
of TLRs could be a way of regulating TLR ligation and signalling. I therefore examined
whether TLR2 and 4 could be detected intracellularly in colonic m . This was not the case,
suggesting that these TLRs are not simply internalised by the cells. This contrasts with
findings that murine colonic m  may retain low levels of intracellular CD14 expression
(202) and therefore it could be that the TLR proteins themselves are still being synthesised
in colonic m , but are then rapidly recycled/degraded. It would be interesting to conduct
formal experiments on the biosynthesis of TLR proteins in colonic m  and examine the262
effects  of  blocking  degradative  processes  such  as  proteasome  activity  or  lysosomal
digestion.
Although I was unable to do such experiments, I did examine TLR transcriptional
activity in colonic m  by PCR analysis. Non-quantitative PCR first showed that BMM,
PEC m  and colonic m  all expressed mRNA for TLR1, 2, 3, 4, 6 and 9. However in
contrast to BMM and PEC m , colonic m  appeared to express only low levels of TLR7
mRNA. This is in contrast to previous studies showing that human colonic m  from the
normal mucosa fail to express TLR1-5 mRNA (199), although human small intestinal m 
have  been  shown  to  express  TLR2  and  4  mRNA  (194).  This  has  not  been  studied
previously in mice, but these results suggested TLR mRNA synthesis might be regulated
differentially in m  depending on the region of the gastrointestinal tract and/or the species.
Because of these apparent contradictions, I performed Q-PCR analysis of TLR mRNA
expression. These experiments showed that colonic m  expressed reduced amounts of
mRNA for TLR2 and 4 compared with the other m  populations, indicating that control of
their expression may occur at both the transcriptional and post-transcriptional levels. Little
is  known  about  the  transcriptional  control  of  TLR  expression,  although  LPS  and
inflammatory cytokines such as IL-1 , IFN  and TNF  can induce the expression of the
TLR2 gene in m  via NF B activation (101). The transcription factor PU. 1 and the IFN
consensus sequence-binding protein are also involved in the basal regulation of TLR4 in
human m  (99), and therefore it would be interesting to examine their expression in colonic
m . In contrast, TLR9 mRNA levels were normal in colonic m , showing that it is
regulated post-transcriptionally, either during translation, protein folding or chaperoning to263
the correct cellular locale. As discussed above, functional TLR9 could be synthesised in
colonic m  but then be degraded rapidly. To examine the level of expression of other TLRs
and examine how this is controlled in colonic m , it would also be important to perform Q-
PCR for other TLRs such as TLR7, which appeared reduced in the end-product PCR
experiments, and also for the TLRs for which protein expression could not be analysed due
to a lack of available antibodies.
If TLR proteins could be detected in colonic m  by Western blotting, it is possible
that these cells have a defect in the ability to fold TLR proteins correctly and/or deliver
them to the appropriate cellular compartment. Indeed murine colonic m  have been
reported to lack the TLR chaperone, gp96, which controls TLR2, 4, 5, 7 and 9 expression
(351). However gp96 is expressed in normal human intestinal m , suggesting this is either
not the explanation, or again that distinct mechanisms may be involved in the two species.
Therefore it would be interesting to determine whether gp96 expression correlates with
TLR expression in murine colonic m . A further candidate regulator I could examine might
be Triad3A, which targets TLR4 and 9, but not TLR2, for degradation (110). Triad3A has
never been examined in intestinal m , but as it may explain the specific pattern of TLR
expression I observed, it would be important to determine its expression.
To investigate whether the lack of TLR expression was a permanent feature, or was
dependent on constant exposure to the intestinal environment, I cultured purified F4/80
+
cells overnight and found no differences in the expression of TLR2 or 4. This is consistent
with the finding that CD14 and CD89 were not expressed by human intestinal m  cultured264
for long periods ex vivo (194). This suggests that if the intestinal microenvironment is
conditioning these cells, then the altered phenotype may be irreversible. It would be
important to culture purified colonic m  for longer periods to see if a longer withdrawal
from the intestinal microenvironment could induce the expression of TLRs, but I found
such experiments difficult due to the poor viability of colonic m  after prolonged culture.
8.4 Effects of TLR signalling on TLR expression by macrophages
Given that colonic m  are thought to be derived mostly from circulating monocytes,
which express a range of functional TLRs (199), it could be that the unusual phenotype of
colonic m  is due to a conditioning effect by the intestinal microenvironment. Thus, I
hypothesised that this lack of TLR expression by colonic m  could reflect the presence of
TLR ligands in the colon, as constant ligation of certain TLR on m  has been shown to
result in the downregulation of the corresponding receptor. This accounts for the well
known phenomenon of LPS tolerance, in which exposure to LPS downregulates TLR4
(102) and it has also been described for some other TLRs, such as TLR2 (105).
To examine if TLR ligation might explain the global lack of TLR on colonic m , I
first examined whether culture of TLR
+ BMM with various TLR ligands would alter the
expression of the cognate and non-cognate TLRs. These experiments confirmed that LPS
dramatically  reduced  the  surface  expression  of  TLR4,  but  some  intracellular  TLR4
remained detectable and LPS had no effects on other TLR proteins. In addition, the other
TLR ligands, BLP, poly I:C and CpG did not affect the expression of their corresponding265
TLRs, or of the other TLRs. This is in contrast to previous findings that BLP treatment
reduces TLR2 expression in the THP-1 monocyte cell line (105), and that low dose CpG
reduces intracellular TLR9 in RAW m  cell line (352). Similar studies have not been
performed previously for TLR3. Given that I used similar culture periods, the reasons for
these discrepancies could include the use of cell lines and different doses of TLR agonists
in the previous studies. The inability of LPS to affect the expression of the other TLR
proteins, together with the fact that I could not detect TLR4 in colonic m  following
permeablisation, suggests that LPS itself is not the only factor involved in the regulation of
TLR  in  colonic  m .  In  addition,  as  none  of  the  other  TLR  agonists  affected  TLR
expression, they themselves also seem unlikely to be responsible for the phenotype of
colonic m .
To follow up the effects of TLR ligation on TLR expression in more detail, I next
assessed the effect of prior TLR stimulation on the expression of TLR mRNA in BMM, as
colonic m  retained mRNA for TLR which were not expressed at the protein level. When I
cultured BMM overnight in medium alone, I found increased expression of mRNA for
TLR2, 4 and 9 compared with freshly harvested BMM. To my knowledge this phenomenon
has not been looked at previously, but it could reflect differentiation of the BMM during the
additional culture period and is clearly an essential control for any experiments of this kind.
Treatment of BMM with BLP or LPS abrogated the increase in TLR4 mRNA expression,
but had no effect on the induction of TLR2 mRNA. This is in contrast to a previous finding
showing that LPS increases TLR2, but not TLR4 mRNA in murine splenic m , although
this study did not compare TLR levels in freshly isolated m  with those cultured in medium266
alone (101). Others have reported that treatment of murine peritoneal m  with LPS results
in a decrease in TLR4 mRNA within a few hours, but this returned to normal by 24 hours
(102). However LPS had no effect on TLR9 mRNA expression. BLP also reduced TLR9
mRNA levels to below the baseline found in freshly harvested BMM, despite having no
effect on TLR9 protein expression. I could not find any previous evidence for the effects of
BLP on TLR9 mRNA expression in m , but these results suggest that TLR2 ligation
selectively inhibits the transcription of TLR9 mRNA, rather than at the protein level where
TLR9  may  be  more  stable,  suggesting  different  TLR  ligands  might  regulate  TLR
expression at distinct levels. Specifically, LPS has a selective effect on the expression of its
own TLR protein and mRNA, while BLP appears to have somewhat more wide ranging
effects, especially at the mRNA level. These results also indicate that TLR mRNA
expression does not necessarily correlate with the regulation of protein levels.
I found that treatment of BMM with poly I:C or LPS prevented subsequent TNF 
and IL-6 responses to all the other ligands I used. The hyporesponsiveness of LPS-treated
BMM to subsequent LPS was expected as a result of endotoxin tolerance. In addition, the
phenomenon of functional cross-tolerance between TLR2 and 4 has been documented
previously (353). BLP had a similar, if somewhat lesser effect, as it decreased the
production of TNF , but not IL-6, in response to subsequent stimulation with poly I:C or
LPS. Cross-tolerance between the other TLR ligands has not been documented previously,
but it should be noted that TLR4 ligation reduces the association of MyD88 with IRAK
(103, 104), which could explain the effects of LPS (and other TLR ligands) on signalling
via other TLRs which share the same signalling cascade. Altogether, these in vitro findings267
show that TLR function can be modulated without affecting expression of the receptor and
that individual TLR ligands can have different effects at the level of protein/mRNA
expression and function. Importantly, they also show that individual TLR ligands cannot
reproduce the overall phenotype of colonic m .
Together these findings indicate that the global downregulation of TLRs seen in
resident colonic m  is not simply ligation of individual TLRs, suggesting this involves
additional  mechanisms/factors.  However,  the  actual  level  of  TLR  protein  would  be
important to measure, for example by Western blot analysis, to assess whether TLR ligands
affected the quantity of protein rather than the percentage of cells expressing TLR. In
addition, my in vitro culture system does not replicate the long-term exposure to multiple
TLR agonists and other PRR ligands that intestinal m  encounter in vivo, and therefore
experiments combining TLR agonists and with longer culture periods could reveal a role
for TLR ligation in the regulation of TLR expression.
To address some of the artefacts that might be involved in the in vitro system, I used
an in vivo approach in which I assessed TLR expression by colonic m  from TLR2KO and
C3H/HeJ mice, which have a non-functional point mutation in TLR4 (76). Colonic m 
from both strains showed the usual absence of TLR2, 3, 4 and 9 and although these studies
should be repeated using additional KO mice and appropriate C3H/HeN congenic controls,
they support my in vitro experiments that TLR2 and TLR4 signalling are not involved in
the regulation of TLR expression by colonic m  in vivo. Again these in vivo studies do not
preclude the possibility that the combined effects of multiple TLR ligands and possibly268
related PRRs such as Nod receptors, might reproduce the overall phenomenon. Therefore, it
would be important to assess the expression of TLRs by colonic m  from MyD88KO or
MyD88/TRIF double KO mice, or in germ-free animals where the majority of PRR
signalling would be abrogated. Surprisingly, such experiments have not been published,
although interestingly it has been shown that intestinal epithelial cells actually exhibit
reduced expression of TLR9 in germ-free animals compared with mice colonised with
microflora (354).
Interestingly, prolonged stimulation of monocyte-derived m  with MDP also results
in tolerance to subsequent Nod2 and TLR stimulation. Although the levels of Nod2/TLR
expression were not examined in this study, the phenomenon was associated with failure to
activate IRAK-1 and/or over-expression of inhibitory IRAK-M (106). However it has been
demonstrated that Nod1 and Nod2 play an important role in bacterial recognition after m 
have been stimulated via TLR (355). That the colonic m  that I have described were
unresponsive to both LPS and MDP could suggest therefore that they have been exposed
chronically to MDP in the intestine. Supporting this argument, it has been shown that
Nod2-deficient m  exhibit heightened TLR2 responses (344), and it would be interesting to
examine TLR expression by Nod2-deficient colonic m .
As TLR signalling alone did not seem to account for the lack of TLR expression by
colonic m , I went on to explore the effects of some of the potentially immunomodulatory
factors that are present in the intestinal microenvironment. VIP has been shown to
downregulate iNOS, as well as pro-inflammatory cytokine and chemokine production by269
m  in response to LPS (222-225), and it has been shown to downregulate TLR4 in murine
m  (217). Retinoic acid is required for the ability of intestinal DCs and m  to drive
regulatory T cell differentiation (30, 235), and it has also been shown to downregulate
TLR2 in human monocytes (326). As noted above, IL-4 and IL-13 drive the differentiation
of AAM, and can also decrease TLR3 and TLR4 mRNA expression in intestinal epithelial
cells (325). Therefore I decided to examine the effects of these immunomodulatory factors
on TLR expression by m . However, the concentrations of VIP, IL-4 and retinoic acid I
used all failed to have any effect on TLR expression by BMM. Nevertheless, given the
findings from previous studies, it would be interesting to repeat these experiments using
different doses and culture regimens, including combining the various mediators.
In view of these negative findings, I went on to examine the role of IL-10, by
characterising colonic m  in IL-10-deficient mice. These mice develop spontaneous colitis
in which colonic m  produce increased levels of pro-inflammatory cytokines in response to
stimulation with whole bacteria or LPS (115, 195). Furthermore, STAT-3-deficiency in
myeloid cells results in the development of colitis (233), suggesting that IL-10-mediated
control of m  function is critical for gut homeostasis. I found that colonic m  from IL-10-
deficient animals expressed increased levels of TLR2 and TLR4 even when examined at an
age before colitis had appeared, consistent with the colitis in IL-10KO mice being TLR-
dependent (239). Interestingly, increased expression of intracellular TLR3 or 9 was not
detected in colonic m  from IL-10KO mice, suggesting that these TLRs may be regulated
by distinct mechanisms. The increased expression of TLR2 and 4 by colonic m  from pre-
colitic IL-10-deficient mice was associated with increased production of TNF  in response270
to the corresponding ligands, BLP and LPS. There were no substantial differences in co-
stimulatory molecule expression between WT and KO mice, but the expression of class II
MHC was significantly higher on IL-10KO colonic m  than on WT m . These results
indicate that in the absence of IL-10, m  in the colon are more susceptible to stimulation by
microbial  products  even  before  overt  disease  develops.  Although  there  was  little
spontaneous cytokine production by colonic m , the fact that BMM from IL-10KO mice
showed a dramatic increase in IL-12p70 production compared with WT BMM, suggests
that m  from these mice may be intrinsically hyper-responsive. These findings from pre-
colitic mice support the idea that the unusual colonic m  found in IL-10KO mice are not
simply an additional population that has been recruited in response to inflammation.
There were no differences between the individual subsets of F4/80
+ cells, or Gr-
1
+F4/80
+ m  in the WT and IL-10KO mice used in these studies, although the proportion of
F4/80
+CD11b
+CD11c
int  cells was lower in both of these BALB/c background strains
compared with the C57Bl/6 mice used in my earlier studies. This suggests that although the
proportion of the subsets may differ between mouse strains, IL-10 does not play a direct
role in establishing the heterogeneity of resident colonic m  populations.
I based my interpretation that there was no colitis in the young IL-10KO mice, on
the absence of clinical signs of colitis, normal histology, lack of blood in faeces as
measured by the Haemoccult test, and normal numbers/proportions of m . However, it is
difficult to rule out completely the possibility that a low level of inflammation was present
in the younger IL-10-deficient animals that was not detectable by these means. Indeed, two271
reports have demonstrated that IL-10-deficient mice show increased epithelial permeability
in the small intestine before 4 weeks of age and prior to histological inflammation (356,
357). Therefore it remains possible that there was already minor inflammation that could
have  affected  m   function, and this would also need more detailed examination of
inflammatory cell infiltration at these early timepoints.
Thus, IL-10 appears to condition TLR2 and 4 expression and function by intestinal
m , without markedly affecting the nature of the resident colonic population. However the
hyper-responsive phenotype of IL-10KO BMM may argue that all m  are intrinsically
altered in these mice. The source of the IL-10 is unknown, but could include m  themselves
(195), DCs (26) and regulatory T cells (220). Blocking IL-10R in cultures of purified m 
would help assess whether this is an autocrine effect, and would also help investigate any
active conditioning effects of IL-10 on TLR expression or function. It would also be
important to explore how IL-10 might be acting and to what extent it can account for the
phenotype of colonic m . As IL-10 is involved in the differentiation of regulatory T cells
(358), colonic m  could contribute to T regulatory cell-dependent tolerance. Furthermore,
IL-10 can inhibit TLR-mediated NF B activation by inhibiting IKK and NF B DNA-
binding activity (114), and by inducing nuclear expression of the inhibitory I B family
members, I BNS and Bcl-3 (115, 116). Interestingly, one report found that IL-10 could
induce LPS tolerance in human monocytes without modulating TLR4 expression (359).
Thus, it remains unclear if IL-10 is the factor ultimately responsible for the colonic m 
phenotype, but is certainly involved either directly or indirectly in their unresponsiveness.272
8.5 Phenotype and function of macrophages in the inflamed colon
During intestinal inflammation, there is a large infiltration of m  that differ from the
resident  population  in  many  respects,  exhibiting  heightened  bactericidal  and  pro-
inflammatory properties (251-253). To gain a greater insight into the nature and role of m 
in colonic inflammation, I used the DSS model of colitis as this develops rapidly, follows a
relatively well-defined pattern and produces a consistent and characteristic form of colitis
(281). In my hands, DSS fed mice developed consistent weight loss by day 5, accompanied
by colon shortening, diarrhoea and rectal bleeding. Histological analysis revealed crypt
loss, epithelial denudation, ulceration, loss of intestinal architecture and cellular infiltration
of the LP and submucosa. These histological changes were accompanied by a large influx
of F4/80
+ cells, which was first apparent by day 4, and was approximately 6-fold higher
than WT by day 7 of colitis. There was also an earlier infiltration of Ly6C
int cells into the
colon which was seen by day 3 of colitis. The majority of these cells failed to express F4/80
or CD11b, but resembled mononuclear cells in terms of FSC/SSC properties. A similar
Ly6C
int population of monocytic cells has been described in the inflamed peritoneum, but
these expressed high levels of CD11b (173) and I was unable to find any previous
description  of  mononuclear  Ly6C
+  cells  that  failed  to  co-express  CD11b.  Further
phenotypic analysis of these cells would be needed to identify this population definitively.
During these experiments, I also found a substantial population of Ly6C
hi cells in the
resting colon, the proportion of which did not change during inflammation. These cells
were quite heterogeneous in terms of FSC/SSC properties, with most appearing to be
mononuclear in nature. However some of these Ly6C
hi cells were small enough to fall273
within the lymphocyte gate, and indeed Ly6C is expressed by a subset of memory CD8
+ T
cells and small intestinal LP IgA
+ plasma cells (360, 361). However, the identity of the
larger Ly6C
hi cells is unclear and would require further characterisation.
There was also infiltration of Ly6G
hi neutrophils into the inflamed colon, but this
was delayed with respect to the monocytic cells, not being seen until day 7. This was
unexpected  given  that  neutrophils  are  usually  one  of  the  first  cells  to  appear  in
inflammatory  sites.  Nevertheless,  a  population  of  Ly6G
-  cells  with  the  FSC/SSC
appearance of granulocytes did appear by day 4 of colitis and these could be eosinophils.
Eosinophils and m  are sometimes considered mutually exclusive in models of colitis, with
eosinophils being found in Th2-type models, such as that induced by oxazalone, whereas
m  are associated with the Th1-like TNBS model of colitis (282). However, during DSS
colitis and human ulcerative colitis, eosinophils and m  are present together and in fact,
intestinal m  have been shown to express the eosinophil chemoattractant, eotaxin-1 (291,
362). Again, it would be interesting to assess the expression of eosinophil-specific markers
such as Siglec F and CCR3 to confirm the nature of these granulocytic cells that appear
early in DSS colitis.
The increase in the number of m   during  colitis  accounted for  a  substantial
proportion of the increase in total cellularity, and was associated with a switch in the
phenotype  of  the  dominant  m    population,  with  70%  now  being
F4/80
+CD11b
+CD11c
intTLR2
+. The majority of this population also expressed class II
MHC, but still expressed only low levels of co-stimulatory molecules. There was also an274
increase in the proportion of colonic m  that expressed TLR4 during colitis and I assume
that these were the m  that also expressed TLR2
+, although there were insufficient colours
available to determine this directly by flow cytometry. The increased proportion of TLR-
expressing m  was particularly apparent at the distal end of the colon, reflecting the pattern
of disease severity in this model (281), presumably due to the higher level of microbiota in
this location. TLR expression by colonic m  has not been studied previously in mouse
models of colitis, but the TLR2
+ m  I found may be similar to the ‘inflammatory’ CD14
+
m  subset recently described in biopsies from Crohn’s disease patients, that produce TNF ,
IL-6 and IL-23 (272). Consistent with this and in stark contrast to the resting state, a large
proportion of the TLR
+ m  population I found in the inflamed colon produced TNF 
spontaneously, and this was increased slightly by stimulation with BLP or LPS. In contrast,
the TLR2
- m  remained unable to produce TNF  under any conditions. Although some of
the TNF -producing cells in the inflamed colon expressed little or no F4/80, they all
expressed high levels of CD11b, and were mononuclear in terms of FSC/SSC properties.
These were not present in the resting colon and it is possible that they may represent
recently recruited monocytes, which have been shown to express reduced levels of F4/80
(43). Their ability to produce TNF   ‘spontaneously’ without addition of exogenous
stimulus suggests that these m  had been exposed to pro-inflammatory stimuli in situ.
My findings support the idea that monocytes/m  are the major source of TNF  in
this  model  of  colitis  and  suggest  that  they  play  a  central  role  in  TNF -dependent
pathologies in the intestine. However, the role of TNF  in DSS colitis is not clear, as anti-
TNF  has been shown to aggravate acute DSS colitis but ameliorate chronic colitis, (363).275
Furthermore, acute DSS colitis is exacerbated in TNF   null mice (364). It would be
interesting to assess whether the TLR2
+ m  expressed other pro-inflammatory mediators
such as IL-6, IL-23 and iNOS, which can play a detrimental role in experimental models of
colitis (365-367), but I was unable to do this due to time constraints.
8.6 Turnover of macrophages in the resting and inflamed colon
To  explore  the  relationship  between  the  TLR
+  and  TLR
-  subsets  of  m , I
investigated the turnover kinetics of the two subsets in the resting and inflamed state. BrdU
pulse-chase experiments would provide some insight into the origin of the TLR
+, TNF -
producing m  population present during colitis. By comparing BrdU uptake during pulse-
chase experiments with in situ cell division, I could assess whether the appearance of the
TLR
+, TNF -producing m  reflected differentiation of the resident population, or active
proliferation of F4/80
+ cells and whether these cells had divided outside the intestine and
been recruited. This was important to investigate as the manipulation of m  behaviour or
alternatively, effective blocking of mononuclear cell infiltration into the gut, could prove to
be effective therapeutic approaches.
I first assessed the turnover of monocyte precursors in the BM by measuring BrdU
uptake, as I postulated that this population would be proliferating actively and thus allow
me to assess the usefulness of the technique, and also give me an insight into the dynamics
of monocyte precursors. Remarkably, within 2 hours after BrdU administration, >50% of276
F4/80
+ cells in the BM had divided, indicating that a substantial turnover of monocyte/m 
precursors occurs in the BM in the steady state.
In the colon, I found that ~5% of the total F4/80
+ population in control animals had
incorporated BrdU during the 24 hour period, and there was also considerable uptake
among the non-haematopoietic cell compartment, probably epithelial cells. However,
during colitis, less than 30% of these F4/80
- BrdU
+ cells were CD45
-, suggesting that there
was a decrease in proliferation of non-haematopoietic cells and/or a proportional increase in
the proliferation of CD45
+ F4/80
- cells. More significantly, during colitis, ~17% and ~19%
of the total F4/80
+ population incorporated BrdU on days 3 4 and 5 6, respectively.
Together with the substantial increase in total m  numbers, these results show there was a
considerable increase in the accumulation of recently divided m  during colitis.
Interestingly, when colonic m  were divided on the basis of TLR2 expression, the
recently divided m  belonged to the TLR2
+ population, with negligible proliferation being
seen among the TLR
- subset in both the resting and inflamed colon. The proportion of
BrdU
+ cells among the TLR2
+ population also increased during intestinal inflammation
(~20% versus ~6% in resting colon), but the low levels of BrdU uptake by the TLR
- subset
did not alter substantially during inflammation. Together these findings suggested that
TLR
+ m  might behave differently even in the resting colon.
To explore this further and to gain a better idea of the turnover of m  subsets in the
normal and inflamed colon, I assessed the turnover rates of colonic m  over a prolonged277
period during the development of colitis and in control mice. This confirmed the increased
accumulation of recently divided m  during colitis and again, the TLR
+ subset showed
higher levels of turnover both in the resting and inflamed colon. Although I did not prove it
directly, the BrdU
+ cells are probably the spontaneous TNF -producing cells present
during colitis which also have the capacity to produce TNF  when stimulated via TLR2 in
the resting state. In addition, some of the BrdU
+ cells I found in the colitic mucosa were
F4/80
lo. Like the F4/80
lo TNF -producing cells I had identified earlier, these F4/80
loBrdU
+
cells were only present in the inflamed colon, expressed high levels of CD11b and
exhibited mononuclear FSC/SSC properties. This together with their considerable level of
BrdU uptake, supports the idea that these cells are recently derived from the monocyte pool
which is known to express a lower level of F4/80 (43). The TLR
+ subset of colonic F4/80
+
cells also differed from their TLR
- counterparts in their expression of Gr-1 in both the
resting and inflamed state, with a higher proportion of the TLR
+ subset positive for this
marker. In addition, the TLR2
+ subset of colonic m , but not the TLR2
- subset, expressed
CCR2 in the resting and inflamed colon. Together these differences in phenotype and
population kinetics suggest that the TLR
+ and TLR
- m  may represent independent lineages
of  m ,  rather  than  the  effects  of  a  local  conditioning  event  in  which  one  subset
differentiates into the other.
The increased number of TLR
+BrdU
+ m  during colitis compared to the resting
state could reflect increased local proliferation, increased recruitment to the colon, possibly
under the influence of increased chemokines, and/or increased survival. The increased
number of TLR
+ m  in colitis appeared not to be due to increased local proliferation, as278
although Ki-67 expression was slightly increased in colitic m , this was too small to
account for the differences in BrdU uptake.
Increased CCR2-dependent recruitment could be a critical mechanism underlying
the expanded population of TLR
+ m  during colitis. The CCR2 chemokine receptor is
known to be involved in recruitment of inflammatory m  to the intestine (327), and the fact
that the subset of colonic m  that expressed TLR2 also expressed high levels of CCR2
suggests ligands for this receptor may be involved in the recruitment of these cells into the
colon in the resting and inflamed state. Their increased numbers in colitis would be
consistent with the increased expression of one of the CCR2 ligands, MCP-1 in IBD
mucosa (368). The production of CCR2 ligands in colitic mucosa would help test the
hypothesis that increased recruitment is important for the increased accumulation of TLR
+
m  during DSS colitis. In addition, the accumulation of adoptively transferred CCR2
+
versus CCR2
- monocytes in the colon could be determined. Alternatively, measuring
F4/80
+TLR2
+ cell infiltration into the colon of control or DSS-fed CCR2-deficient mice, or
WT mice treated with anti-CCR2 blocking antibody would allow the importance of CCR2
in monocyte recruitment during colitis to be addressed.
Interestingly, the release of Ly6C
hi monocytes from the BM into the circulation in
response to L.  monocytogenes infection, but not from the circulation into the infected
spleen, is dependent on CCR2 (172). In addition, analysis of uninfected CCR2KO mice
demonstrated a paucity of Ly6C
hi monocytes in the blood, suggesting CCR2 contributes to
monocyte emigration from the BM even under physiological conditions (172, 369),279
however this may be different for recruitment into tissues. Therefore, by comparing the
accumulation of transferred, fluorescently labelled CCR2
+/+CD45.1
+ and CCR2
-/-CD45.2
+
monocytes into the colon of normal or colitic WT recipients, with monocyte recruitment in
CCR2 KO mice, I could distinguish between a role for CCR2 in BM egress versus
recruitment  from  blood  into  the  tissue  in  this  model. It  may  also  be  interesting  to
investigate whether the absolute numbers of monocytes and the proportions of monocyte
subsets are altered in the blood of colitic mice compared with control animals. Furthermore,
repeating the BM monocyte experiment during colitis to investigate how monocyte
precursor turnover in the BM changes during colitis would be interesting.
However, as discussed below, I was unable to establish an effective method to
investigate monocyte recruitment to the colon, and the exact contribution of CCR2-
dependent m  recruitment to the pathogenesis of colitis is unclear. Although antibody-
mediated triple blockade of CCR2, CCR5 and CXCR3 reduces DSS-induced colitis (279),
this study did not examine the effect of blocking CCR2 function alone and indeed, CCR2-
deficient mice are still susceptible to DSS colitis (370). However they exhibit reduced
mucosal ulceration, suggesting that different aspects of pathology may involve different
cells and mechanisms. It is important to emphasise that as the majority of TLR2-expressing
m  are also CCR2
+ in the resting colon, this process must also be occurring in the absence
of inflammation. These TLR
+ m  in the resting colon may therefore represent recently
recruited, BM-derived monocytes and resemble the small proportion of CD14
+ m  seen in
the normal human intestine (201, 272). Again it would be interesting to investigate directly
the role of CCR2 in the recruitment of these cells to the normal colon.280
The increased number of TLR2
+ m  in the inflamed colon could also reflect
increased  survival  of  this  subset  under  these  conditions,  possibly  via  heightened
immunostimulatory signals present in the inflamed intestine. Their survival could be
investigated by long term BrdU incorporation studies in which the rate of loss of labelled
m  subsets could be compared, along with examining the survival of the subsets ex vivo.
However, the long term BrdU studies could still be complicated by emigration of cells to
other tissues, and it would also be difficult to exclude conversion of phenotype over long
periods. It would therefore also be interesting to assess the presence of apoptotic m 
directly using methods such as the TUNEL assay.
8.7 Colonic macrophage subsets in the resting and inflamed state
I found several differences between the TLR
+ and TLR
- m  that suggest that these
cells are two distinct subsets (Table 8.2). The TLR
- subset is F4/80
+CD11b
+/-CD11c
- and
lacks CCR2 and Gr-1 expression. These cells turn over slowly and are unresponsive to
stimulation,  even  during  inflammation.  In  contrast,  the  TLR
+  subset  is
F4/80
+CD11b
+CD11c
int, expresses some Gr-1 and high levels of CCR2. These turn over
rapidly and produce pro-inflammatory mediators such as TNF .281
Marker/Function TLR
- ‘resident’ subset TLR
+ ‘inflammatory’ subset
Description Dominant in resting (70%) Dominant in colitis (70%)
TLR - TLR2++, TLR4+
Class II MHC ++ +++
Co-stimulatory
molecules
- +
CCR2 - +++
Gr-1 - (30%) +
CD11b +/- +
CD11c - +
In vivo cell turnover + +++
Pro-inflammatory
cytokine production
- +++
Table 8.2 Comparison of TLR
- and TLR
+ macrophage subsets in the colon
For markers:
-  - No expression; +/- proportion negative and positive for CD11b; + low; ++
moderate; +++ high
-  % The proportion of the population expressing marker
For cell turnover:
-  + Low turnover; +++ high turnover
For cytokine production:
-  - No production; +++ high production282
As discussed above, I propose these represent independent lineages of monocyte-
derived m  and when I cultured total purified F4/80
+ cells from the resting colon ex vivo,
TLR2 expression did not alter, indicating conversion did not occur in vitro. However it
would be necessary to repeat these experiments using sorted TLR
+ and TLR
- subsets to
address this directly. Furthermore, there was no evidence from the long term BrdU studies
that the BrdU uptake slopes of the two subsets converge in either the resting or inflamed
state, as might be expected if one subset were the precursor of the other. Furthermore, the
fact that the TLR
- m  subset remains unresponsive during colitis suggests that these cells
cannot simply convert to the TLR
+, responsive phenotype in response to inflammatory
signals.
My  hypothesis  is  consistent  with  current  views  on  monocyte/m   precursor
heterogeneity. Specifically, it could be that the TLR
+ subset are derived from the short-
lived CCR2
+CX3CR1
-Gr-1
+ inflammatory monocyte subset, whereas the TLR
- subset may
be derived from the long lived CCR2
-CX3CR1
+Gr-1
lo monocyte subset.
I did attempt to study this by examining precursor cell migration into the intestine
using BMM, which were used as it was impossible to obtain sufficient numbers of blood
monocytes. Adoptively transferred BMM were undetectable in all tissues examined apart
from the peritoneum, where they were only present in small numbers. Therefore, this model
of adoptive transfer proved unsuitable for tracking the migration and/or behavioural
adaptation of m  in the colon, possibly because BMM are different from blood monocytes
and may not have the ability to migrate into tissues. Thus to track the migration and283
behaviour of m  in the colon, it would be necessary to repeat these experiments using
monocytes from RAG KO donors, where there is a higher proportion of blood monocytes
making isolation of sufficient monocyte numbers a more feasible approach. Alternatively,
an approach pioneered by Randolph and colleagues involves intravenous injection of
particulate tracers that are taken up preferentially by the Gr-1
lo monocyte subset, allowing
differential fluorescent labelling and tracking of monocyte subsets (371).
A crucial question is what the m  subsets do in the healthy and inflamed intestine.
Interestingly, following myocardial infarction, Ly6C
hi and Ly6C
lo monocytes are recruited
sequentially to the heart via CCR2 and CX3CR1, respectively (175). Ly6C
hi monocytes
dominate the early stages of the reaction in the myocardium and exhibit inflammatory and
proteolytic functions, driving tissue destruction. Conversely, non-inflammatory Ly6C
lo
monocytes do not appear until later, express vascular-endothelial growth factor (VEGF),
and promote myofibroblast accumulation, angiogenesis, collagen deposition and tissue
healing. Thus in the inflamed colon, it could be that the two subsets are responsible for
different phases of inflammation. The TLR
+ m  could drive inflammation by producing
pro-inflammatory mediators such as TNF , whilst the TLR
- m   may  promote  tissue
healing by producing cytoprotective factors. However this raises the interesting question of
why both subsets are also present in the normal colon, what they are doing there and how
their activities are balanced. The TLR
- m  subset may be able to clear bacteria without
initiating any inflammation, and so may be present solely to regulate the levels of
commensal flora in the colon. It could be that these m  gain access to commensals via
temporary breaches in the epithelial barrier, or could send out cellular processes between284
epithelial cells and into the lumen, as has been described for DCs. Another role for the
TLR
- population of m  could be the protective functions m  play in regulating epithelial
renewal and integrity under physiological and inflammatory conditions (235, 237, 241).
However this would seem difficult to reconcile with the fact that TLR signalling in BM-
derived cells appears to be necessary for epithelial homeostasis and repair after DSS-
induced injury (238, 239). In addition, colitis induced by infection with  Citrobacter
rodentium is exacerbated in TLR2 null mice due to impaired barrier function (240, 372).
Here it is thought that m  send out processes to contact epithelial progenitors, and that
MyD88 signalling in m  drives the repositioning of prostaglandin-endoperoxide synthase-2
(Ptgs2)-expressing stromal cells from the upper/middle crypts to the crypt base adjacent to
the progenitor cells (241, 373). If TLR2
- m  are truly protective, these findings raise the
question of whether TLR expression is downregulated after arrival in the mucosa, and if the
TLR
+ and TLR
- m  populations are actually distinct lineages. In addition, due to the lack of
CCR2 expression, the question remains if, and how, the TLR
-  m  subset is actively
recruited to the intestine. It could be that these cells have expressed TLR and CCR2 at the
time of entry into the gut, before downregulating TLR and CCR2, but my findings in the
cell turnover experiments suggest that this may not be the case.
In contrast, TLR2
+ m  may be recruited continuously from recently divided CCR2
+
precursors and patrol the mucosa constantly for pathogens. Although potentially responsive
to stimulation, these cells may not persist for long periods in the gut in the absence of
invasive pathogens or other exogenous stimuli and so are unable to generate significant
inflammation. However, it is quite possible that this may contribute to the low level of285
‘physiological  inflammation’  that  appears  to  characterise  the  normal  intestine.  The
possibility of reduced survival of these cells is supported by the fact that TLR2 signalling
has been shown to deliver pro-apoptotic signals in TLR2-transfected human embryonic
kidney (HEK) 293 cells (374). In addition, the TLR2
+ m  may be situated in a part of the
mucosa distant from the epithelium, sequestered from non-invasive commensal bacteria,
and so may only respond to pathogenic organisms that breach the epithelial barrier. Thus, it
would be interesting to compare the relative localisation of the TLR
- and TLR
+ m  subsets
with respect to the epithelium in the resting and inflamed colon by immunohistochemistry.
In addition, to address the impact of CCR2-mediated signals on the location of m  in the
intestine, it would interesting to look at what happens to the physiology of the gut in
CCR2KO mice.
Thus, further studies focusing on the functional characterisation of TLR
+ and TLR
-
m  during intestinal inflammation, epithelial repair and homeostasis are required. Indeed, it
would be interesting to compare the gene expression profiles of the m  subsets in the
healthy colon and at different stages of DSS colitis to explore the ways in which these cells
contribute to homeostasis and pathology. As discussed, the differences between the TLR
+
and TLR
- m  may reflect a distinct nature and/origin of these two subsets. To test if the m 
subsets have distinct precursors and if one subset is preferentially recruited to the inflamed
colon, I could use the same system as that used by Littman and colleagues (168). These
authors co-injected the two monocyte subsets, separated on the basis of CX3CR1-GFP
expression, into congenically different mice, before tracking the migration of these subsets
into inflamed and non-inflamed tissues. By comparing control and DSS-fed recipients, I286
could track and compare the ability of the two subsets of monocytes to accumulate in the
colon under both conditions. It would also be important to assess the phenotype, and the
expression of TLR2, of monocyte subsets before transfer and following their arrival in the
resting or inflamed colon.
8.8 Effects of ES-62 on macrophage function
The nematode glycoprotein, ES-62, has been shown to modulate pro-inflammatory
functions of m , reducing the production of cytokines such as TNF  and IL-12, but not NO
(315). Therefore I attempted to use ES-62 in the DSS model of colitis where m  play a
central role. Culture with ES-62 did not result in classical activation of m , in that there
was no upregulation of class II MHC, co-stimulatory molecule expression, iNOS or
production of pro-inflammatory cytokines. In my hands, there was also no cytokine
production induced by ES-62 alone, in contrast to earlier reports (315). I also planned to
confirm the previous findings that ES-62 treatment could inhibit subsequent activation of
m  by LPS and IFN  (315), but due to time constraints I was unable to do this.
As  discussed  earlier,  it  has  been  suggested  that  helminths  can  induce  the
polarisation of m  toward the AAM subtype (375). Unlike LPS and IFN , ES-62 did not
reduce the expression of the AMM markers, arginase and Ym-1, which were both present
in freshly harvested BMM and arginase appeared to increase during culture in medium
alone. Although this could suggest that ES-62 favours the differentiation of m  into an
AMM-like phenotype, the fact that control BMM also expressed these markers makes it287
difficult to know whether ES-62 is actively driving this phenotype, or is simply just not
preventing the loss of these properties. Repeat experiments and further quantitative PCR
analyses, together with measurement of the markers at the protein level would provide a
greater insight into the ability of ES-62 to drive an AAM phenotype.
When I carried out these experiments using ES-62, my project had not yet focused
specifically on m , so I also conducted some of the studies examining the effects of ES-62
on  DCs.  I  first  attempted  to  replicate  work  that  had  shown  ES-62  to  reduce  TLR
responsiveness in DCs (318). However, I could not confirm the findings that ES-62 inhibits
TLR-mediated upregulation of class II MHC or co-stimulatory molecules, or the production
of pro-inflammatory cytokines. Although TNF  and IL-6 responses to BLP were somewhat
reduced by ES-62, this was not statistically significant and repeat experiments would be
necessary to address properly the ability of ES-62 to modulate TLR-induced functions in
DCs. Therefore, it is clear that ES-62 does not drive the full classical activation of m , and
instead may favour the differentiation of AMM and although I was unable to show this, it
has previously been shown to induce hyporesponsiveness in DCs and m .
8.9 Effects of ES-62 on intestinal inflammation
For these reasons, I went on to examine the effects of ES-62 on DSS colitis to
determine if it would have a similar ability to inhibit this form of inflammation, as it does
in other models such as joint and lung inflammation (306, 319). ES-62 treatment had no
effect on weight loss, colon shortening, pro-inflammatory cytokine production or cellular288
infiltrates in the colon during acute DSS colitis. However, ES-62 did seem to have a subtle
effect on some of the clinical aspects of disease, particularly rectal bleeding. Because of
this partial effect, I set up another experiment, in which I used a lower dose of DSS to try
and produce a less severe disease. The ES-62 dose used was the same as in the previous
experiment, but the ES-62 was injected s.c. to slow absorption into the bloodstream and
maintain  a  more  constant  level  of  ES-62  in  the  circulation.  Colon  shortening  was
significantly reduced in the ES-62-treated group, as were the clinical aspects of disease.
However, again there were no effects of ES-62 on weight loss and pro-inflammatory
cytokine production, and although there was a significant increase in the proportion of
CD8
+ T cells in the ES-62-treated group, this was very small and was not seen in the other
experiments.  To  try  to  modulate  the  pathology  more  substantially,  I  repeated  the
experiment using a higher dose of ES-62 and using female mice, thought to have reduced
susceptibility to DSS-induced colitis (376). However, this disease was not less severe in
terms of time of onset and severity, and the only difference was that ES-62 delayed the
onset of clinical disease by 24hrs.
As ES-62 had only minor and inconsistent effects on acute colitis, I next assessed its
effects in a chronic form of the disease which I postulated might allow any modulatory
effects of ES-62 to be seen more clearly. However, after the first cycle of DSS and body
weight had recovered, further cycles of DSS treatment induced little overt disease in ES-62-
treated or control animals. There was also reduced infiltration by Ly6G
+ neutrophils and
colon shortening compared with what was seen in acute DSS colitis. Here, ES-62 had no
effect on clinical scores, rectal bleeding, colon shortening or the cellular infiltrates.289
Taken together, my data suggest that ES-62 may have some protective effects in
acute colonic inflammation, but these were subtle and I was unable to develop a suitable
model of chronic disease in which the effects of ES-62 could be investigated. It is possible
that the inability of ES-62 to substantially modulate DSS-induced pathology could reflect
an insufficient concentration reaching the colon. Although I used the same or higher doses
of ES-62 used in other tissue-specific models of inflammation, oral administration of ES-62
might be needed to obtain sufficiently high local levels in the intestine. Alternatively, ES-
62 has been shown to complex with TLR4 and PKC , to be internalised into vesicular
compartments (319). Thus it may be that colonic m , even in the inflamed colon, do not
express TLR4 at sufficient levels for ES-62 to be internalised in sufficient concentration to
exert its effects. I was unable to explore these possibilities further due to the need for large
quantities of ES-62 and mice, and the fact that I had begun to obtain interesting data on m 
characteristics in the resting and inflamed colon, and thus my project changed focus to this
area.
8.10 Concluding Remarks
Taken together, my results show that colonic m  retain some characteristics of
activated m , such as class II MHC expression, endocytosis and phagocytosis, but they
have lost the ability to produce pro-inflammatory mediators. This would imply that
intestinal m  could potentially clear bacteria without initiating an inflammatory cascade. In
addition, unlike other m  populations, colonic F4/80
+ cells were extremely heterogeneous290
and could be split into three subsets on the basis of CD11b and CD11c expression. Their
lack of co-stimulatory molecule expression, but high phagocytic capacity and expression of
class II MHC, suggests that m  may take up commensals and induce tolerance. If m  in the
resting  colon  were  found  to  be  tolerogenic,  it  could  provide  a  mechanism  for  the
maintenance of peripheral tolerance in the intestine, whereby uptake and presentation of
innocuous antigens to T cells in a non-inflammatory manner could maintain tolerance to
these antigens. In addition, intestinal m  are likely to play an important role in epithelial
renewal in homeostasis and inflammation.
The apparent stimulus-independent downmodulation of pro-inflammatory activities
in the dominant population of resting intestinal m  indicates a global reprogramming of
cellular function under physiological conditions. That mucosal m  are quiescent and
refractory to inflammatory signals seems somewhat paradoxical given their continuous
exposure to microbial stimuli. However, by being specifically and exquisitely adapted to a
unique and extreme microenvironment, this population is critical for the maintenance of
tissue homeostasis. These are actively functioning cells which not only reflect their
microenvironment, but can also influence the milieu and other cell populations around
them.
However, under resting conditions, there is also a small population of TLR
+CCR2
+
m  that more closely resemble conventional monocytes/m , and which are potentially
responsive to inflammatory stimuli. These turn over rapidly, being derived from recently
divided precursors and may not have yet undergone ‘conditioning’ by the intestinal291
microenvironment, or alternatively they may represent a distinct subset of m . These
potentially responsive m  may not be present in sufficient numbers to elicit inflammatory
responses in the normal intestine, but during intestinal inflammation or infection, this
balance is altered by increased recruitment and/or survival of TLR
+CCR2
+TNF 
+ m  to the
mucosa. Together with the altered microenvironment of heightened immunostimulatory
signals,  this  may  shift  the  overall  balance  in  favour  of  m   activation  and  overt
inflammation. The inertia of resident m  is physiologically crucial, as failure of intestinal
m  to become tolerant to TLR ligands and other pro-inflammatory stimuli can produce
inflammation in the intestine. Whatever the explanation for the hyporesponsiveness of the
dominant resident population, it appears that health and inflammation in the intestine reflect
a delicate balance between these two mutually opposed populations of m , whose numbers
and behaviour are intimately related to the state of the local environment. Understanding
the mechanism(s) of immunoregulation in intestinal m  has clear implications for the
understanding of oral tolerance, oral vaccine development, and treatment of diseases such
as IBD.292
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